"<font color=""#800080"">Causes of pain in palliative care</font>"	Soft tissue<div><br /></div><div>Visceral</div><div><br /></div><div>Nervous</div><div><br /></div><div>Bone</div><div><br /></div><div>Spasm</div><div><br /></div><div>Raised IC pressure</div><div><br /></div><div>Exacerbated by PSYCH, SOCIAl, SPIRITUAL factors</div>
"<font color=""#800080"">Ceiling doses of the weak opioids</font>"	Codeine = 240mg/24hrs<div><br /></div><div>Tramadol = 400mg/24hrs</div><div><br /></div><div><br /></div>
"<font color=""#800080"">Should you combine weak opioids?</font>"	NO!! Seriously why would you?&nbsp;<div><br /></div><div>Switch to a STRONG OPIOID you bellend</div>
"<font color=""#800080"">Dosage of morphine</font>"	Start at 5-10mg 4HRLY of immediate release<div><br /></div><div>OR</div><div><br /></div><div>Start at 10-20mg 4HRLY if moving up from step 2</div>
"<font color=""#800080"">Side effects of morphine</font>"	<div>Act on mu opioid receptors</div><div><br /></div>Initial:<div>Drowsiness</div><div>N+V</div><div><br /></div><div>Common:</div><div>Constipation</div><div><br /></div><div>Rare:</div><div>Sweating</div><div>Itching</div><div><br /></div><div><br /></div><div><br /></div>
"<font color=""#800080"">Signs of opioid toxicity</font>"	<div>Potential toxicity:</div><div>Drowsiness increasing despite no dose increase</div><div>Hallucinations</div><div>Confusion</div><div>Myoclonus</div><div>Resp depression - v. serious but rare with oral titration</div><div><br /></div><div>NB/ pinpoint pupils not a reliable sign</div>
"<font color=""#800080"">Rx of opioid toxicity</font>"	<div>NALOXONE - only in emergencies</div><div>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - RR&lt;8, pt unrousable</div><div><br /></div>Usually dose reduction is adequate - do NOT stop abruptly as pain can be catastrophic<div><br /></div><div>Consider change to immediate release prep with short halflife e.g. ORAMORPH 4hrly</div>
"<font color=""#800080"">Dosage conversion between analgesics</font>"	"<img src=""Screen Shot 2014-02-15 at 18.53.58.png"" />"
"<font color=""#800080"">Calculations in prescribing morphine</font>"	If progressing from morphine - <b><u>1/10th of codeine dose</u></b><div><b><u><br /></u></b></div><div>PRN - <b><u>1/6th of daily morphine dose</u></b></div><div><b><u><br /></u></b></div><div>If converting to syringe driver - <b><u>1/2 daily morphine dose &nbsp;over 24hrs in 21mls water in 30ml syringe</u></b></div>
"<font color=""#800080"">What must be addressed when prescribing morphine</font>"	ALWAYS regular LAXATIVE<div><br /></div><div>ANTI-EMETIC if needed</div><div><br /></div><div>Warn about initial drowsiness&nbsp;</div><div><br /></div><div>Can drive if on STABLE DOSE + NOT DROWSY</div><div><br /></div>
"<font color=""#800080"">Dosage of fentanyl&nbsp;</font>"	Transdermal patches - 12, 25, 50, 75, 100 mcg/hr patches<div><br /></div><div>Last 3 days - takes 24hrs to get out of system</div><div><br /></div><div>Can take one week to reach stable dose</div><div><br /></div><div>SAFE in RENAL FAILURE</div><div><br /></div><div>Half as constipating as morphine</div>
"<font color=""#800080"">Hx and Rx of neuropathic pain</font>"	Pt complains of burning, shooting, stabbing etc<div><br /></div><div>Escalate WHO pain ladder but may require adjuvants:</div><div><br /></div><div>1) ANTICONVULSANTS e.g. gabapentin</div><div>2) TCAs e.g. amitryptylline</div><div>3) STEROIDS</div><div>4) NERVE BLOCK</div>
"<font color=""#800080"">Hx of bone pain</font>"	Caused by bone mets, if sudden onset suspect FRACTURE
"<font color=""#800080"">Rx of bone pain</font>"	1) Escalate WHO pain ladder<div><br /></div><div>2) NSAIDs esp. effective</div><div><br /></div><div>3) RADIOTHERAPY</div><div><br /></div><div>4) BISPHOSPHONATES - myeloma</div><div>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - breast Ca</div><div>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- prostate Ca</div><div><br /></div><div>5) Ix for fractures</div><div><br /></div><div>6) Ix for increased Ca2+</div><div><br /></div><div>7) Watch out for CORD COMPRESSION</div>
"<font color=""#800080"">How common is SOB in palliative care?</font>"	Pathological if breathing difficulties limit normal activities<div><br /></div><div>70% Ca pts in last weeks</div><div><br /></div><div>Severe in 25% Ca pts in last week</div><div><br /></div><div>98% COPD in last year</div><div><br /></div><div><br /></div>
"<font color=""#800080"">Causes of SOB</font>"	<b>Disease related:</b><div>Tumour in chest&nbsp;</div><div>Pleural effusion</div><div>Massive ascites</div><div><br /></div><div><b>Rx related:</b></div><div>Pneumonectomy&nbsp;</div><div>Radiation fibrosis</div><div>Chemotherapy pneumonitis</div><div>Cardiomyopathy</div><div><b><br /></b></div><div><b>Concurrent problems:</b></div><div>COPD</div><div>HF</div><div>Asthma</div><div>ANXIETY</div><div><b><br /></b></div><div><b>Debility related:</b></div><div>Anaemia</div><div>PE</div><div>Paraneoplastic</div><div>Pneumonia</div><div>Muscle weakness</div>
"<font color=""#800080"">What is Lymphangitis Carcinomatosa? How is it treated?</font>"	Diffuse infiltration of lymphatics of lungs by cancer cells&nbsp;<div><br /></div><div>Poor prognostic feature - mean survival of 3 months</div><div><br /></div><div>CORTICOSTEROIDS can improve&nbsp;</div>
"<font color=""#800080"">Factors exacerbating SOB</font>"	Anxiety (often get into cycle of SOB-Panic-Anxiety-SOB)<div><br /></div><div>Cough</div><div><br /></div><div>Constipation</div><div><br /></div><div>Anaemia</div><div><br /></div><div>Pain</div><div><br /></div><div>Previous experience</div>
"<font color=""#800080"">General Rx of SOB</font>"	1) Rx of reversible causes - Abx, blood transfusion, anti-Ca therapy.<div><br /></div><div>2) Specific Rx - stenting, aspiration/pleurodesis, steroids</div><div><br /></div><div>3) Non-drug Rx - reassurance, use of FAN, positioning, family explanation</div><div><br /></div><div>4) Symptomatic drug Rx</div>
"<font color=""#800080"">Drugs used for SOB</font>"	1) OPIOIDS - 2.5mg-5mg PRN to start<div>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - reduce sensitivity of resp centre and chemoreceptors, reduce pain, reduce anxiety</div><div>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- no evidence for nebulised us<br /><div><br /></div><div>2) ANXIOLYTICS e.g BENZODIAZEPENES - only for anxiety-related SOB</div><div>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - low dose as can decrease resp drive</div><div><br /></div><div>3) OXYGEN - reversal of hypoxia, but studies dont show much benefit</div></div><div>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - causes dry mouth + potential loss of drive</div>
"<font color=""#800080"">Rx of chronic cough</font>"	Anti-tussives e.g. cough syrup<div><br /></div><div>Local anaesthetics e.g. BUPOVICAINE NEB</div><div><br /></div><div>OPIOIDS suppress reflex</div><div><br /></div><div>Glucocorticoids, ipatropium, neb indomethacin to REDUCE SECRETIONS</div>
"<font color=""#800080"">Definition of constipation</font>"	Difficulty in defaecation (freq is less important - compare with normal habits)<div><br /></div><div>50% incidence</div>
"<font color=""#800080"">Causes of constipation</font>"	Hypercalcaemia<div><br /></div><div>Inactivity&nbsp;</div><div><br /></div><div>Poor nutrition</div><div><br /></div><div>Dehydration (esp if N+V, polyuria, fever)</div><div><br /></div><div>Drugs&nbsp;</div>
"<font color=""#800080"">Drugs causing constipation</font>"	OPIOIDS - acts on mu2 to reduce peristalsis, increase sphincter tone, block H20 secretion<div>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- persist in gut lumen<br /><div><br /></div><div>NSAIDS</div><div><br /></div><div>ANTICHOLINERGICS</div><div><br /></div><div>5HT3 ANTAGONISTS</div><div><br /></div><div>DIURETICS</div></div>
"<font color=""#800080"">Rx of constipation</font>"	1) Softeners - SODIUM DOCUSATE<div><br /></div><div>2) Osmotic - LACTULOSE, MOVICOL</div><div><br /></div><div>3) Stimulants - SENNA&nbsp;</div><div><br /></div><div>4) Bulking - FIBRE gels</div>
"<font color=""#800080"">SEs of constipation Rx</font>"	Osmotics:<div>Lactulose - bloating, cramps</div><div>Movicol - irritating, take with lots of water</div><div><br /></div><div>Stimulants:</div><div>Senna - cramps, avoid in obstruction</div><div><br /></div><div>Fibre -&nbsp;avoid in obstruction</div>
"<font color=""#800080"">What constipation Rx to use</font>"	Soft stool + infrequent = STIMULANT e.g. senna<div><br /></div><div>Hard stool + frequent = OSMOTIC e.g. lactulose or SOFTENER e.g. Na docusate</div><div><br /></div><div>Hard stool + infrequent = STIMULANT + OSMOTIC or SOFTENER</div>
"<font color=""#800080"">Causes of bowel obstruction revision</font>"	LUMINAL:<div>faeces</div><div>gallstones</div><div>foreign body</div><div><br /></div><div>MURAL:</div><div>malignancy</div><div>inflamm. strictures&nbsp;</div><div><br /></div><div>EXTRAMURAL:</div><div>hernias</div><div>adhesions</div><div>intussuception</div>
"<font color=""#800080"">What proportion of Ca pts suffer N+V?</font>"	40-70%<div><br /></div><div>Higher in STOMACH and BREAST Ca</div><div><br /></div><div>F&gt;M</div><div><br /></div><div>Younger&gt;Older</div>
"<font color=""#800080"">What are the reversible causes of N+V and how are they treated?</font>"	Cough - give anti-tussives<div><br /></div><div>Gastritis - reduce acid and remove irritants</div><div><br /></div><div>Constipation - laxatives</div><div><br /></div><div>Increased ICP - steroids</div><div><br /></div><div>Hypercalcaemia - IV fluids, bisphosphonates</div><div><br /></div><div>Ascites - drain</div><div><br /></div><div>Pain - analgesia</div><div><br /></div><div>Anxiety - reassurance + support</div>
"<font color=""#800080"">CYCLIZINE method of action&nbsp;</font>"	ANTICHOLINERGIC - Histamine H1 and ACh receptor antagonist&nbsp;<div><br /></div><div>Slows and dries gut and has a central effect (crosses BBB)</div><div><br /></div><div><br /></div>
"<font color=""#800080"">Dosage and uses of CYCLIZINE</font>"	<div>50mg TDS PO or SC</div><div><br /></div>Useful in:<div>COMPLETE OBSTRUCTION</div><div>RAISED ICP</div><div>VESTIBULAR/ MOTION</div>
"<font color=""#800080"">SEs of CYCLIZINE</font>"	<div>Sedation + Drowsiness</div><div><br /></div>Anti-cholinergic:<div><br /></div><div>Dry mouth</div><div><br /></div><div>Constipation</div><div><br /></div><div>Tachycardia</div><div><br /></div><div>Blurred vision</div><div><br /></div><div>Urinary retention</div><div><br /></div><div>Hypotension</div>
"<font color=""#800080"">METOCLOPROMIDE method of action</font>"	Dopamine and 5HT antagonist<div><br /></div><div>Central effect</div><div><br /></div><div>SPEEDS UP GUT (opposite of cyclizine)</div>
"<font color=""#800080"">Dosage and uses of METACLOPROMIDE</font>"	10mg TDS PO or SC<div><br /></div><div>Good for GASTRIC STASIS, INCOMPLETE OBSTRUCTION, MORPHINE INDUCED, TOXIC</div>
"<font color=""#800080"">SEs of METOCLOPRAMIDE</font>"	Extrapyrimidal effects e.g. akinesia<div><br /></div><div>Diarrohea + colic</div>
"<font color=""#800080"">HALOPERIDOL method of action</font>"	Dopamine antagonist<div><br /></div><div>Only central action - minimal effect on gut</div>
"<font color=""#800080"">Dosage and use of HALOPERIDOL</font>"	1.5mg NOCTE PO or SC (can go higher)<div><br /></div><div>Good for TOXIC or CHEMICAL causes e.g. drugs, Ca2+ or renal failure</div>
"<font color=""#800080"">SEs of HALOPERIDOL</font>"	Extra pyrimidal e.g. parkinsonian, akinesia, dyskinesia
"<font color=""#800080"">Other anti-emetics</font>"	ONDANSETRON - serotonin antagonist for chemo N+V<div>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- constipating</div><div><br /></div><div>DOMPERIDONE - D2 antagonist - prokinetic</div><div>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- safe for parkinsons pts as doesnt cross BBB</div><div><br /></div><div>LEVOMEPROMAZINE - acts on multiple receptors, last resort</div>
"<font color=""#800080"">Can you prescribe two anti-emetics?</font>"	Yes if DIFFERENT method of action<div><br /></div><div>One is sufficient in 2/3rd of pts</div>
"<font color=""#800080"">Causes of spinal cord compression</font>"	Occurs in 5-10% of cancer<div><br /></div><div>BONE METS - breast, lung, prostate account for 50% (also myeloma, NH lymphoma, renal).</div><div><br /></div><div><br /></div>
"<font color=""#800080"">Features of cord compression</font>"	Pain in &gt;90% - radicular band like pain<div>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- predates other symptoms</div><div>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - worse extending neck or coughing</div><div><br /></div><div>Weakness in &gt;75%</div><div><br /></div><div>Sensory level &gt;50% (late)</div><div><br /></div><div>Bladder dysfunction &gt;40% (late)</div><div><br /></div><div>Usually THORACIC (60-80%)</div>
"<font color=""#800080"">Mx of spinal cord compression</font>"	<div><b>MRI within 24hrs</b> if high suspicion</div><div><br /></div>Corticosteroids - <b>DEXAMETHASONE 16mg IV stat then 8mg BD PO</b><div><br /></div><div>Urgent <b>SURGICAL DECOMPRESSION</b> + mechanical stabilisation</div><div>(better than radiotherapy alone, most benefit if single site)</div><div><br /></div><div>Urget <b>RADIOTHERAPY</b> + continue steroids</div><div>(90% ambulatory after DXT if no bony compression)</div>
"<font color=""#800080"">Prognosis of cord compression</font>"	No mobility recovery - 3 MONTHS<div><br /></div><div>If walking after Rx - 5 to 8 MONTHS</div>
"<font color=""#800080"">Definition of malignant hypercalcaemia</font>"	Corrected calcium &gt;2.6mmol/L<div><br /></div><div>Occurs in 10-20% pts with cancer</div><div><br /></div><div>Up to 50% if breast or myeloma</div><div><br /></div><div>Associated with metastatic disease (80%)</div>
"<font color=""#800080"">Pathogenesis of malignant hypercalcaemia</font>"	Cancer secreted parathyroid hormone related protein - PTHrP<div><br /></div><div>Not detectable in the immunoassay for PTH</div><div><br /></div><div>But PTH levels V.LOW</div><div><br /></div><div>Stimulates osteoclastic bone resorption + impairs calcium renal excretion&nbsp;</div>
"<font color=""#800080"">What % of cases of malignant hypercalcaemia are due to skeletal metastases?</font>"	80%
"<font color=""#800080"">Features of malignant hypercalcaemia</font>"	MILD:<div>Polyuria + polydipsia</div><div>Fatigue + lethargy</div><div>Mental dullness</div><div>Anorexia + constipation</div><div><br /></div><div>SEVERE:</div><div>N+V</div><div>Ileus</div><div>Delerium</div><div>Drowsines</div><div>Coma</div><div><br /></div><div>If untreated, Ca &gt;4mmol/L = FATAL</div>
"<font color=""#800080"">Mx of malignant hypercalcaemia</font>"	Treat if &gt;2.8mmol/L and symptomatic/ first episode<div><br /></div><div>1) FLUIDS - IV saline up to 6L/24hrs</div><div>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - promotes calciuresis</div><div><br /></div><div>2) BISPHOSPHONATES - inhibit osteoclasts</div><div>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - dose depends on GFR + Ca2+&nbsp;</div><div>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- PAMIDRONATE 60-90mg IV if GFR normal</div><div>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- onset of effect &lt;3days</div><div><br /></div><div>3) HALOPERIDOL - central anti-emetic</div><div>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- anti-psychotic</div><div><br /></div><div>4) Motility agent for constipation e.g. senna</div>
"<font color=""#800080"">Causes of SVC obstruction</font>"	Extrinsic compression by mets to upper mediastinal lymph nodes<div>- Lung Ca responsible for 80% and occurs in 15% of lung Ca pts</div><div>- Others associated inc. lymphoma, breast, testicular seminoma<br /><div><br /></div><div>Intravascular extension or thrombosis can contribute</div></div>
"<font color=""#800080"">Features of SVC obstruction</font>"	DYSPNOEA<div><br /></div><div>NECK SWELLING</div><div><br /></div><div>TRUNK + ARM SWELLING</div><div><br /></div><div>CHOKING SENSATION</div><div><br /></div><div>THORACIC VEIN DISTENSION</div><div><br /></div><div>FACIAL OEDEMA</div><div><br /></div><div>TACHYOPNEA</div><div><br /></div><div>I LOVE CAPS LOCK SO MUCH</div>
"<font color=""#800080"">Mx of SVC obstruction</font>"	1) DEXAMETHASONE 16mg IV STAT (reduce oedema and extrinsic compression)<div><br /></div><div>2) Then 8mg dexamethasone BD PO</div><div><br /></div><div>3) SVC STENT for severe - but needs anticoagulation first</div><div><br /></div><div>4) RADIOTHERAPY to mediastinum - NSCLC</div><div><br /></div><div>5) CHEMOTHERAPY - SCLC or lymphoma</div>
"<font color=""#800080"">Mx of terminal haemorrhage</font>"	STAY WITH PATIENT<div><br /></div><div>Get dark coloured towels&nbsp;</div><div><br /></div><div>Anticipatory prescription of ANXIOLYTIC e.g. Midazolam 10mg IM/buccal</div>
"<font color=""#800080"">What percentage of people die in hospital?&nbsp;</font>"	Over 50%<div><br /></div><div>2/3rds can be anticipated at least 4hrs before</div>
"<font color=""#800080"">Prevalence of depression in medically ill</font>"	Cancer - outpatients - 5-16%<div>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - inpatients 4-15%</div><div>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- palliative 7-49%</div>
"<font color=""#800080"">Diagnosis of depression</font>"	5 or more symptoms with at least 1 of either a) or b)<div>Symptoms for at least 2wks, most of day, nearly every day<br /><div><br /></div><div>a) Depressed mood most of day</div><div>b) Diminished interest/ pleasure</div><div>c) Weight/ appetite loss or gain</div><div>d) Insomnia or hypersomnia</div><div>e) Psychomotor retardation or agitation</div><div>f) Fatigue or loss of energy</div><div>g) Worthlessness or guilt</div><div>h) Loss of concentration</div><div>i) Suicidal ideation</div></div>
"<font color=""#800080"">Mx of depression</font>"	1) Accurate diagnosis<div><br /></div><div>2) Assess suicide risk</div><div><br /></div><div>3) Pyschological Rx e.g. CBT</div><div><br /></div><div>4) Medication</div><div><br /></div>
Medication for depression	1st line:<div>SSRI e.g. SERTRALINE, FLUOXETINE, CITALOPRAM</div><div>SEs inc. headache, GI, risk of bleeding</div><div><br /></div><div>2nd line:</div><div>SNRI VENLAFAXINE (affects BP)</div><div>NaSSA MIRTAZAPINE (weight gain, sedative)</div><div>TCA AMITRIPTILLINE (dry mouth, constipation, seizure threshold).&nbsp;</div>
"<font color=""#800080"">Features of delirium</font>"	Disturbed consciousness - reduced awareness, unable to focus, disturbed sleep-wake cycle<div><br /></div><div>Change in cognition - memory deficit, disorientation, perceptual disturbance</div><div><br /></div><div>Develops over SHORT TIME + FLUCTUATES</div><div><br /></div><div>Normally evidence of MEDICAL CAUSE</div>
"<font color=""#800080"">Rx of delirium</font>"	1) Non-pharmalogical:<div>- correct electrolytes, malnutrition or dehydration</div><div>- mobilise</div><div>- correct sensory deficit</div><div>- minimise isolation</div><div><br /></div><div>2) Pharmalogical:</div><div>- review current meds</div><div>- treat pain (dont use opioids for behavioural symptoms</div><div>- low dose HALOPERIDOL 0.5mg-1mg TDS PO if possible, IM if not (avoid if parkinsonian)</div>
Mechanism of action of diabetes drugs	Increases peripheral sensitivity to insulin - metformin/glucophage<div>Stimulates beta cells in the pancreas to secrete more insulin - sulphonylureas (gliclazide/glipizide/glimpiride)</div><div>Inhibits the breakdown of incretin - gliptins (sitaglipin)</div><div>Stimulates insulin secretion via stimulating GLP-1 - exenatide</div>
Mechanism of action of tolvaptan	Selective arginine vasopressor antagonist at the V<sub>2 </sub>receptor<div><br /></div><div>Blocks reabsorption of water in the collecting duct (but not electrolytes)</div>
Risk factors for venous thromboembolism according to NICE	Active cancer or cancer treatment<div>Age &gt;60 years</div><div>Admission to critical care</div><div>Dehydration</div><div>Known thrombophilias</div><div>BMI &gt;30 kg/m<sup>2</sup></div><div>One or more significant medical co-morbidities</div><div>Personal history/1<sup>st </sup>degree relative with VTE</div><div>HRT</div><div>Oestrogen-containing contraceptive therapy</div><div>Varicose veins with phlebitis</div>
What is amitriptyline used for?	Depression<div>Neuropathic pain</div><div>Sweating (anti-muscarinic effect)</div><div>Bladder spasm&nbsp;(anti-muscarinic effect)</div><div>Drooling/sialorrhoea&nbsp;(anti-muscarinic effect)</div><div>Pathological laughing/crying</div>
What is sertraline used for?	SSRI<div>Depression with predominant anxiety picture</div><div>Cholestatic pruiritus</div>
What is Mirtazapine used for?	NaSSA<div>Depression</div><div>Intractable itch (all cause)</div>
Diagnosis of death?	Absence of the following for 5 minutes:<div>- central pulse</div><div>- heart sounds</div><div><br></div><div>Absence of the following after 5 minutes:</div><div>- pupillary light reflex</div><div>- corneal reflexes</div><div>- motor response to supra-orbital pressure</div>
According to the Mental Capacity Act 2007, how is capacity defined?	When making a decision, and given information, the following is satisfied:<div><br><div>1. Ability to understand the information given</div><div>2. Ability to retain information long enough to do 3 and 4</div><div>3. Ability to weigh up the pros and cons of the decision</div><div>4. Ability to communicate the decision.</div><div><br></div><div>Capacity is decision-specific, independent of cognitive ability, and time specific.</div></div>
According to the DPP, what are the public interest factors which trend toward prosecution in assisted suicide?	<div>The victim was:</div><div>- under 18</div><div>- did not have capacity</div><div>- did not seek encouragement or assistance of the suspect</div><div><br></div><div>The suspect was:</div><div>- not wholly motivated by compassion</div><div>- pressured victim to commit suicide</div><div>- gave specific information via a website or publication</div><div>- paid by the victim</div><div>- acting in his or her capacity as a medical doctor, nurse, other AHP, professional carer and the victim was in his/her care</div>
According to the DPP, what are the public interest factors which trend against prosecution for assisted suicide?	<div>The victim:</div><div>- reached a voluntary, clear, settled and informed decision to commit suicide</div><div><br></div><div>The suspect:</div><div>- was wholly motivated by compassion</div><div>- only gave minor encouragement tor assistance</div><div>- The actions of the suspect were reluctant encouragement or assistance in the face of a determined wish of the victim</div><div>- reported the victims suicide to the police and took part in enquiries/investigation</div>
Categories of evidence?	1a Metaanalysis of RCTs<div>1b RCTs</div><div>2a Non randomised controlled studies</div><div>2b Quasi-experimental studies</div><div>3 Non-experimental descriptive studies (comparative, correlation, case studies)</div><div>4 Expert opinion, consensus documents, clinical committees&nbsp;</div>
Grading strength of recommendations?	A: Directly based on Cat1 evidence without extrapolation<div>B:&nbsp;Directly based on Cat2 evidence, or Cat1 with extrapolation</div><div>C:&nbsp;Directly based on Cat3 evidence,&nbsp;or Cat1/2 with extrapolation</div><div>D:&nbsp;Directly based on Cat4 evidence, or Cat1/2/3 with extrapolation. Indicates there are no good studies or no readily available good studies</div>
What is the definition of 'off-label' drugs?	The use of a drug beyond the marketing authorisation specification, i.e. an unauthorised:<div>- specification</div><div>- dose</div><div>- population</div><div>- preparation</div><div>- route</div>
What is the definition of an 'unauthorised drug'?	A drug without a marketing authorisation for use in humans.&nbsp;
What are the NNTs for anticonvulsants in neuropathic pain?	<div>Post-herpetic neuralgia<br></div>- Carbamazapine 2.5<div>- Gabapentin 3.2</div><div><br></div><div>Diabetic neuropathy:</div><div>- Carbamazapine 2.3</div><div>- Gabapentin 3.8</div><div>- Phenytoin 2.1</div>
What is the evidence for opioids for breathlessness?	A small statistically significant effect for a small population of people (Jennings 2007)
What are the NNT for bisphosponates in bone mets?	- 11 at four weeks of therapy<div>- 7 at twelve weeks of therapy</div>
What is the evidence for benzodiazepines in breathlessness	No significant evidence
Itch in palliative care (cochrane review)	- indomethacin for HIV-associated itch<div>- gabapentin and nalfurafine for itch associated with chronic kidney disease</div><div>- rifampicin and flumecinol for itch associated with liver problems</div><div>- Paroxetine may be a drug of general relevance whatever the cause of the itching</div><div>- Cimetidine for Lymphoma-related itch</div>
What is the management of sweating?	1. Antipyretic:<div>- paracetamol</div><div>- NSAID</div><div><br></div><div>2. Antimuscarinic:</div><div>- amitryptilline</div><div>- hyoscine hydrobromide</div><div>- glycopyrronium</div><div><br></div><div>3. Other options:</div><div>- propranolol</div><div>- cimetidine</div><div>- thalidomide (with caution, as it causes painful peripheral neuropathy)</div>
What is the definition of NNT?	<div>Number needed to treat for one person to benefit</div>Inverse of ARR
What is the definition of absolute risk reduction?	The difference between the control group’s event rate (CER) and the experimental group’s event rate (EER).
What is the relative risk reduction?	A measure calculated by dividing the absolute risk reduction by the control event rate.
What are the risk factors for venous thromboembolism?	<div>- Active cancer or cancer treatment</div><div>- Age &gt; 60 years</div><div>- Critical care admission</div><div>- Dehydration</div><div>- Known thrombophilias</div><div>- Obesity (BMI &gt; 30 kg/m2)</div><div>- One or more significant medical comorbidities (for example: heart disease; metabolic, endocrine or respiratory pathologies; acute infectious diseases; inflammatory conditions)</div><div>- Personal history or first-degree relative with a history of VTE</div><div>- Use of HRT</div><div>- Use of oestrogen-containing contraceptive therapy</div><div>- Varicose veins with phlebitis</div>
What is the inital management of delirium tremens according to NICE?	Oral or parentral lorazepam, then haloperidol or olanzapine
What are the findings of the Acupuncture in cancer pain Cochrane review?	"1. RCTs were identified<div>2. Small sample sizes</div><div>3. Generally of poor quality</div><div>4. I<span style=""font-family: 'Source Sans Pro', sans-serif; font-size: 16px; letter-spacing: -0.3px; line-height: 22.4px;"">nsufficient evidence to judge whether acupuncture is effective in relieving cancer-related pain in adults</span></div>"
What are the phases of a clinical trial?	0 -&nbsp;Pharmacodynamics and pharmacokinetics in humans,&nbsp;the trial documents the absorption, distribution, metabolization, and removal (excretion) of the drug, and the drug's interactions within the body, to confirm that these appear to be as expected.<div><br><div>1 -&nbsp;Screening for safety. Generally small groups,to evaluate safety, determine safe dosage ranges, and begin to identify side effects.</div></div><div><br></div><div>2 -&nbsp;Establishing the efficacy of the drug, usually against a placebo.&nbsp;</div><div><br></div><div>3 -&nbsp;Final confirmation of safety and efficacy.</div><div><br></div><div>4 -&nbsp;Sentry studies during sales, after market authorisation. Postmarketing studies delineate additional information, including the treatment's risks, benefits, and optimal use.</div>
What are the contraindications for ketamine?	- Raised intracranial pressure<div>- Uncontrolled hypertension</div><div>- Recent seizures</div><div>- History of psychosis</div><div>- Delirium</div>
According to NICE, the management of prostate cancer after gosrelin and bicalutamide is?	Docetaxel, but only in men who have progressed on the above, and have a Karnofsky status of 60% or more.&nbsp;<div>10 cycles should be completed.</div><div>It should be stopped at the completion of 10 cycles, adverse reactions or with evidence of disease progression.&nbsp;</div>
What is the QT length which makes you vulnerable to torsade de pointes?	500ms
What is arimidex (anastrozole)?	Non-steroidal aromatase inhibitor
What is&nbsp;Trastuzumab?	A monoclonal antibody.&nbsp;<div>All -mabs are antibodies.</div>
What is loperamide's mode of action?	Mu-receptor agonist.<div>Completely metabolised by first-pass metabolism (CP450) in the liver</div>
What is the level of evidence regarding laxatives and palliative care?	Grade 4 - Consensus, best practice and expert opinion
What is the mode of action of methylnaltrexone?	Peripherally acting mu-receptor antagonist.<div>Used for opioid-related constipation refractory to usual laxatives</div><div>Given SC</div><div>Expensive</div>
In Scotland, what are the three types of power of attorney?	1. Continuing PoA – gives powers to deal with money and/or property<div>2.&nbsp;Welfare PoA – gives powers to make decisions around health or personal welfare matters, only when the person has lost capacity</div><div>3.&nbsp;Combined PoA – gives continuing and welfare powers</div>
What information can you request  under the Freedom of information act? 	Information about the running of an institution eg audit data. 
Within what time period does an institution have to respond to a Freedom of information request? 	20 days
What information can be requested in a Data Protection Act request? 	Personal and confidential data about the requestee only,  or by a named deputy (this has to be confirmed in writing).
Within what time does a response have to be given in a Data Protection request? 	40 days
What is an ordinary power of attorney? 	A document which allows the holder to deal with specific financial decisions whilst the donor has capacity. 
In England and Wales, what types of Lasting power of attorney are there? 	1. Property and Affairs LPA. Entrusts the named person with the responsibility of handling money and property.  Can be when donor has / lacks capacity<br><br>2. Personal Welfare LPA. Decisions re health, welfare and / or treatment. Only when donor has lost capacity. 
What must an LPA be in order to be valid? 	Registered at the Office of the Public Guardian. 
What is the annual mortality for Stage 5 CKD? 	20%
What is the survival benefit of dialysis in patients between 70 and 78?	2 years
What is the survival benefit of dialysis of patients over 79? 	None
What is the median survival on stopping dialysis? 	8 to 10 days
What is the evidence for a NSAID safe in renal failure? 	There is no evidence for a NSAID safe in renal failure. 
What is the EAPC advice regards opioids in an EGFR below 30? 	First choice is fentanil or bupronorphine.
What other drugs have to be reduced in renal failure other than opioids? 	Definitely:<br>insulin<br>digoxin<br>anticoagulants<br><br>Maybe:<br>Gabapentin<br>Pregabalin<br>Amitriptyline<br>Alfentanil (larger free fraction) <br>Metaclopromide
Are pregabalin and gabapentin dialysed out? 	Yes!<br>An extra dose is often required after a dialysis session. 
At what eGFR is itch likely to develop? 	12
What happens to the blood brain barrier in renal failure? 	Increased permeability, so increased risk of CNS side effects. 
What is the max dose of paracetamol in 24h in an eGFR less than 10? 	3g. May be nephrotoxic in high doses. 
What is the equivalent of the IT route to oral route of morphine? 	1:100
Which antipsychotic has the highest risk of extrapyramidal side effects? 	Risperidone
Which is the safest antidepressant to use in epilepsy? 	Citalopram
What is the normal QT interval? 	men <430ms<br>women <450ms<br><br>Above 500ms is high risk for dysrhythmias.
In non cancer surgical patients : <br><br>a) above what period of time should prophylactic lmwh be given?<br><br>b) for how long?  	a) 3 days<br>b) 2 weeks 
What is the evidence  for routine  anticoagulants in indwelling venous catheters? 	RCTs show no benefit in lmwh or warfarin use. 
What is DIC? 	Disseminated intravascular coagulation. Defined by :<br><br>- thrombopenia (<150 in 95%)<br>- decreased or normal fibrinogen<br>- low D -dimers in 85 %
What is the treatment of chronic DIC? 	LMWH
How does chronic DIC present? 	Venous thromboembolism in both superficial and deep veins, which do not respond to warfarin. 
What is the mode of action of tranexemic acid? 	Bind to plasminogen and prevents its binding to fibrin. 
What is the mode of action of etamsylate? 	Increasing capillary vascular wall resistance and adhesiveness of platelets .
Do you need to dose reduce tranexemic acid in renal failure? 	yes! 
What is the effect of desmopressin?	ADH antagonist<br>Augments platelet function 
What is the treatment of spasticity in MS? 	1st line : baclofen<br>2nd line : dantroline, tizanadine<br>3rd line : benzodiazepines<br><br>Sativex is not licenced for MS spasticity. 
What is the 1 year mortality in NYFH class :<br>a) 3<br>b) 4	a) 10 to 15%<br>b) 30 to 40%
What is the mode of action of riluzole ? 	Glutamate inhibitor 
What needs monitoring when starting riluzole? 	Liver function tests
What are the absolute contraindications to organ donation?	<div>Age &gt;85 years (on or after their 85th birthday)</div><div>Primary intra-cerebral lymphoma</div><div>All secondary intracerebral tumours</div><div>Any active cancer with evidence of spread outside affected organ within 3 years of donation</div><div>Melanoma (except completely excised Stage 1 cancers)</div><div>Active (not in remission) haematological malignancy (myeloma, lymphoma, leukaemia)</div><div>Definite, probable or possible case of human transmissible spongiform encephalopathy (TSE), including CJD and vCJD, individuals whose blood relatives have had familial CJD, other neurodegenerative diseases associated with infectious agents.</div><div>TB: active and untreated</div><div>West Nile Virus (WNV) infection</div><div>HIV disease (but not HIV infection)&nbsp;</div>
For what period of time would a personal licence be required for controlled drugs?	3 months
How long prior to travel should you apply for a licence to carry controlled drugs?	10 days
What supersedes an ARDT?	If there is a Personal health and Welfare LPA made and registered <b>after</b>&nbsp;the ARDT.
According to the ONS, 'old age' can be given as the sole cause of death when?	- age &gt;80<div><div>- You have personally cared for the deceased over a long period (years, or many months)</div><div>- You have observed a gradual decline in your patient's general health and functioning</div><div>- You are not aware of any identifiable disease or injury that contributed to the death</div><div>- You are certain that there is no reason that the death should be reported to the coroner&nbsp;</div></div>
What is utilitarianism?	Consequence based theory that advocates an analysis of the overall good achieved by a given action.
What is&nbsp;Casuistry?	A theory which uses history, past paradigmatic cases and factual circumstances to determine appropriate decision making.
What is&nbsp;Deontology?	A philosophical theory which advocates that actions are morally right if they are consistent with a predetermined moral rule.
What are&nbsp;Virtue ethics?	A theory which emphasises the pursuit of virtuous characteristics by healthcare providers.
What is&nbsp;Kantian thought?	A theory which states that there are absolute moral requirements on actions that can be determined through the use of certain categorical imperatives.
Who can register a death?	<div>- relatives of the deceased,</div><div>- someone present at the death,</div><div>- an administrator from the hospital,</div><div>- the person making arrangements with the funeral directors.</div>
What would make an ADRT invalid?	<div>- The person withdrew the decision while they still had capacity.</div><div>- After making the ADRT the person made a Lasting Power of Attorney (LPA) giving an attorney authority to make treatment decisions that are the same as those covered by the advance decision.</div><div>- The person has done something that clearly goes against the advance decision which suggests that they have changed their mind.</div>
Which scenarios would an ADRT <b>not </b>apply?	<div>- Patient still has capacity.</div><div>- If the proposed treatment is not the treatment specified in the advance decisions.</div><div>- If the circumstances are different from those set out in the advance decision.</div><div>- If there are reasonable grounds for believing that there have been changes in circumstance, which would have affected the decision if the person had known about them at the time they made the advance decision.</div>
What is the legal definition of NoK?	There isn't one.&nbsp;Next of kin has no legal meaning but, in practice, hospitals and other organisations generally recognise spouses and close blood relatives as next of kin.
What do the UK ambulance service clinical practice guidelines say about the circumstances in which they can withold CPR?	<div>If:</div><div>- A formal DNAR order is in place</div><div>- The patient is in the final stages of a terminal illness where death is imminent and unavoidable and CPR would not be successful, but for whom no formal DNAR decision has been made</div><div>- An Advance Decision (Living Will) has been accepted by the treating physician (patient’s GP or hospital Consultant) as a DNAR order</div>
Who inherits if there is no will?	Spouse/Civil partner (must survive the deceased by at least 28 days)<div>Children - or next closest blood relative</div><div>Living parents (estate is split between them)</div><div><br /></div>
What are the main contraindications for&nbsp;ocular tissue transplantation?	<div>Infection: (HIV, Hep A, B, C, syphilis, behaviour leading to increased risk of HIV, Hep B and C, viral encephalitis, viral meningitis, rabies, congenital rubella, tuberculosis, Reyes syndrome, PML, septicaemia (answer C), active malaria).</div><div><br /></div><div>Previous surgery: receipt of an organ transplant, receipt of dura mater/spinal surgery before August 1992, receipt of pituitary derived hormones, receipt of a corneal, sceral or limbal graft.</div><div><br /></div><div>Unknown aetiology and CNS disorders: death from an unknown cause, CJD and CNS disease of unknown aetiology [Alzheimer's disease, other dementias, Parkinson's disease, MS], MND, ME.</div><div><br /></div><div>Malignancies and Pre-malignancies: Leukaemia, lymphoma, myeloma, sideroblastic anaemia, polycythaemia rubra vera</div><div><br /></div><div>Eye Disease: Ocular inflammation (including extra-articular manifestations of autoimmune disease), any congenital or acquired disorders of the eye, or corneal refractive surgery that would preclude successful graft outcome, retinoblastoma, malignant tumours of the anterior segment.</div>
What are the different theories of learning?	Humanistic:&nbsp;each individual is unique and has a desire to grow positively. Assumes a hierarchy of need which motivates.<div><br /><div>Behaviourist:Learning is in response to external stimuli without any intention by the learner. Focuses on positive reinforcement and repetition to change behaviour.</div></div><div><br /></div><div>Cognitive:&nbsp;Considers cognition to be the key to learning.</div><div><br /></div><div>Social:&nbsp;Much learning is by observation, other individuals provide role models for how we think, feel and act, and their influence should not be underestimated.</div><div><br /></div><div>Psychodynamic:&nbsp;past experiences and internal forces such as emotional conflicts and ego shape motivation and learning.</div>
What can an IMCA do?	Has the authority to make enquiries about the patient and contribute to the decision by representing the patient's interests, but <b>cannot make a decision on behalf of the patient</b>.
How is a clinical risk rating calculated?	Risk score = consequence score x likelihood score<div><br /></div><div>It's a probablity of a bad thing occuring often.</div>
What are the major categories of clinical governance?	<div>Accountability</div><div>Clinical Audit</div><div>Clinical risk management</div><div>Clinical effectiveness</div><div>Continuing professional development</div><div>Patient and Public involvement</div><div>Managing information</div>
What does CURB-65 stand for?	<p>C = confusion</p><p>U = urea &gt;7</p><p>R = respiratory rate &gt;30</p><p>B = Diastolic BP &lt;60</p><p>65 = age over 65</p>
In the context of neurological disease and urinary incontinence, to whom should urodynamic studies should be offered according to NICE?	<p>Patient groups who are known to have a high risk of renal complications:</p><p>- spina bifida</p><p>- spinal cord injury</p><p>- anorectal abnormalities</p>
In the context of neurological disease and urinary incontinence, to whom should urodynamic studies&nbsp;not be&nbsp;offered to according to NICE?	<p>Patient groups with a low risk of renal complications:</p><p>- most people with multiple sclerosis</p>
According to NICE, to whom should anti-muscarinic drugs be offered in urinary incontinence in the context of a neurological disorder?	Patient with spinal cord disease (for example, spinal cord injury or multiple sclerosis) <strong>and </strong>symptoms of an overactive bladder such as increased frequency, urgency and incontinence. 
According to NICE, to whom should anti-muscarinic drugs be considered in urinary incontinence in the context of a neurological disorder?	Patients with conditions affecting the brain (for example, cerebral palsy, head injury or stroke) <strong>and</strong> symptoms of an overactive bladder. 
"<p>A patient with a neuromuscular disorder was referred for urodynamic studies for investigation of their urinary incontinence. The report of the study showed impaired bladder storage.</p><p>&nbsp;</p><p>According to NICE '<a title=""View CG148 at NICE website"" href=""http://www.nice.org.uk/guidance/CG148"" target=""_blank"">Urinary incontinence in neurological disease</a> (2012)', what pharmacological treatment should be considered?</p>"	Anti-muscarinic agent.
"According to '<a title=""View CG148 at NICE website"" href=""http://www.nice.org.uk/guidance/CG148"" target=""_blank"">Urinary incontinence in neurological disease</a> (2012)', NICE, when should botulinin A toxin be offered?"	<p>Adults with spinal cord disease (for example, spinal cord injury and multiple sclerosis) <strong>and</strong> with symptoms of an overactive bladder <strong>and</strong> in whom antimuscarinic drugs have proved to be ineffective or poorly tolerated.</p><p>&nbsp;</p><p>Adults with spinal cord disease <strong>and</strong> with urodynamics showing impaired bladder storage <strong>and</strong> in whom antimuscarinic drugs have proved to be ineffective or poorly tolerated.</p>
"According to '<a title=""View CG148 at NICE website"" href=""http://www.nice.org.uk/guidance/CG148"" target=""_blank"">Urinary incontinence in neurological disease</a> (2012)', NICE, what should be explained to the patient and family prior to offering botulinin toxin A?"	A&nbsp;catheterisation regimen is needed in most people with neurogenic lower urinary tract dysfunction after treatment <strong>and</strong> ensure that they are able and willing to manage such a regimen should urinary retention develop after the treatment.
"According to <a title=""View CG148 at NICE website"" href=""http://www.nice.org.uk/guidance/CG148"" target=""_blank"">Urinary incontinence in neurological disease</a> (2012), NICE, when should augmentation cystoscopy be considered?"	In patient groups with non-progressive neurological disorders <strong>and</strong> complications of impaired bladder storage (for example, hydronephrosis or incontinence) <strong>and</strong> only after a thorough clinical and urodynamic assessment and discussion with the patient and/or their family members and carers about complications, risks and alternative treatments. 
"According to <a title=""View CG148 at NICE website"" href=""http://www.nice.org.uk/guidance/CG148"" target=""_blank"">Urinary incontinence in neurological disease</a> (2012), NICE, what are the complications of augmentation cystoscopy?"	"<p>Metabolic effects, such as:</p><p>-&nbsp;vitamin B<sub><font size=""2"">12</font></sub> deficiency</p><p>Other effects:</p><p>- bladder cancer</p>"
"<p>According to '<a title=""View CG148 at NICE website"" href=""http://www.nice.org.uk/guidance/CG148"" target=""_blank"">Urinary incontinence in neurological disease</a> (2012)' NICE, in patient with a high risk of renal complications, what should be offered as screening?</p><p>a) Urodynamic studies</p><p>b) Cystoscopy</p><p>c) Plain abdominal film</p><p>d) Renal scintigaphy</p><p>e) Mid-stream urine culture</p>"	<p>a) Urodynamic studies</p><p>b,c, and d are not to be used.</p><p>USS KUB should be offered at 2 yearly intervals.</p>
What are the signs of neuroleptic malignant syndrome?	<p>Hyperthermia</p><p>Muscle rigidity ('lead pipe')</p><p>Autonomic dysfunction</p><p>Altered mental status</p>
What are the symptoms of serotonin syndrome?	<p>Altered mental state</p><p>Autonomic hyperactivity</p><p>Neuromuscular abnormalities (shivering and myoclonus. These are absent in neuroleptic malignant syndrome)</p>
What is the risk of spinal cord damage with permanent paraplegia and incontinence from a coeliac axis block?	1 in 1000
What is the risk of diarrhoea after a coeliac plexus block?	60% - but it is transient, and usualy resolves within 2 weeks.
What does a cordotomy target?	<p>Midline pain</p><p>Spinothalamic tracts (pain and temperature sensation)</p>
In adult basic life support, what is the ratio of breaths to chest compressions?	2:30
What is the dose of adrenaline to give IM in anaphylaxis?	0.5ml of 1:1000 (500mcg)
<p>You are doing a paracentesis. You look for local anasthetic, and find lidocaine, 2%.</p><p>&nbsp;</p><p>What does this mean?</p><p>a) 2mg lidocaine in 1000ml</p><p>b) Purity of 2% ABV</p><p>c) 20mg lidocaine in 1000ml</p><p>d) The vial needs to be diluted with 2% of the vial in 100ml normal saline</p><p>e) You only need to use 2% of the vial.</p>	c) 20mg in 1000ml
What is nalogexol?	"<p>A pegalated naloxol</p><p>A selective peripheral&nbsp;mu-receptor antagonist</p><p>It is used in opioid-induced constipation symptoms of at least moderate severity in at least <span class=""no-break"">1 of</span> the <span class=""no-break"">4 stool</span> symptom domains (that is, incomplete bowel movement, hard stools, straining or false alarms) while taking at least <span class=""no-break"">1 laxative</span> class for at least <span class=""no-break"">4 days</span> during the prior <span class=""no-break"">2 weeks refractory to the usual laxatives.</span></p>"
Is methylnaltrexone recommended by NICE for use in refractory opioid-related constipation?	No
What is prucalporide?	<p>A selective 5HT4 agonist</p><p>Used in women with constipation</p>
In the NICE guidelines for constipation, when can prucalporide be used?	"<div class=""p"">-&nbsp;treatment of chronic constipation&nbsp;</div><div class=""p"">&nbsp;</div><div class=""p"">-&nbsp;women</div><div class=""p"">&nbsp;</div><div class=""p"">- treatment with at least two laxatives from different classes, at the highest tolerated recommended doses for at least <span class=""no-break"">6 months</span>, has failed to provide adequate relief and invasive treatment for constipation is being considered.</div><div class=""p"">&nbsp;</div><div class=""p"">If treatment with prucalopride is not effective after <span class=""no-break"">4 weeks</span>, the woman should be reexamined and the benefit of continuing treatment reconsidered.</div>"
Who should a patient notify when they have oxygen installed at home?	<p>Fire brigade</p><p>Home insurance</p>
In the Cochrane review for radiotherapy for painful bone mets (2008) what is the evidence of efficacy?	Good evidence of efficacy
In the Cochrane review for radiotherapy for painful bone mets (2008) what is the percentage of patients who have a complete response?	25%
In the Cochrane review for radiotherapy for painful bone mets (2008) what is the percentage of people who have a response of 50%?	40%
In the Cochrane review for radiotherapy for painful bone mets (2008) what is the number needed to treat?	NNT = 4.2 to achieve complete response at 1 month
In the Cochrane review for radiotherapy for painful bone mets (2008), when can an effect be observed?	4 weeks
In the Cochrane review for radiotherapy for painful bone mets (2008) what is the median duration of a complete response?	12 weeks
In the Cochrane Review 'Insertion of a stent improves symptoms in superior vena cava obstruction caused by lung cancer, while chemotherapy and radiotherapy can also be effective (2001)', what proportion of patients are relieved by chemotherapy and radiotherapy?	SCLC - 77%<div>NSCLC - 60%</div>
In the Cochrane Review 'Insertion of a stent improves symptoms in superior vena cava obstruction caused by lung cancer, while chemotherapy and radiotherapy can also be effective (2001)' what is the recurrence rate after chemotherapy and radiotherapy?	17-19%
In the Cochrane Review 'Insertion of a stent improves symptoms in superior vena cava obstruction caused by lung cancer, while chemotherapy and radiotherapy can also be effective (2001)' what is the proportion of patients who report relief after stent insertion?	95% with 92% long-term patency
In the Cochrane Review 'Insertion of a stent improves symptoms in superior vena cava obstruction caused by lung cancer, while chemotherapy and radiotherapy can also be effective (2001)', what is the effect of steroids?	No evidence
In the Cochrane Review 'Coeliac plexus block for pain in pancreatic cancer (2012)' what is the level of evidence?	High level of evidence<div>Small effect (0.42 on 10 point scale)</div>
In the Cochrane Review 'Coeliac plexus block for pain in pancreatic cancer (2012)', after how many weeks can a reduction in opioids be expected?	4 weeks
In the Cochrane Review 'Bisphosphonates for bone pain secondary to bone metastases (2009), what is the level of evidence?	Good level of evidence<div>Effect not immediate</div>
In the Cochrane review 'Interventions for the treatment of metastatic extradural spinal cord compression (2008)', what is the proportion of ambulant patients who remain ambulant after radiotherapy?	~90%
In the Cochrane review 'Interventions for the treatment of metastatic extradural spinal cord compression (2008)', what is the proportion of non-ambulant patients who regain mobility after radiotherapy?	28%
In the Cochrane review 'Interventions for the treatment of metastatic extradural spinal cord compression (2008)', what is the evidence of benefit from decompressive surgery in ambulant patients with poor prognostic features for radiotherapy?	Some evidence of benefit
In the Cochrane Review 'Bisphosphonates in multiple myeloma (2011)' what is the level of evidence that bisphosphonates reduce skeletal events?	Moderate to high evidence
In the Cochrane Review 'Bisphosphonates in multiple myeloma (2011)', what is the level of evidence that bisphosphonates reduce pathological vertebral fractures?	Moderate to high level evidence
In the Cochrane Review 'Bisphosphonates in multiple myeloma (2011)', what is the NNT for skeletal related events?	NNT 6-15
In the Cochrane Review 'Bisphosphonates in multiple myeloma (2011)', what is the NNT to prevent pathological vertebral fractures?	NNT 8-20
In the Cochrane Review 'Bisphosphonates in multiple myeloma (2011)', what is the NNT to prevent pain?	NNT 5-13
According to Cochrane Reviews, what is the level of evidence for antiepileptics in the management of neuropathic pain?	Moderate evidence for pregabalin and gabapentin in the treatment of diabetic neuropathy, postherpetic neuralgia and central neuropathic pain<div><br /></div><div>Evidence of no effect for carbamazapine</div>
According to Cochrane Reviews, what is the level of evidence for combining drugs for chronic neuropathic pain in adults?	Multiple, good quality studies demonstrate superior efficacy<div>Unable to recommend a particular two-drug combination due to heterogeny of evidence</div>
According to Cochrane Reviews, what is the NNH for the use of tramadol in neuropathic pain?	NNH 8.3<div>Effective treatment for neuropathic pain</div>
According to Cochrane Reviews, do diuretics reduce the risk of death from heart failure?	Yes, when compared to placebo
According to Cochrane Reviews, what is the level of evidence that methadone is effective in cancer pain?	RCT level evidence&nbsp;<div>As good as morphine</div><div>No evidence of superiority for neuropathic pain</div>
In Cochrane Reviews, what proportion of patients report an increase in appetite with megesterol?	25%
In Cochrane Reviews, what proportion of patients report slight weight gain with megesterol?	50%
In Cochrane Reviews, what are the reported side effects from megesterol?	Oedema<div>VTE</div><div>Death (1/23 patients)</div>
In Cochrane Reviews, what is the evidence for 5HT3 antagonsists for highly emetogenic chemotherapy?	RCT level evidence<div>Ondansetron and granisetron &nbsp;are equally effective</div>
In Cochrane Reviews, what is the evidence of transdermal fentanyl for cancer pain?	Moderate evidence
What is the evidence that oral morphine is efficacious in cancer pain?	Cochrane review<div>Good evidence of efficacy</div><div>&gt;90% had pain scores &lt;3 on treatment</div><div>No difference between IR/MR</div>
What is the evidence for opioids in neuropathic pain?	Cochrane review<div>Intermediate level evidence, with biased studies</div><div>Unclear long-term efficacy</div>
What is the NNT for opioids in neuropathic pain?	4 for 33% pain relief<div>5.9 for 50% pain relief</div>
What is the level of evidence for NIV in MND?	RCT level&nbsp;
According to Cochrane Reviews, what is the effect of NIV on MND?	Increases median survival by 48 days<div>Maintains quality of life</div>
What is the level of evidence for the treatment of excessive saliva in MND?	RCT level
According to Cochrane Reviews, what is the effect of the treatment of excessive saliva by botox in MND?	Statistically significant reduction at 2 and 4 weeks
According to Cochrane, what is the level of evidence for riluzole for MND?	RCT level
According to Cochrane, what is the effect on survival for riluzole for MND?	Prolongs median survival by 2-3 months
What is the level of evidence that oxycodone is effective in cancer pain?	RCT level<div>Similar levels of efficacy to morphine, no evidence of superiority</div>
What is the evidence for exercise in the management of cancer-related fatigue?	Cochrane<div>Meta-analysis of RCTs</div>
What is the efficacy of exercise in the management of cancer-related fatigue?	Statisically significant improvements
What is the evidence for parasympathomimetic drugs in the treatment of salivary dysfunction due to radiotherapy?	Moderate evidence<div>RCT level</div><div>Pilocarpine &gt;placebo</div>
What is the time to response of parasympathomimetic drugs for the management of salivary gland dysfunction due to radiotherapy?	12 weeks
What is the level of evidence for radioisotopes in bone pain?	RCT level<div>Moderate quality evidence in the short-medium term (1-6 months)</div>
NNT&nbsp;for radioisotopes in bone pain?	Complete pain relief = 8<div>Partial pain relief = 5</div>
NNH for radioisotopes in bone pain?	14
When should&nbsp;radioisotopes in bone pain be reserved for?	Pain refractory to:<div>- radiotherapy</div><div>- bisphosphonates</div><div>- hormone treatments</div>
What is the evidence for the use of codeine or codeine + paracetamol in cancer pain?	RCT level<div>Increased risk of nausea</div>
What is the level of evidence for corticosteroids in malignant bowel obstruction (gynae and GI)?	Low level evidence (unpublished RCTs)
What is the NNT for corticosteroids in malignant bowel obstruction (gynae and GI)?	NNT=6
What is the effect on mortality of corticosteroids in the treatment of malignant bowel obstruction (gynae and GI)?	No effect on mortality
What is the efficacy of amitryptiline in neuropathic pain and fibromyalgia?	Probably doesn't work in HIV or treatments for cancer<div>Probably does work in diabetic neuropathy, post stroke, postherpetic neuralgia, fibromyalgia</div>
How much evidence is there for interventions in cough in cancer?	Insufficient evidence to guide practice
What is the level of evidence for opioids in the treatment of cough in cancer?	Low level evidence<div>Also low level evidence for sodium chromoglycate, linctus and brachytherapy</div>
Laxatives or methynaltrexone for managing constipation in palliative care patients?	Little evidence between different laxatives<div>Methylnaltrexone is effective in opioid-induced constipation where conventional laxatives have failed</div>
What is the evidence for the use of antiepileptics in the treatments of seizures in adults with brain tumours?	No robust, randomised controlled evidence to support a particular choice of antiepileptic<div>Keppra is of equal efficacy as phenytoin</div>
What is the level of evidence for the topical management of dry mouth?	Low level evidence:<div>- saliva substitutes</div><div>- chewing gum</div><div><br /></div><div>No evidence that either is superior to the other</div>
What is the level of evidence that corticosteroids are effective in cancer-related pain?	Weak evidence from poor quality RCTs
What is the level of evidence for the use of amantadine for fatigue in patients with MS?	Weak level of evidence
What is the level of evidence for the use of methylphenidate in cancer-related fatigue?	Weak meta-analysis estimates a superior effect
What is the level of evidence for methylphenidate and pemoline for HIV related fatigue?	Some effect<div>RCT level, moderately sized</div>
What is the evidence for pharmacological treatments in managing fatigue associated with palliative care?	No evidence to support the use of a specific agent
What is the level of evidence to support the use of steroids in fatigue in palliative care?	Insufficient
What is the level of evidence for the use of palliative pharmacological sedation in the terminally ill?	Insufficient evidence for quality of life<div>Low level, poor quality evidence that it does not hasten death</div>
What is the level of evidence for medically assisted hydration?	Insufficient evidence
What is the level of evidence for medically assisted nutrition?	Insufficient evidence
What is the level of evidence for PEG feeding in MND?	No RCTs<div>Insufficient evidence</div>
What is the level of evidence for blood transfusion in advanced cancer?	No RCTs<div>Insufficient evidence</div><div>Low level evidence for subjective benefits which wane after 2 weeks</div>
What is the level of evidence for TENS in cancer pain?	Insufficient evidence
What is the level of evidence for the pharmacological and non-pharmacological treatment of intractable hiccups (&gt;48h)?	Insufficient evidence
What is the evidence for the use of drug therapy for delirium in terminally ill patients?	AIDS - haloperidol and chlorpromazine show similar efficacy, lorazepam ineffective and causes significant side effects<div>Insufficient evidence overall</div>
What is the evidence for the use of thalidomide in cancer cachexia?	Insufficient evidence
What is the evidence for the use of medication for anxiety in palliative care?	Insufficient evidence
What is the evidence for the efficacy of treating oral candidiasis for patients with cancer?	Insufficient evidence for efficacy or non-efficacy
What is the evidence for the use of clonazepam in neuropathic pain/fibromyalgia?	Insufficient evidence
What is the evidence for the use of end of life pathways improving outcomes in caring for the dying?	Insufficient evidence
What is the evidence for the use of exercise in cancer cachexia?	No RCTs<div>Insufficient evidence</div>
What is the evidence for the use of levomepromazine in nausea/vomiting?	No RCTs, but uncontrolled studies suggest efficacy<div><br /></div>
What is the evidence for the use of drugs in death rattle?	No evidence
What is the evidence of the use of calcitonin in metastatic bone pain?	No evidence of improvement in pain/complications/quality of life or survival
What is the evidence of efficacy for steroids in IPF?	No evidence<div><br /></div><div>BUT - there is evidence of efficacy in <b>UPF and non-specific instititial pneumonia</b></div>
What is the evidence for home O<sub>2</sub>&nbsp;in instititial lung disease?	No benefit in the single RCT
What is the evidence for nebulised morphine for severe interstitial lung disease?	No evidence of benefit from the single RCT
What is the level of evidence for neuromuscular stimulation and chest wall vibration in breathlessness?	High level of evidence
What is the level of evidence for walking aids and breathing exercises in breathlessness?	Moderate level of evidence
What is the level of evidence for acupuncture in breathlessness?	Low level of evidence
What is the level of evidence for music therapy in breathlessness?	No evidence
What is the level of evidence for fans, relaxation, councelling and psychotherapy in breathlessness?	Insufficient evidence
What is the level of evidence for NSAIDS or paracetamol in cancer pain?	Moderate level: NSAIDs &gt; placebo<div>No evidence: combining opioid and NSAID</div>
What is the level of evidence of the impact of opioids on conscious level, thirst and appetite?	77 studies<div>Poor study quality<div>Mixed results, with no direct evidence that opioids affect&nbsp;conscious level, thirst or appetite.</div></div>
According the DVLA, for how long should a licence holder not drive after an unprovoked seizure in the following?<div><br /></div><div>a) Category 1 licence</div><div>b) Category 2 licence</div>	a) 6 months<div>b) 5 years</div>
According the DVLA, for how long should a licence holder not drive after a provoked seizure or diagnosis of epilepsy in the following?<div><br /></div><div>a) Category 1 licence</div><div>b) Category 2 licence</div>	a) 12 months<div>b) 10 years</div>
According the DVLA, for how long should a licence holder not drive after a loss of consciousness in vasovagal syncope?&nbsp;	If good Hx or no provocation, no driving restructions
If a person has lost consciousness once, and is found to be of a CVS origin, what is the effect on their licence to drive?	Category 1 licence: not to drive for 6 months&nbsp;<div>Category 2 licence: not to drive for 12 months&nbsp;</div>
If a person has lost consciousness twice, and is found to be of a CVS origin, what is the effect on their licence to drive?	Category 1: not to drive for 12 months<div>Category 2: not to drive for 5 years</div>
If a person has a neurological disorder (i.e. MND, MS) what is the effect on their licence to drive?	Can continue to drive following medical assessment.<div>Stricter controls for licence 2 holders.</div>
If a person has a TIA/CVA, what is the effect on their licence to drive?	Category 1: not drive for 1 month<div>Category 2: not drive for 1 year</div><div><br /></div><div>After this period, depends on residual deficit</div>
If a person has a malignant brain tumour, what is the effect on their licence to drive?	<div>Category 1:</div>- Low grade tumour: 1 year off from the completion of treatment<div>- High grate tumour/multiple brain mets: 2 years off driving from completion of treatment</div><div>- solitary met: consider relicencing 1 year post treatment if completely excised and recurrence free</div><div><br /></div><div>Category 2:</div><div>- licence to drive revoked</div>
If a person has angina, what is the effect on their licence to drive?	Avoid driving when getting angina at rest<div>Restart when symptom controlled</div>
If a person has ACS/NSTEMI, what is the effect on their licence to drive?	Can drive:<div>- 1 week after PCI</div><div>- 4 weeks after CABG/not revascularised</div>
If a person has an arrhythmia, what is the effect on their licence to drive?	Avoid driving if likely to compromise
If a person has a PPM, what is the effect on their licence to drive?	Avoid driving for 1 week post insertion
If a person has an ICD, what is the effect on their licence to drive?	Avoid driving for 6 months post-insertion/post theraputic shock<div>Avoid driving for 1 month post prophylactic shock</div>
If a person has diabetes, what is the effect on their licence to drive?	Can drive if:<div>- no hypo within a year requiring help</div><div>- hypo awareness</div><div><br /></div><div>Inform DVLA if:</div><div>- lose hypo awareness</div><div>- &gt;1 severe hypo in 12 months</div><div>- starting insulin</div><div>- visual changes in both eyes</div><div>- circulatory changes</div><div>- neuropathy</div>
If a person has severe anxiety/depression, what is the effect on their licence to drive?	Needs medical assessment
If a person has acute psychosis, what is the effect on their licence to drive?	<div>Category 1: Avoid driving for 3 months</div><div>Category 2: Avoid driving for 3 years</div>
If a person has dementia, what is the effect on their licence to drive?	Needs formal assessment
If a person has alcohol dependence, what is the effect on their licence to drive?	Refrain from driving until post 12 months abstinence
If a person has evidence of drug misuse of opiates/BZD/ketamine, what is the effect on their licence to drive?	Stop driving until 1 year drug-free
If a person is currently taking an opiate/BZD/ketamine for theraputic reasons, and is found to be impaired whilst driving by the police, what is the effect on their licence to drive?	Proceed to procecution under Drug Driving legislation<div>If a patient is doubt about their performace being impaired, they should not drive</div>
What is the mode of action of tapentadol?	Centrally acting mu-receptor agonist<div>NA reuptake inhibitor</div>
What is the guidance regarding targinact?	NICE: no guidance<div>SMC: not approved</div>
What is the marketing authorisation of melatonin?	- primary insomnia in adults &gt;55 years<div>- secondary insomnia<br /><div>- sleep-phase disorder</div></div>
What is the marketing authorisation for targinact?	Severe pain which can only be managed by opioids
What is the marketing authorisation for tapentadol?	Severe chronic pain
What is the mode of action of melatonin?	Pineal gland hormone which acts on the suprachiamatic nucleus (SCN)(circadian pacemaker in hypothalamus).&nbsp;<div>Suppresses the wakefulness-promoting activity of the SCN via MT1 receptors</div>
What is the NNT for melatonin?	5-9
What is the NNH for melatonin?	&gt;33
What groups of patients has melatonin been demonstrated to be most useful?	Brain injury<div>Haemodialysis patients</div><div>Shift work</div><div>Jet lag</div>
What is the marketing authorisation for denosumab?	A:&nbsp;<div>- Primary/secondary prevention of osteoporotic fragility fractures</div><div>- Post menopausal women</div><div>- Unable to take standard treatment</div><div><br /></div><div>B:</div><div>- Prevention of skeletal events</div><div>- Adults with bone mets from breast ca and solid tumours (not prostate in general)</div><div>- Men with prostate cancer on an androgen deprivation drug, who have osteoporosis</div><div>- Where a bisphosponate would have been prescribed</div><div>- With a patient access scheme discount</div>
What is the mode of action of denosumab?	Monoclonal antibody which binds to RANKL<div>Inhibits osteoclast formation/function/survival</div>
Do you need to monitor renal function with denosumab?	No, and no dose adjustment
What is the NICE guidance for the use of rivaroxaban?	- In VTE post hip/knee surgery<div>- Treatment of DVT and prophalaxis for recurrent VTE</div><div>- Alternative to warfarin in non-valvular AF with risk factors</div>
What is the mechanism of action of rivaroxaban?	Factor Xa inhibitor
What is the level of evidence for rivaroxaban?	RCT<div>When compared to LMWH - little evidence in a cancer population</div>
What is the marketing authorisation for aprepitant?	Prevention of acute and delayed chemotherapy-induced nausea and vomiting<div>Prevention of post-operative nausea and vomiting</div>
What is the mechanism of action of aprepitant?	Selective NK-1 receptor antagonist<div>Increases 5HT3 and dexamethasone activity</div>
What is the marketing authorisation for a granisetron patch?	Prevention of N/V associated with moderate-highly emetogentic chemotherapy, where orals are inappropriate
What is the mechanism of action of a gransetron patch?	Highly selective 5HT<sub>3 </sub>antagonist<div>Max concentration at 24-28 hours</div>
Which chemotherapies is alopecia commonly seen in?	<div>Common in:</div>- Epirubicin<div>- Docetaxel</div><div>- Doxorubicin</div><div>- Etoposide</div><div>- Paclitaxel</div><div><br /></div>
Which chemotherapies is there an moderate risk of alopecia?	Cyclophosphomide
In chemoptherapy-related alopecia, what can be used to reduce its incidence?	Cold caps<div>Can't be used in leukaemia/lymphoma</div>
In which chemotherapies are there an high risk of vomiting?	Cisplatin<div>Cyclophosphomide</div><div>Ifosdamide</div><div>Melphalan</div>
Which chemotherapies is there a risk of peripheral neuropathy?	Vincristin<div>Platinum-based agents</div><div>Taxanes</div><div>Thalidomide</div><div>Etoposide</div>
Which chemotherapies is there a risk of pulmonary side-effects?	"Bleomycin:<div>- 20% risk of pneumonitis</div><div>- increased chance with high-flow<span style=""font-size: 17px"">&nbsp;oxygen</span></div><div><br /></div><div><span style=""font-size: 17px;"">Methotrexate:</span></div><div><span style=""font-size: 17px;"">- reversible with steroids</span></div><div><span style=""font-size: 17px;""><br /></span></div><div><span style=""font-size: 17px;"">Busulphan, cyclophosphamide and fludaribine</span></div>"
Which chemotherapies is there a risk of reversible cardiomyopathy?	Trastuzamab (Herceptin):<div>- a <b>third</b>&nbsp;of patients can be affected by a reduction in LVEF</div><div>- stop if EF &lt;50%</div><div>- <b>mostly reversible</b> on stopping</div><div>- Oncologist should redecide if to restart</div><div><br /></div><div><br /></div>
Which chemotherapies are there a risk of irreversible cardiomyopathy?	<div>Anthracyclines (<b>doxorubicin, epirubicin, mitoxantrone</b>):</div><div>- can appear within a year of last Rx</div><div>- heart failure can occure within 10 years&nbsp;</div><div>- <b>Irreversible and dose-related</b></div><div>- 30% with high-dose doxorubicin</div>
Which chemotherapies is there a risk of Hand-Foot syndrome/Palma-plantar erythrodyesthesia?	Capecitabine<div>Fluorouracil</div><div>Doxorubicin</div>
Which chemotherapies have a risk of joint pain?	Docetaxel
What are the side effects of LH blockers?	In men (goserelin, buserelin):<div>- impotence</div><div>- Hot flushes/sweating</div><div>- Tumour flare at start to Rx</div><div>- joint pains</div><div><br /></div><div>In women (leuprorelin), in addtion to the above:</div><div>- menopausal symptoms</div>
What are the effects of anti-androgens such as bicalutamide?	- some impotence<div>- some flushes</div><div>- gynaecomastia/breast tenderness (Rx tamoxifen)</div><div>- hepatotoxicity</div>
What are the effects of anti-oestrogens like tamoxifen?	- menopausal symptoms<div>- reduced libido</div><div>- vaginal dryness</div><div>- increased risk of VTEs</div><div>- endometrial hyperplasia and increased risk of cancer</div>
What are the effects of aromatase inhibitors (exemestane, anastrazole, letrozole)?	- menopausal symptoms<br /><div>- increased fractures</div><div>- joint pain</div><div>- reduced libido</div><div>- nausea</div><div>- skin rashes</div>
When should aromatase inhibitors (exemestane, anastrazole, letrozole) be used?	<b>Post-menopausal</b> breast cancer
What is the mode of action of abiraterone?	Enzyme inhibitor which acts on all tissues producing testosterone to reduce circulating levels
What should abiraterone be taken with?	Prednisolone
What are the side effects of abiraterone?	Fluid retention<div>Hypertension</div><div>Fatigue</div><div>Hepatotoxicity</div>
When should herceptin be used?	HER+2 breast cancer<div>Gastric cancers</div>
What are the side effects of herceptin?	Flu-like reaction<div>One third have diarrhoea</div><div>Reversible cardiomyopathy</div>
What is the mode of action of gefitinib/erlotinib?	Tyrosine kinase inhibitor
What is the indication of gefitinib/erlotinib?	"<div>First line:</div>- EGFR +ve, locally advanced NSCLC<div><br /></div><div>Second line:</div><div>- E<span style=""font-family: 'Liberation Sans'"">rlotinib only</span></div><div><span style=""font-family: 'Liberation Sans';"">- EGFR -ve cancer post chemotherapy</span></div>"
What are the side effects of gefitinib/erlotinib?	Acneform rash<div>Diarrhoea</div><div>Abnormal LFTs</div>
Anti-parkinson's medications should not be withdrawn abruptly as this can lead to&nbsp;<span class=cloze>[...]</span>	Anti-parkinson's medications should not be withdrawn abruptly as this can lead to&nbsp;<span class=cloze>acute akinesia or neuroleptic malignant syndrome</span><br><br>
Apomorphine should be reserved for Parkinson's patients with&nbsp;<span class=cloze>[...]</span>	Apomorphine should be reserved for Parkinson's patients with&nbsp;<span class=cloze>severe motor complications refractory to medication</span><br><br>
<span class=cloze>[...]</span> can worsen autonomic dysfunction in Parkinson's disease, so&nbsp;SSRIs or mirtazapine are preferred instead.	<span class=cloze>Tricyclic antidepressants</span> can worsen autonomic dysfunction in Parkinson's disease, so&nbsp;SSRIs or mirtazapine are preferred instead.<br><br>
Tricyclic antidepressants can worsen autonomic dysfunction in Parkinson's disease, so&nbsp;<span class=cloze>[...]</span> instead.	Tricyclic antidepressants can worsen autonomic dysfunction in Parkinson's disease, so&nbsp;<span class=cloze>SSRIs or mirtazapine are preferred</span> instead.<br><br>
Avoid using <span class=cloze>[...]</span> as an antipsychotic in Parkinson's disease as it has a high risk of extrapyramidal side effects.	Avoid using <span class=cloze>risperidone</span> as an antipsychotic in Parkinson's disease as it has a high risk of extrapyramidal side effects.<br><br>
Avoid using risperidone as an antipsychotic in Parkinson's disease as it has a high risk of <span class=cloze>[...]</span>.	Avoid using risperidone as an antipsychotic in Parkinson's disease as it has a high risk of <span class=cloze>extrapyramidal side effects</span>.<br><br>
<span class=cloze>[...]</span> is considered in Parkinson's patients whose symptoms are&nbsp;refractory to best medical therapy, and are fit, with&nbsp;no mental health problems.	<span class=cloze>Thalamic/subthalamic stimulation</span> is considered in Parkinson's patients whose symptoms are&nbsp;refractory to best medical therapy, and are fit, with&nbsp;no mental health problems.<br><br>
Thalamic/subthalamic stimulation is considered in Parkinson's patients whose symptoms are&nbsp;<span class=cloze>[...]</span>, and are fit, with&nbsp;no mental health problems.	Thalamic/subthalamic stimulation is considered in Parkinson's patients whose symptoms are&nbsp;<span class=cloze>refractory to best medical therapy</span>, and are fit, with&nbsp;no mental health problems.<br><br>
Thalamic/subthalamic stimulation is considered in Parkinson's patients whose symptoms are&nbsp;refractory to best medical therapy, and are fit, with&nbsp;<span class=cloze>[...]</span>.	Thalamic/subthalamic stimulation is considered in Parkinson's patients whose symptoms are&nbsp;refractory to best medical therapy, and are fit, with&nbsp;<span class=cloze>no mental health problems</span>.<br><br>
In Parkinson's disease, <span class=cloze>[...]</span> are potentially triggered by&nbsp;anti-Parkinsonian medication, especially&nbsp;rotigitine and&nbsp;apomorphine.	In Parkinson's disease, <span class=cloze>Psychotic symptoms</span> are potentially triggered by&nbsp;anti-Parkinsonian medication, especially&nbsp;rotigitine and&nbsp;apomorphine.<br><br>
In Parkinson's disease, Psychotic symptoms are potentially triggered by&nbsp;<span class=cloze>[...]</span>, especially&nbsp;rotigitine and&nbsp;apomorphine.	In Parkinson's disease, Psychotic symptoms are potentially triggered by&nbsp;<span class=cloze>anti-Parkinsonian medication</span>, especially&nbsp;rotigitine and&nbsp;apomorphine.<br><br>
In Parkinson's disease, Psychotic symptoms are potentially triggered by&nbsp;anti-Parkinsonian medication, especially&nbsp;<span class=cloze>[...]</span> and&nbsp;apomorphine.	In Parkinson's disease, Psychotic symptoms are potentially triggered by&nbsp;anti-Parkinsonian medication, especially&nbsp;<span class=cloze>rotigitine</span> and&nbsp;apomorphine.<br><br>
In Parkinson's disease, Psychotic symptoms are potentially triggered by&nbsp;anti-Parkinsonian medication, especially&nbsp;rotigitine and&nbsp;<span class=cloze>[...]</span>.	In Parkinson's disease, Psychotic symptoms are potentially triggered by&nbsp;anti-Parkinsonian medication, especially&nbsp;rotigitine and&nbsp;<span class=cloze>apomorphine</span>.<br><br>
The best antiemetic in Parkinson's disease is&nbsp;<span class=cloze>[...]</span> as it&nbsp;does not cross the blood brain barrier, or ondansetron/granisetron, or anti-muscarinics.	The best antiemetic in Parkinson's disease is&nbsp;<span class=cloze>domperidone</span> as it&nbsp;does not cross the blood brain barrier, or ondansetron/granisetron, or anti-muscarinics.<br><br>
The best antiemetic in Parkinson's disease is&nbsp;domperidone as it&nbsp;<span class=cloze>[...]</span>, or ondansetron/granisetron, or anti-muscarinics.	The best antiemetic in Parkinson's disease is&nbsp;domperidone as it&nbsp;<span class=cloze>does not cross the blood brain barrier</span>, or ondansetron/granisetron, or anti-muscarinics.<br><br>
The best antiemetic in Parkinson's disease is&nbsp;domperidone as it&nbsp;does not cross the blood brain barrier, or <span class=cloze>[...]</span>, or anti-muscarinics.	The best antiemetic in Parkinson's disease is&nbsp;domperidone as it&nbsp;does not cross the blood brain barrier, or <span class=cloze>ondansetron/granisetron</span>, or anti-muscarinics.<br><br>
The best antiemetic in Parkinson's disease is&nbsp;domperidone as it&nbsp;does not cross the blood brain barrier, or ondansetron/granisetron, or <span class=cloze>[...]</span>.	The best antiemetic in Parkinson's disease is&nbsp;domperidone as it&nbsp;does not cross the blood brain barrier, or ondansetron/granisetron, or <span class=cloze>anti-muscarinics</span>.<br><br>
In an acute flare of MS&nbsp;<span class=cloze>[...]</span> is used for&nbsp;3-5 days.	In an acute flare of MS&nbsp;<span class=cloze>IV or PO methylprednisolone</span> is used for&nbsp;3-5 days.<br><br>
In an acute flare of MS&nbsp;IV or PO methylprednisolone is used for&nbsp;<span class=cloze>[...]</span>.	In an acute flare of MS&nbsp;IV or PO methylprednisolone is used for&nbsp;<span class=cloze>3-5 days</span>.<br><br>
In managing fatigue in MS,&nbsp;<span class=cloze>[...]</span> has some clinical effect.	In managing fatigue in MS,&nbsp;<span class=cloze>amantadine</span> has some clinical effect.<br><br>
In managing fatigue in MS,&nbsp;amantadine has <span class=cloze>[...]</span>.	In managing fatigue in MS,&nbsp;amantadine has <span class=cloze>some clinical effect</span>.<br><br>
For bladder dysfunction, UTIs should be&nbsp;<span class=cloze>[...]</span>, but there is&nbsp;no role for prophalactic antibiotics.&nbsp;	For bladder dysfunction, UTIs should be&nbsp;<span class=cloze>treated actively</span>, but there is&nbsp;no role for prophalactic antibiotics.&nbsp;<br><br>
For bladder dysfunction, UTIs should be&nbsp;treated actively, but there is&nbsp;<span class=cloze>[...]</span>.&nbsp;	For bladder dysfunction, UTIs should be&nbsp;treated actively, but there is&nbsp;<span class=cloze>no role for prophalactic antibiotics</span>.&nbsp;<br><br>
In MS for nocturia,&nbsp;<span class=cloze>[...]</span> can be used.	In MS for nocturia,&nbsp;<span class=cloze>desmopressin</span> can be used.<br><br>
In MS, if regualar medical therapies fail in urinary incontinence, consider a <span class=cloze>[...]</span>.	In MS, if regualar medical therapies fail in urinary incontinence, consider a <span class=cloze>long term cathether</span>.<br><br>
In MS for the management of spasicity, 1<sup>st </sup>line is&nbsp;<span class=cloze>[...]</span>, 2<sup>nd </sup>line is&nbsp;tizanadine, diazepam, clonazepam or dantrolene.	In MS for the management of spasicity, 1<sup>st </sup>line is&nbsp;<span class=cloze>baclofen or gabapentin</span>, 2<sup>nd </sup>line is&nbsp;tizanadine, diazepam, clonazepam or dantrolene.<br><br>
In MS for the management of spasicity, 1<sup>st </sup>line is&nbsp;baclofen or gabapentin, 2<sup>nd </sup>line is&nbsp;<span class=cloze>[...]</span>.	In MS for the management of spasicity, 1<sup>st </sup>line is&nbsp;baclofen or gabapentin, 2<sup>nd </sup>line is&nbsp;<span class=cloze>tizanadine, diazepam, clonazepam or dantrolene</span>.<br><br>
Baclofen withdrawal syndrome can include symptoms similar to&nbsp;<span class=cloze>[...]</span> and perceptual disturbance (hallucinations, delirium, confusion), in the context of abruptly stopping baclofen.	Baclofen withdrawal syndrome can include symptoms similar to&nbsp;<span class=cloze>neuroleptic malignant syndrome</span> and perceptual disturbance (hallucinations, delirium, confusion), in the context of abruptly stopping baclofen.<br><br>
Baclofen withdrawal syndrome can include symptoms similar to&nbsp;neuroleptic malignant syndrome and perceptual disturbance (hallucinations, delirium, confusion), in the context of <span class=cloze>[...]</span>.	Baclofen withdrawal syndrome can include symptoms similar to&nbsp;neuroleptic malignant syndrome and perceptual disturbance (hallucinations, delirium, confusion), in the context of <span class=cloze>abruptly stopping baclofen</span>.<br><br>
Baclofen withdrawal syndrome can include symptoms similar to&nbsp;neuroleptic malignant syndrome and <span class=cloze>[...]</span>, in the context of abruptly stopping baclofen.	Baclofen withdrawal syndrome can include symptoms similar to&nbsp;neuroleptic malignant syndrome and <span class=cloze>perceptual disturbance (hallucinations, delirium, confusion)</span>, in the context of abruptly stopping baclofen.<br><br>
When should PEG feeding be considered in MS?	Recurrent chest infections<div>Inadequate intake</div><div>Prolonged or distressed feeding times</div><div>NG tube in situ &gt;1 month</div>
In MS, beta-interferon/glatiramer is offered to patients with&nbsp;<span class=cloze>[...]</span>, with&nbsp;2 or more relapses in 2 years and who are&nbsp;mobile &gt;100m.	In MS, beta-interferon/glatiramer is offered to patients with&nbsp;<span class=cloze>relapsing/remitting disease</span>, with&nbsp;2 or more relapses in 2 years and who are&nbsp;mobile &gt;100m.<br><br>
In MS, beta-interferon/glatiramer is offered to patients with&nbsp;relapsing/remitting disease, with&nbsp;<span class=cloze>[...]</span> and who are&nbsp;mobile &gt;100m.	In MS, beta-interferon/glatiramer is offered to patients with&nbsp;relapsing/remitting disease, with&nbsp;<span class=cloze>2 or more relapses in 2 years</span> and who are&nbsp;mobile &gt;100m.<br><br>
In MS, beta-interferon/glatiramer is offered to patients with&nbsp;relapsing/remitting disease, with&nbsp;2 or more relapses in 2 years and who are&nbsp;<span class=cloze>[...]</span>.	In MS, beta-interferon/glatiramer is offered to patients with&nbsp;relapsing/remitting disease, with&nbsp;2 or more relapses in 2 years and who are&nbsp;<span class=cloze>mobile &gt;100m</span>.<br><br>
In MS, beta-interferon/glatiramer is offered to patients with secondary progressive MS when there are&nbsp;<span class=cloze>[...]</span>, and who are&nbsp;mobile &gt;10m, but the disease is&nbsp;not rapidly progressive.	In MS, beta-interferon/glatiramer is offered to patients with secondary progressive MS when there are&nbsp;<span class=cloze>2 or more relapses in 2 years</span>, and who are&nbsp;mobile &gt;10m, but the disease is&nbsp;not rapidly progressive.<br><br>
In MS, beta-interferon/glatiramer is offered to patients with secondary progressive MS when there are&nbsp;2 or more relapses in 2 years, and who are&nbsp;<span class=cloze>[...]</span>, but the disease is&nbsp;not rapidly progressive.	In MS, beta-interferon/glatiramer is offered to patients with secondary progressive MS when there are&nbsp;2 or more relapses in 2 years, and who are&nbsp;<span class=cloze>mobile &gt;10m</span>, but the disease is&nbsp;not rapidly progressive.<br><br>
In MS, beta-interferon/glatiramer is offered to patients with secondary progressive MS when there are&nbsp;2 or more relapses in 2 years, and who are&nbsp;mobile &gt;10m, but the disease is&nbsp;<span class=cloze>[...]</span>.	In MS, beta-interferon/glatiramer is offered to patients with secondary progressive MS when there are&nbsp;2 or more relapses in 2 years, and who are&nbsp;mobile &gt;10m, but the disease is&nbsp;<span class=cloze>not rapidly progressive</span>.<br><br>
"<span style=""font-family: Arial"">In MS, beta-interferon/glatiramer is stopped when?</span>"	Intolerable side effects<div>Loss of ability to walk for 6 months</div><div>Rapid progression &gt;6 months</div><div>2 or more relapses in 1 year</div>
In heart failure&nbsp;<span class=cloze>[...]</span> is indicative of a&nbsp;poor prognosis.	In heart failure&nbsp;<span class=cloze>very high levels of BNP</span> is indicative of a&nbsp;poor prognosis.<br><br>
In heart failure&nbsp;very high levels of BNP is indicative of a&nbsp;<span class=cloze>[...]</span>.	In heart failure&nbsp;very high levels of BNP is indicative of a&nbsp;<span class=cloze>poor prognosis</span>.<br><br>
Treatment for left ventricular failure is 1<sup>st </sup>line&nbsp;<span class=cloze>[...]</span>.&nbsp;<div>2<sup>nd</sup>&nbsp;line&nbsp;spironolactone (especially if&nbsp;NYHF III/IV in the past month),&nbsp;eplenerone,&nbsp;ARB, if Afro-caribbean -&nbsp;hydralazine.</div><div>3<sup>rd </sup>line&nbsp;digoxin if refractory to 1<sup>st</sup>&nbsp;or 2<sup>nd</sup>&nbsp;line treatment, cardioresynchronisation therapy.</div>	Treatment for left ventricular failure is 1<sup>st </sup>line&nbsp;<span class=cloze>ACE inhibitor or ARB if ACE-i intolerant</span>.&nbsp;<div>2<sup>nd</sup>&nbsp;line&nbsp;spironolactone (especially if&nbsp;NYHF III/IV in the past month),&nbsp;eplenerone,&nbsp;ARB, if Afro-caribbean -&nbsp;hydralazine.</div><div>3<sup>rd </sup>line&nbsp;digoxin if refractory to 1<sup>st</sup>&nbsp;or 2<sup>nd</sup>&nbsp;line treatment, cardioresynchronisation therapy.</div><br><br>
Treatment for left ventricular failure is 1<sup>st </sup>line&nbsp;ACE inhibitor or ARB if ACE-i intolerant.&nbsp;<div>2<sup>nd</sup>&nbsp;line&nbsp;<span class=cloze>[...]</span> (especially if&nbsp;NYHF III/IV in the past month),&nbsp;eplenerone,&nbsp;ARB, if Afro-caribbean -&nbsp;hydralazine.</div><div>3<sup>rd </sup>line&nbsp;digoxin if refractory to 1<sup>st</sup>&nbsp;or 2<sup>nd</sup>&nbsp;line treatment, cardioresynchronisation therapy.</div>	Treatment for left ventricular failure is 1<sup>st </sup>line&nbsp;ACE inhibitor or ARB if ACE-i intolerant.&nbsp;<div>2<sup>nd</sup>&nbsp;line&nbsp;<span class=cloze>spironolactone</span> (especially if&nbsp;NYHF III/IV in the past month),&nbsp;eplenerone,&nbsp;ARB, if Afro-caribbean -&nbsp;hydralazine.</div><div>3<sup>rd </sup>line&nbsp;digoxin if refractory to 1<sup>st</sup>&nbsp;or 2<sup>nd</sup>&nbsp;line treatment, cardioresynchronisation therapy.</div><br><br>
Treatment for left ventricular failure is 1<sup>st </sup>line&nbsp;ACE inhibitor or ARB if ACE-i intolerant.&nbsp;<div>2<sup>nd</sup>&nbsp;line&nbsp;spironolactone (especially if&nbsp;<span class=cloze>[...]</span>),&nbsp;eplenerone,&nbsp;ARB, if Afro-caribbean -&nbsp;hydralazine.</div><div>3<sup>rd </sup>line&nbsp;digoxin if refractory to 1<sup>st</sup>&nbsp;or 2<sup>nd</sup>&nbsp;line treatment, cardioresynchronisation therapy.</div>	Treatment for left ventricular failure is 1<sup>st </sup>line&nbsp;ACE inhibitor or ARB if ACE-i intolerant.&nbsp;<div>2<sup>nd</sup>&nbsp;line&nbsp;spironolactone (especially if&nbsp;<span class=cloze>NYHF III/IV in the past month</span>),&nbsp;eplenerone,&nbsp;ARB, if Afro-caribbean -&nbsp;hydralazine.</div><div>3<sup>rd </sup>line&nbsp;digoxin if refractory to 1<sup>st</sup>&nbsp;or 2<sup>nd</sup>&nbsp;line treatment, cardioresynchronisation therapy.</div><br><br>
Treatment for left ventricular failure is 1<sup>st </sup>line&nbsp;ACE inhibitor or ARB if ACE-i intolerant.&nbsp;<div>2<sup>nd</sup>&nbsp;line&nbsp;spironolactone (especially if&nbsp;NYHF III/IV in the past month),&nbsp;<span class=cloze>[...]</span>,&nbsp;ARB, if Afro-caribbean -&nbsp;hydralazine.</div><div>3<sup>rd </sup>line&nbsp;digoxin if refractory to 1<sup>st</sup>&nbsp;or 2<sup>nd</sup>&nbsp;line treatment, cardioresynchronisation therapy.</div>	Treatment for left ventricular failure is 1<sup>st </sup>line&nbsp;ACE inhibitor or ARB if ACE-i intolerant.&nbsp;<div>2<sup>nd</sup>&nbsp;line&nbsp;spironolactone (especially if&nbsp;NYHF III/IV in the past month),&nbsp;<span class=cloze>eplenerone</span>,&nbsp;ARB, if Afro-caribbean -&nbsp;hydralazine.</div><div>3<sup>rd </sup>line&nbsp;digoxin if refractory to 1<sup>st</sup>&nbsp;or 2<sup>nd</sup>&nbsp;line treatment, cardioresynchronisation therapy.</div><br><br>
Treatment for left ventricular failure is 1<sup>st </sup>line&nbsp;ACE inhibitor or ARB if ACE-i intolerant.&nbsp;<div>2<sup>nd</sup>&nbsp;line&nbsp;spironolactone (especially if&nbsp;NYHF III/IV in the past month),&nbsp;eplenerone,&nbsp;<span class=cloze>[...]</span>, if Afro-caribbean -&nbsp;hydralazine.</div><div>3<sup>rd </sup>line&nbsp;digoxin if refractory to 1<sup>st</sup>&nbsp;or 2<sup>nd</sup>&nbsp;line treatment, cardioresynchronisation therapy.</div>	Treatment for left ventricular failure is 1<sup>st </sup>line&nbsp;ACE inhibitor or ARB if ACE-i intolerant.&nbsp;<div>2<sup>nd</sup>&nbsp;line&nbsp;spironolactone (especially if&nbsp;NYHF III/IV in the past month),&nbsp;eplenerone,&nbsp;<span class=cloze>ARB</span>, if Afro-caribbean -&nbsp;hydralazine.</div><div>3<sup>rd </sup>line&nbsp;digoxin if refractory to 1<sup>st</sup>&nbsp;or 2<sup>nd</sup>&nbsp;line treatment, cardioresynchronisation therapy.</div><br><br>
Treatment for left ventricular failure is 1<sup>st </sup>line&nbsp;ACE inhibitor or ARB if ACE-i intolerant.&nbsp;<div>2<sup>nd</sup>&nbsp;line&nbsp;spironolactone (especially if&nbsp;NYHF III/IV in the past month),&nbsp;eplenerone,&nbsp;ARB, if Afro-caribbean -&nbsp;<span class=cloze>[...]</span>.</div><div>3<sup>rd </sup>line&nbsp;digoxin if refractory to 1<sup>st</sup>&nbsp;or 2<sup>nd</sup>&nbsp;line treatment, cardioresynchronisation therapy.</div>	Treatment for left ventricular failure is 1<sup>st </sup>line&nbsp;ACE inhibitor or ARB if ACE-i intolerant.&nbsp;<div>2<sup>nd</sup>&nbsp;line&nbsp;spironolactone (especially if&nbsp;NYHF III/IV in the past month),&nbsp;eplenerone,&nbsp;ARB, if Afro-caribbean -&nbsp;<span class=cloze>hydralazine</span>.</div><div>3<sup>rd </sup>line&nbsp;digoxin if refractory to 1<sup>st</sup>&nbsp;or 2<sup>nd</sup>&nbsp;line treatment, cardioresynchronisation therapy.</div><br><br>
Treatment for left ventricular failure is 1<sup>st </sup>line&nbsp;ACE inhibitor or ARB if ACE-i intolerant.&nbsp;<div>2<sup>nd</sup>&nbsp;line&nbsp;spironolactone (especially if&nbsp;NYHF III/IV in the past month),&nbsp;eplenerone,&nbsp;ARB, if Afro-caribbean -&nbsp;hydralazine.</div><div>3<sup>rd </sup>line&nbsp;<span class=cloze>[...]</span> if refractory to 1<sup>st</sup>&nbsp;or 2<sup>nd</sup>&nbsp;line treatment, cardioresynchronisation therapy.</div>	Treatment for left ventricular failure is 1<sup>st </sup>line&nbsp;ACE inhibitor or ARB if ACE-i intolerant.&nbsp;<div>2<sup>nd</sup>&nbsp;line&nbsp;spironolactone (especially if&nbsp;NYHF III/IV in the past month),&nbsp;eplenerone,&nbsp;ARB, if Afro-caribbean -&nbsp;hydralazine.</div><div>3<sup>rd </sup>line&nbsp;<span class=cloze>digoxin</span> if refractory to 1<sup>st</sup>&nbsp;or 2<sup>nd</sup>&nbsp;line treatment, cardioresynchronisation therapy.</div><br><br>
Treatment for left ventricular failure is 1<sup>st </sup>line&nbsp;ACE inhibitor or ARB if ACE-i intolerant.&nbsp;<div>2<sup>nd</sup>&nbsp;line&nbsp;spironolactone (especially if&nbsp;NYHF III/IV in the past month),&nbsp;eplenerone,&nbsp;ARB, if Afro-caribbean -&nbsp;hydralazine.</div><div>3<sup>rd </sup>line&nbsp;digoxin if refractory to 1<sup>st</sup>&nbsp;or 2<sup>nd</sup>&nbsp;line treatment, <span class=cloze>[...]</span>.</div>	Treatment for left ventricular failure is 1<sup>st </sup>line&nbsp;ACE inhibitor or ARB if ACE-i intolerant.&nbsp;<div>2<sup>nd</sup>&nbsp;line&nbsp;spironolactone (especially if&nbsp;NYHF III/IV in the past month),&nbsp;eplenerone,&nbsp;ARB, if Afro-caribbean -&nbsp;hydralazine.</div><div>3<sup>rd </sup>line&nbsp;digoxin if refractory to 1<sup>st</sup>&nbsp;or 2<sup>nd</sup>&nbsp;line treatment, <span class=cloze>cardioresynchronisation therapy</span>.</div><br><br>
Which drugs in heart failure improve survival?	ACE-i<div>ARBs</div><div>Beta-blockers</div><div>Spironolactone</div>
Which drugs in heart failure improve symptoms?	Loop diuretics<div>Antiarhythmics</div><div>Antianginals</div>
Which drugs in heart failure improve long term prognosis?	Statins<div>Antihypertensives</div><div>Digoxin</div><div>Antiplatelets</div><div>Warfarin</div>
What are the indications for cardioresynchronsation therapy in heart failure?	NYHF III-IV<div>EF&lt;35%</div><div>Ventricular dysynchrony on ECHO or prolonged QRS (&gt;150ms)</div>
What are the indications for an ICD in heart failure?	Secondary prevention of VT/VF<div>EF &lt;35%/QRS &gt;120ms</div><div>Symptoms no worse than NYHF III</div><div>Congenital predisposition to arrhythmias/sudden death</div>
What drugs are to be avoided in heart failure?	Verapamil/diltiazem<div>Amitryptiline</div><div>NSAIDs</div><div>Cyclizine</div><div>Bulking agents for constipation</div><div>Steroids (fluid retention)</div>
In heart failure,&nbsp;<span class=cloze>[...]</span> should be used for acute gout,&nbsp;allopurinol to prevent acute gout.&nbsp;	In heart failure,&nbsp;<span class=cloze>colchicine</span> should be used for acute gout,&nbsp;allopurinol to prevent acute gout.&nbsp;<br><br>
In heart failure,&nbsp;colchicine should be used for acute gout,&nbsp;<span class=cloze>[...]</span> to prevent acute gout.&nbsp;	In heart failure,&nbsp;colchicine should be used for acute gout,&nbsp;<span class=cloze>allopurinol</span> to prevent acute gout.&nbsp;<br><br>
The EAPC document on depression in heart failure recommends&nbsp;<span class=cloze>[...]</span>,&nbsp;sertraline or&nbsp;mirtazapine.	The EAPC document on depression in heart failure recommends&nbsp;<span class=cloze>SSRIs</span>,&nbsp;sertraline or&nbsp;mirtazapine.<br><br>
The EAPC document on depression in heart failure recommends&nbsp;SSRIs,&nbsp;<span class=cloze>[...]</span> or&nbsp;mirtazapine.	The EAPC document on depression in heart failure recommends&nbsp;SSRIs,&nbsp;<span class=cloze>sertraline</span> or&nbsp;mirtazapine.<br><br>
The EAPC document on depression in heart failure recommends&nbsp;SSRIs,&nbsp;sertraline or&nbsp;<span class=cloze>[...]</span>.	The EAPC document on depression in heart failure recommends&nbsp;SSRIs,&nbsp;sertraline or&nbsp;<span class=cloze>mirtazapine</span>.<br><br>
In COPD, patients should be assessed for LTOT when their sats are <span class=cloze>[...]</span>, their&nbsp;FEV1 &lt;30% or there is evidence of&nbsp;cyanosis,&nbsp;polycythaemia,&nbsp;peripheral oedema or&nbsp;raised JVP.	In COPD, patients should be assessed for LTOT when their sats are <span class=cloze>&lt;92%</span>, their&nbsp;FEV1 &lt;30% or there is evidence of&nbsp;cyanosis,&nbsp;polycythaemia,&nbsp;peripheral oedema or&nbsp;raised JVP.<br><br>
In COPD, patients should be assessed for LTOT when their sats are &lt;92%, their&nbsp;<span class=cloze>[...]</span> or there is evidence of&nbsp;cyanosis,&nbsp;polycythaemia,&nbsp;peripheral oedema or&nbsp;raised JVP.	In COPD, patients should be assessed for LTOT when their sats are &lt;92%, their&nbsp;<span class=cloze>FEV1 &lt;30%</span> or there is evidence of&nbsp;cyanosis,&nbsp;polycythaemia,&nbsp;peripheral oedema or&nbsp;raised JVP.<br><br>
In COPD, patients should be assessed for LTOT when their sats are &lt;92%, their&nbsp;FEV1 &lt;30% or there is evidence of&nbsp;<span class=cloze>[...]</span>,&nbsp;polycythaemia,&nbsp;peripheral oedema or&nbsp;raised JVP.	In COPD, patients should be assessed for LTOT when their sats are &lt;92%, their&nbsp;FEV1 &lt;30% or there is evidence of&nbsp;<span class=cloze>cyanosis</span>,&nbsp;polycythaemia,&nbsp;peripheral oedema or&nbsp;raised JVP.<br><br>
In COPD, patients should be assessed for LTOT when their sats are &lt;92%, their&nbsp;FEV1 &lt;30% or there is evidence of&nbsp;cyanosis,&nbsp;<span class=cloze>[...]</span>,&nbsp;peripheral oedema or&nbsp;raised JVP.	In COPD, patients should be assessed for LTOT when their sats are &lt;92%, their&nbsp;FEV1 &lt;30% or there is evidence of&nbsp;cyanosis,&nbsp;<span class=cloze>polycythaemia</span>,&nbsp;peripheral oedema or&nbsp;raised JVP.<br><br>
In COPD, patients should be assessed for LTOT when their sats are &lt;92%, their&nbsp;FEV1 &lt;30% or there is evidence of&nbsp;cyanosis,&nbsp;polycythaemia,&nbsp;<span class=cloze>[...]</span> or&nbsp;raised JVP.	In COPD, patients should be assessed for LTOT when their sats are &lt;92%, their&nbsp;FEV1 &lt;30% or there is evidence of&nbsp;cyanosis,&nbsp;polycythaemia,&nbsp;<span class=cloze>peripheral oedema</span> or&nbsp;raised JVP.<br><br>
In COPD, patients should be assessed for LTOT when their sats are &lt;92%, their&nbsp;FEV1 &lt;30% or there is evidence of&nbsp;cyanosis,&nbsp;polycythaemia,&nbsp;peripheral oedema or&nbsp;<span class=cloze>[...]</span>.	In COPD, patients should be assessed for LTOT when their sats are &lt;92%, their&nbsp;FEV1 &lt;30% or there is evidence of&nbsp;cyanosis,&nbsp;polycythaemia,&nbsp;peripheral oedema or&nbsp;<span class=cloze>raised JVP</span>.<br><br>
If a COPD patient is acidotic/hypercapnic on LTOT, consider&nbsp;<span class=cloze>[...]</span>.	If a COPD patient is acidotic/hypercapnic on LTOT, consider&nbsp;<span class=cloze>NIV</span>.<br><br>
What is the ABG criteria for starting LTOT in COPD?	- PaO<sub>2 </sub>&lt;7.3<div>- PaO<sub>2</sub>&nbsp;&lt;8 with secondary polycythaemia, pulmonary hypertension, peripheral oedema or nocturnal hypoxaemia</div>
In the context of COPD, do not treat cor pulmonale with&nbsp;<span class=cloze>[...]</span>.	In the context of COPD, do not treat cor pulmonale with&nbsp;<span class=cloze>ACE-i, Ca-channel blockers or alpha-blockers</span>.<br><br>
A person who is not troubled by breathlessness except on strenuous exercise is graded on the MRC breathlessness scale at&nbsp;<span class=cloze>[...]</span>.	A person who is not troubled by breathlessness except on strenuous exercise is graded on the MRC breathlessness scale at&nbsp;<span class=cloze>1</span>.<br><br>
A person who is short of breath when hurrying or walking up a slight hill is graded on the MRC breathlessness scale at&nbsp;<span class=cloze>[...]</span>.	A person who is short of breath when hurrying or walking up a slight hill is graded on the MRC breathlessness scale at&nbsp;<span class=cloze>2</span>.<br><br>
A person who walks slower than contemporaries on level ground because of breathlessness, or has to stop for breath when walking at their own pace is graded on the MRC breathlessness scale at&nbsp;<span class=cloze>[...]</span>.	A person who walks slower than contemporaries on level ground because of breathlessness, or has to stop for breath when walking at their own pace is graded on the MRC breathlessness scale at&nbsp;<span class=cloze>3</span>.<br><br>
A person who has to stop for breath after walking ~100m, or after a few minutes on level ground is graded on the MRC breathlessness scale at&nbsp;<span class=cloze>[...]</span>.	A person who has to stop for breath after walking ~100m, or after a few minutes on level ground is graded on the MRC breathlessness scale at&nbsp;<span class=cloze>4</span>.<br><br>
A person who is too breathless to leave the house, or is breathless when dressing or undressing is graded on the MRC breathlessness scale at&nbsp;<span class=cloze>[...]</span>.	A person who is too breathless to leave the house, or is breathless when dressing or undressing is graded on the MRC breathlessness scale at&nbsp;<span class=cloze>5</span>.<br><br>
&nbsp;Bob is fully active, able to carry on all pre-disease performance without restriction.<div><br /></div><div>His Eastern&nbsp;Cooperative Oncology Group score is&nbsp;<span class=cloze>[...]</span>.</div>	&nbsp;Bob is fully active, able to carry on all pre-disease performance without restriction.<div><br /></div><div>His Eastern&nbsp;Cooperative Oncology Group score is&nbsp;<span class=cloze>0</span>.</div><br><br>
Alice is restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.<div><br /></div><div>Her Eastern&nbsp;Cooperative Oncology Group score is&nbsp;<span class=cloze>[...]</span>.</div>	Alice is restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.<div><br /></div><div>Her Eastern&nbsp;Cooperative Oncology Group score is&nbsp;<span class=cloze>1</span>.</div><br><br>
Eve is ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours.<div><br /></div><div>Her Eastern&nbsp;Cooperative Oncology Group score is&nbsp;<span class=cloze>[...]</span>.</div>	Eve is ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours.<div><br /></div><div>Her Eastern&nbsp;Cooperative Oncology Group score is&nbsp;<span class=cloze>2</span>.</div><br><br>
Carol is capable of only limited selfcare; confined to bed or chair more than 50% of waking hours.<div><br /></div><div>Her Eastern&nbsp;Cooperative Oncology Group score is&nbsp;<span class=cloze>[...]</span>.</div>	Carol is capable of only limited selfcare; confined to bed or chair more than 50% of waking hours.<div><br /></div><div>Her Eastern&nbsp;Cooperative Oncology Group score is&nbsp;<span class=cloze>3</span>.</div><br><br>
Bill is completely disabled; cannot carry on any selfcare and totally confined to bed or chair.<div><br /></div><div>His Eastern&nbsp;Cooperative Oncology Group score is&nbsp;<span class=cloze>[...]</span>.</div>	Bill is completely disabled; cannot carry on any selfcare and totally confined to bed or chair.<div><br /></div><div>His Eastern&nbsp;Cooperative Oncology Group score is&nbsp;<span class=cloze>4</span>.</div><br><br>
Frank is dead.<div><br /></div><div>His Eastern&nbsp;Cooperative Oncology Group score is&nbsp;<span class=cloze>[...]</span>.</div>	Frank is dead.<div><br /></div><div>His Eastern&nbsp;Cooperative Oncology Group score is&nbsp;<span class=cloze>5</span>.</div><br><br>
In idiopathic pulmonary fibrosis, NICE&nbsp;<span class=cloze>[...]</span> the use of&nbsp;steroids for treatment.	In idiopathic pulmonary fibrosis, NICE&nbsp;<span class=cloze>do not recommend</span> the use of&nbsp;steroids for treatment.<br><br>But they do recommend it in other types of pulmonary fibrosis, like UPF.
In idiopathic pulmonary fibrosis, NICE&nbsp;do not recommend the use of&nbsp;<span class=cloze>[...]</span> for treatment.	In idiopathic pulmonary fibrosis, NICE&nbsp;do not recommend the use of&nbsp;<span class=cloze>steroids</span> for treatment.<br><br>But they do recommend it in other types of pulmonary fibrosis, like UPF.
In the management of cough in idiopathic pulmonary fibrosis, what do NICE recommend?	Consider:<div>- other causes, like GORD</div><div>- using opioids as a cough suppressant</div><div>- thalidomide, but via a specialist</div>
Riluzole extends tracheostomy-free survival by&nbsp;<span class=cloze>[...]</span> after&nbsp;18 months of treatment.	Riluzole extends tracheostomy-free survival by&nbsp;<span class=cloze>2-4 months</span> after&nbsp;18 months of treatment.<br><br>
Riluzole extends tracheostomy-free survival by&nbsp;2-4 months after&nbsp;<span class=cloze>[...]</span> of treatment.	Riluzole extends tracheostomy-free survival by&nbsp;2-4 months after&nbsp;<span class=cloze>18 months</span> of treatment.<br><br>
What is the NNT for riluzole to delay death at one year?	11
In MND, what is used to initally assess whether NIV is needed?	Sats<div>FVC</div><div>Sniff test</div>
In MND, if the patient's sats are&nbsp;<span class=cloze>[...]</span>, or&nbsp;&gt;92% with lung disease, with other Ix OK - then NIV is not needed.	In MND, if the patient's sats are&nbsp;<span class=cloze>&gt;94% with no lung disease</span>, or&nbsp;&gt;92% with lung disease, with other Ix OK - then NIV is not needed.<br><br>
In MND, if the patient's sats are&nbsp;&gt;94% with no lung disease, or&nbsp;<span class=cloze>[...]</span>, with other Ix OK - then NIV is not needed.	In MND, if the patient's sats are&nbsp;&gt;94% with no lung disease, or&nbsp;<span class=cloze>&gt;92% with lung disease</span>, with other Ix OK - then NIV is not needed.<br><br>
In MND, if a patient's sats are low, check the ABG. If their&nbsp;<span class=cloze>[...]</span> then refer to the NIV service. If their&nbsp;CO<sub>2 </sub>is &gt;6, then urgently refer for NIV within one week.	In MND, if a patient's sats are low, check the ABG. If their&nbsp;<span class=cloze>CO<sub>2 </sub>is normal</span> then refer to the NIV service. If their&nbsp;CO<sub>2 </sub>is &gt;6, then urgently refer for NIV within one week.<br><br>
In MND, if a patient's sats are low, check the ABG. If their&nbsp;CO<sub>2 </sub>is normal then refer to the NIV service. If their&nbsp;<span class=cloze>[...]</span>, then urgently refer for NIV within one week.	In MND, if a patient's sats are low, check the ABG. If their&nbsp;CO<sub>2 </sub>is normal then refer to the NIV service. If their&nbsp;<span class=cloze>CO<sub>2 </sub>is &gt;6</span>, then urgently refer for NIV within one week.<br><br>
Aim to insert a PEG into patients with MND, before their&nbsp;<span class=cloze>[...]</span> or&nbsp;aspiration pneumonia or&nbsp;significant weight loss.	Aim to insert a PEG into patients with MND, before their&nbsp;<span class=cloze>FVC &lt;50%</span> or&nbsp;aspiration pneumonia or&nbsp;significant weight loss.<br><br>
Aim to insert a PEG into patients with MND, before their&nbsp;FVC &lt;50% or&nbsp;<span class=cloze>[...]</span> or&nbsp;significant weight loss.	Aim to insert a PEG into patients with MND, before their&nbsp;FVC &lt;50% or&nbsp;<span class=cloze>aspiration pneumonia</span> or&nbsp;significant weight loss.<br><br>
Aim to insert a PEG into patients with MND, before their&nbsp;FVC &lt;50% or&nbsp;aspiration pneumonia or&nbsp;<span class=cloze>[...]</span>.	Aim to insert a PEG into patients with MND, before their&nbsp;FVC &lt;50% or&nbsp;aspiration pneumonia or&nbsp;<span class=cloze>significant weight loss</span>.<br><br>
How long can a PEG last?	18 months to 5 years
What is the drug treatment for Alzheimer's dementia?	1<sup>st </sup>line: anticholinesterase inhibitors, for mild-moderate Alzheimers (donezepil, rivastigmine, galantamine)<div><br /></div><div>2<sup>nd</sup>&nbsp;line: NMDA receptor antagonist (memantine), for severe Alzheimers</div>
What is the recommended drug treatment for vascular dementia?	Drugs not recommended
In the NICE guidelines for dementia, regarding behaviours which challenge, most of these will usually stop after&nbsp;<span class=cloze>[...]</span> with no treatment.	In the NICE guidelines for dementia, regarding behaviours which challenge, most of these will usually stop after&nbsp;<span class=cloze>4 weeks</span> with no treatment.<br><br>
<span class=cloze>[...]</span> is the only licenced antipsychotic used in dementia. The licence is for&nbsp;6 weeks, NICE recommend up to&nbsp;12 weeks.	<span class=cloze>Risperidone</span> is the only licenced antipsychotic used in dementia. The licence is for&nbsp;6 weeks, NICE recommend up to&nbsp;12 weeks.<br><br>
Risperidone is the only licenced antipsychotic used in dementia. The licence is for&nbsp;<span class=cloze>[...]</span>, NICE recommend up to&nbsp;12 weeks.	Risperidone is the only licenced antipsychotic used in dementia. The licence is for&nbsp;<span class=cloze>6 weeks</span>, NICE recommend up to&nbsp;12 weeks.<br><br>
Risperidone is the only licenced antipsychotic used in dementia. The licence is for&nbsp;6 weeks, NICE recommend up to&nbsp;<span class=cloze>[...]</span>.	Risperidone is the only licenced antipsychotic used in dementia. The licence is for&nbsp;6 weeks, NICE recommend up to&nbsp;<span class=cloze>12 weeks</span>.<br><br>
In the management of behaviours which challenge in the context of dementia, BZDs have&nbsp;<span class=cloze>[...]</span> and may&nbsp;increase risk of a fall.	In the management of behaviours which challenge in the context of dementia, BZDs have&nbsp;<span class=cloze>no evidence of benefit</span> and may&nbsp;increase risk of a fall.<br><br>
In the management of behaviours which challenge in the context of dementia, BZDs have&nbsp;no evidence of benefit and may&nbsp;<span class=cloze>[...]</span>.	In the management of behaviours which challenge in the context of dementia, BZDs have&nbsp;no evidence of benefit and may&nbsp;<span class=cloze>increase risk of a fall</span>.<br><br>
In the context of dementia, there is&nbsp;<span class=cloze>[...]</span> that PEG feeding increases survival, improves nutritional status or reduces pressure ulcers.	In the context of dementia, there is&nbsp;<span class=cloze>no evidence</span> that PEG feeding increases survival, improves nutritional status or reduces pressure ulcers.<br><br>
Bob has an area of skin which is a non-blanchable erythema of intact skin.<div><br /></div><div>He has a&nbsp;<span class=cloze>[...]</span> pressure ulcer.</div>	Bob has an area of skin which is a non-blanchable erythema of intact skin.<div><br /></div><div>He has a&nbsp;<span class=cloze>Grade 1</span> pressure ulcer.</div><br><br>
Alice has an area of skin which appears to be an ulcer. There is partial thickness skin loss involving the epidermis and dermis.<div><br /></div><div>She has a&nbsp;<span class=cloze>[...]</span> pressure ulcer.</div>	Alice has an area of skin which appears to be an ulcer. There is partial thickness skin loss involving the epidermis and dermis.<div><br /></div><div>She has a&nbsp;<span class=cloze>Grade 2</span> pressure ulcer.</div><br><br>
Eve has an area of skin which appears to be an ulcer. There is Full thickness skin loss with visible subcutaneous fat. Bone, tendon and muscle are not exposed.<div><br /></div><div>She has a&nbsp;<span class=cloze>[...]</span> pressure ulcer.</div>	Eve has an area of skin which appears to be an ulcer. There is Full thickness skin loss with visible subcutaneous fat. Bone, tendon and muscle are not exposed.<div><br /></div><div>She has a&nbsp;<span class=cloze>Grade 3</span> pressure ulcer.</div><br><br>
Frank has an area of skin which appears to be an ulcer. There is full thickness tissue loss with exposed bone (or directly palpable), and tendon.<div><br /></div><div>He has a&nbsp;<span class=cloze>[...]</span> pressure ulcer.</div>	Frank has an area of skin which appears to be an ulcer. There is full thickness tissue loss with exposed bone (or directly palpable), and tendon.<div><br /></div><div>He has a&nbsp;<span class=cloze>Grade 4</span> pressure ulcer.</div><br><br>
Prescriptions for Schedule 2, 3 and 4 are valid for&nbsp;<span class=cloze>[...]</span>.	Prescriptions for Schedule 2, 3 and 4 are valid for&nbsp;<span class=cloze>28 days</span>.<br><br>
Prescriptions for schedule 5 controlled drugs are valid for&nbsp;<span class=cloze>[...]</span>.	Prescriptions for schedule 5 controlled drugs are valid for&nbsp;<span class=cloze>6 months</span>.<br><br>
The eGFR is caclulated by the&nbsp;<span class=cloze>[...]</span>.	The eGFR is caclulated by the&nbsp;<span class=cloze>abbreviated Modification of Diet in Renal Disease equation</span>.<br><br>
What is a more accurate calculation of creatinine clearance?	Cockcroft-Gault score
What eGFR is Stage 3 kidney disease?	30 to 59
If the eGFR is 15-29, then the patient has&nbsp;<span class=cloze>[...]</span> kidney disease.	If the eGFR is 15-29, then the patient has&nbsp;<span class=cloze>Stage 4</span> kidney disease.<br><br>
What eGFR does a patient with Stage 5 kidney disease have?	&lt;15
The GFR level where a patient would start dialysis is&nbsp;<span class=cloze>[...]</span>.	The GFR level where a patient would start dialysis is&nbsp;<span class=cloze>~9</span>.<br><br>
What is the management of restless legs in renal impairment?	Low dose clonazepam<div>Low dose gabapentin</div>
A Caldecott Guardian is a senior person responsible for&nbsp;<span class=cloze>[...]</span> and&nbsp;enabling appropriate information-sharing.	A Caldecott Guardian is a senior person responsible for&nbsp;<span class=cloze>protecting the confidentiality of patient and service-user information</span> and&nbsp;enabling appropriate information-sharing.<br><br>
A Caldecott Guardian is a senior person responsible for&nbsp;protecting the confidentiality of patient and service-user information and&nbsp;<span class=cloze>[...]</span>.	A Caldecott Guardian is a senior person responsible for&nbsp;protecting the confidentiality of patient and service-user information and&nbsp;<span class=cloze>enabling appropriate information-sharing</span>.<br><br>
All NHS organisations are&nbsp;<span class=cloze>[...]</span> Caldecott Guardian.	All NHS organisations are&nbsp;<span class=cloze>required to have a</span> Caldecott Guardian.<br><br>
A Caldecott Guardian's role is to ensure the&nbsp;<span class=cloze>[...]</span>.	A Caldecott Guardian's role is to ensure the&nbsp;<span class=cloze>highest practical standards for handling patient identifiable information</span>.<br><br>
The Caldecott Guardian's role is&nbsp;<span class=cloze>[...]</span> and they&nbsp;represent and champion IG requirements/issues at the&nbsp;Board or management level.	The Caldecott Guardian's role is&nbsp;<span class=cloze>strategic</span> and they&nbsp;represent and champion IG requirements/issues at the&nbsp;Board or management level.<br><br>
The Caldecott Guardian's role is&nbsp;strategic and they&nbsp;<span class=cloze>[...]</span> at the&nbsp;Board or management level.	The Caldecott Guardian's role is&nbsp;strategic and they&nbsp;<span class=cloze>represent and champion IG requirements/issues</span> at the&nbsp;Board or management level.<br><br>
The Caldecott Guardian's role is&nbsp;strategic and they&nbsp;represent and champion IG requirements/issues at the&nbsp;<span class=cloze>[...]</span>.	The Caldecott Guardian's role is&nbsp;strategic and they&nbsp;represent and champion IG requirements/issues at the&nbsp;<span class=cloze>Board or management level</span>.<br><br>
It is a statutory requirement for NHS and Social care Caldecott Guardians to be&nbsp;<span class=cloze>[...]</span>. Other health and social organisations can be registered, but&nbsp;this is optional.	It is a statutory requirement for NHS and Social care Caldecott Guardians to be&nbsp;<span class=cloze>registered on the publicly available National Register of Caldecott Guardians</span>. Other health and social organisations can be registered, but&nbsp;this is optional.<br><br>
It is a statutory requirement for NHS and Social care Caldecott Guardians to be&nbsp;registered on the publicly available National Register of Caldecott Guardians. Other health and social organisations can be registered, but&nbsp;<span class=cloze>[...]</span>.	It is a statutory requirement for NHS and Social care Caldecott Guardians to be&nbsp;registered on the publicly available National Register of Caldecott Guardians. Other health and social organisations can be registered, but&nbsp;<span class=cloze>this is optional</span>.<br><br>
What drugs are cytochrome P450 inhibitors?	Clarithromycin<div>Diltiazem</div><div>Erythromycin</div><div>Fluconazole</div><div>Grapefruit juice</div><div>Some antiretrovirals</div><div>Midazolam</div><div>Omeprazole</div>
Which drugs are cytochrome P450 inducers?	Carbamazapine<div>Dexamethasone</div><div>Phenobarbital</div><div>Phenytoin</div><div>Rifampicin</div><div>St John's Wort</div>
Schedule 1 drugs have&nbsp;<span class=cloze>[...]</span>	Schedule 1 drugs have&nbsp;<span class=cloze>no recognised medical use</span><br><br>Essentially recreational drugs like:<div>- coca leaf</div><div>- LSD</div><div>- Ecstasy</div><div>- Cannabis</div>
A&nbsp;<span class=cloze>[...]</span> is required to export&nbsp;Schedule 2 drugs.	A&nbsp;<span class=cloze>licence</span> is required to export&nbsp;Schedule 2 drugs.<br><br>
A&nbsp;licence is required to export&nbsp;<span class=cloze>[...]</span> drugs.	A&nbsp;licence is required to export&nbsp;<span class=cloze>Schedule 2</span> drugs.<br><br>
What is required of Schedule 2 drugs?	Register<div>Locked away</div><div>Special script</div><div>Specially destroyed</div>
What is required of Schedule 3 drugs?	Special script<div>No register</div><div>Invoices retained</div>
A&nbsp;<span class=cloze>[...]</span> is not required of&nbsp;Schedule 3, 4, and 5 drugs.	A&nbsp;<span class=cloze>register</span> is not required of&nbsp;Schedule 3, 4, and 5 drugs.<br><br>
A&nbsp;register is not required of&nbsp;<span class=cloze>[...]</span> drugs.	A&nbsp;register is not required of&nbsp;<span class=cloze>Schedule 3, 4, and 5</span> drugs.<br><br>
A&nbsp;<span class=cloze>[...]</span> is required to import/export&nbsp;Schedule 3 drugs.	A&nbsp;<span class=cloze>licence</span> is required to import/export&nbsp;Schedule 3 drugs.<br><br>
A&nbsp;licence is required to import/export&nbsp;<span class=cloze>[...]</span> drugs.	A&nbsp;licence is required to import/export&nbsp;<span class=cloze>Schedule 3</span> drugs.<br><br>
According to the British Lymphology Society Concensus document, lymphangeictasia should be managed with&nbsp;<span class=cloze>[...]</span>.	According to the British Lymphology Society Concensus document, lymphangeictasia should be managed with&nbsp;<span class=cloze>multi layer lymphoedema bandaging</span>.<br><br>
The cause of most cellulitis in lymphoedema is&nbsp;<span class=cloze>[...]</span>.	The cause of most cellulitis in lymphoedema is&nbsp;<span class=cloze>Group A beta-haemolytic streptococcus</span>.<br><br>
A patient with lymphoedema and suspected cellulitis should be admitted to hospital if they have&nbsp;<span class=cloze>[...]</span>,&nbsp;continued deterioration of systemic clinical signs after 48 hours of PO antibiotics,&nbsp;continued worsening of local signs despite trials of first and second line ABx.	A patient with lymphoedema and suspected cellulitis should be admitted to hospital if they have&nbsp;<span class=cloze>signs of severe sepsis</span>,&nbsp;continued deterioration of systemic clinical signs after 48 hours of PO antibiotics,&nbsp;continued worsening of local signs despite trials of first and second line ABx.<br><br>
A patient with lymphoedema and suspected cellulitis should be admitted to hospital if they have&nbsp;signs of severe sepsis,&nbsp;<span class=cloze>[...]</span>,&nbsp;continued worsening of local signs despite trials of first and second line ABx.	A patient with lymphoedema and suspected cellulitis should be admitted to hospital if they have&nbsp;signs of severe sepsis,&nbsp;<span class=cloze>continued deterioration of systemic clinical signs after 48 hours of PO antibiotics</span>,&nbsp;continued worsening of local signs despite trials of first and second line ABx.<br><br>
A patient with lymphoedema and suspected cellulitis should be admitted to hospital if they have&nbsp;signs of severe sepsis,&nbsp;continued deterioration of systemic clinical signs after 48 hours of PO antibiotics,&nbsp;<span class=cloze>[...]</span>.	A patient with lymphoedema and suspected cellulitis should be admitted to hospital if they have&nbsp;signs of severe sepsis,&nbsp;continued deterioration of systemic clinical signs after 48 hours of PO antibiotics,&nbsp;<span class=cloze>continued worsening of local signs despite trials of first and second line ABx</span>.<br><br>
If a patient with lymphoedema is being managed at home for cellulitis, the first line antibiotic is&nbsp;<span class=cloze>[...]</span>, the second line is&nbsp;clindamycin 300mg QDS.	If a patient with lymphoedema is being managed at home for cellulitis, the first line antibiotic is&nbsp;<span class=cloze>amoxicillin 500mg TDS</span>, the second line is&nbsp;clindamycin 300mg QDS.<br><br>
If a patient with lymphoedema is being managed at home for cellulitis, the first line antibiotic is&nbsp;amoxicillin 500mg TDS, the second line is&nbsp;<span class=cloze>[...]</span>.	If a patient with lymphoedema is being managed at home for cellulitis, the first line antibiotic is&nbsp;amoxicillin 500mg TDS, the second line is&nbsp;<span class=cloze>clindamycin 300mg QDS</span>.<br><br>
If a patient with lymphoedema is being managed in hospital for cellulitis, the first line antibiotic is&nbsp;<span class=cloze>[...]</span>, the second line is&nbsp;clindamycin 1.2g QDS.	If a patient with lymphoedema is being managed in hospital for cellulitis, the first line antibiotic is&nbsp;<span class=cloze>IV amoxicillin 2g TDS with gentamicin 5mg/kg</span>, the second line is&nbsp;clindamycin 1.2g QDS.<br><br>
If a patient with lymphoedema is being managed in hospital for cellulitis, the first line antibiotic is&nbsp;IV amoxicillin 2g TDS with gentamicin 5mg/kg, the second line is&nbsp;<span class=cloze>[...]</span>.	If a patient with lymphoedema is being managed in hospital for cellulitis, the first line antibiotic is&nbsp;IV amoxicillin 2g TDS with gentamicin 5mg/kg, the second line is&nbsp;<span class=cloze>clindamycin 1.2g QDS</span>.<br><br>
If there is a history of animal bite in cellulitis where the patient has lymphoedema, then the first line antibiotic is&nbsp;<span class=cloze>[...]</span>. If penicillin-allergic, then ciprofloxacin 500mg 12 hourly. For a second line,&nbsp;discuss with a microbiologist	If there is a history of animal bite in cellulitis where the patient has lymphoedema, then the first line antibiotic is&nbsp;<span class=cloze>co-amoxiclav 625mg TDS</span>. If penicillin-allergic, then ciprofloxacin 500mg 12 hourly. For a second line,&nbsp;discuss with a microbiologist<br><br>
If there is a history of animal bite in cellulitis where the patient has lymphoedema, then the first line antibiotic is&nbsp;co-amoxiclav 625mg TDS. If penicillin-allergic, then ciprofloxacin 500mg 12 hourly. For a second line,&nbsp;<span class=cloze>[...]</span>	If there is a history of animal bite in cellulitis where the patient has lymphoedema, then the first line antibiotic is&nbsp;co-amoxiclav 625mg TDS. If penicillin-allergic, then ciprofloxacin 500mg 12 hourly. For a second line,&nbsp;<span class=cloze>discuss with a microbiologist</span><br><br>
If there is a history of animal bite in cellulitis where the patient has lymphoedema, then the first line antibiotic is&nbsp;co-amoxiclav 625mg TDS. If penicillin-allergic, then <span class=cloze>[...]</span>. For a second line,&nbsp;discuss with a microbiologist	If there is a history of animal bite in cellulitis where the patient has lymphoedema, then the first line antibiotic is&nbsp;co-amoxiclav 625mg TDS. If penicillin-allergic, then <span class=cloze>ciprofloxacin 500mg 12 hourly</span>. For a second line,&nbsp;discuss with a microbiologist<br><br>
<span class=cloze>[...]</span>, or if penicillin-allergic, erythromycin 250mg OD&nbsp;is used for prophalaxis in recurrent cellulitis in patients with lymphoedema.	<span class=cloze>Phenoxypenicillin 500mg OD</span>, or if penicillin-allergic, erythromycin 250mg OD&nbsp;is used for prophalaxis in recurrent cellulitis in patients with lymphoedema.<br><br>
Phenoxypenicillin 500mg OD, or if penicillin-allergic, <span class=cloze>[...]</span>&nbsp;is used for prophalaxis in recurrent cellulitis in patients with lymphoedema.	Phenoxypenicillin 500mg OD, or if penicillin-allergic, <span class=cloze>erythromycin 250mg OD</span>&nbsp;is used for prophalaxis in recurrent cellulitis in patients with lymphoedema.<br><br>
In patients with lymphoedema who have cellulitis, antibiotics should be continued for&nbsp;<span class=cloze>[...]</span>.	In patients with lymphoedema who have cellulitis, antibiotics should be continued for&nbsp;<span class=cloze>14 days</span>.<br><br>
Patients with lymphoedema who have two or more attacks a year of cellulitis, should be offered <span class=cloze>[...]</span>.	Patients with lymphoedema who have two or more attacks a year of cellulitis, should be offered <span class=cloze>prophalactic antibiotics</span>.<br><br>
Diamorphine is a schedule&nbsp;<span class=cloze>[...]</span> drug.	Diamorphine is a schedule&nbsp;<span class=cloze>2</span> drug.<br><br>
Cocaine is a Schedule&nbsp;<span class=cloze>[...]</span> drug.	Cocaine is a Schedule&nbsp;<span class=cloze>2</span> drug.<br><br>
Phenobarbitone is a Schedule&nbsp;<span class=cloze>[...]</span> drug.	Phenobarbitone is a Schedule&nbsp;<span class=cloze>3</span> drug.<br><br>
Sativex is a Schedule&nbsp;<span class=cloze>[...]</span> drug, which is subject to&nbsp;full export/import control.	Sativex is a Schedule&nbsp;<span class=cloze>4</span> drug, which is subject to&nbsp;full export/import control.<br><br>
Sativex is a Schedule&nbsp;4 drug, which is subject to&nbsp;<span class=cloze>[...]</span>.	Sativex is a Schedule&nbsp;4 drug, which is subject to&nbsp;<span class=cloze>full export/import control</span>.<br><br>
"<div>What does this ECG show?</div><img src=""torsadesdepointessoutenue.jpg"" />"	Torsade de pointes
The coeliac plexus innervates the abdominal viscera from the&nbsp;<span class=cloze>[...]</span>, to&nbsp;half-way along the transverse colon, including the&nbsp;liver, pancreas, spleen and kidneys.	The coeliac plexus innervates the abdominal viscera from the&nbsp;<span class=cloze>bottom of the oesophagus</span>, to&nbsp;half-way along the transverse colon, including the&nbsp;liver, pancreas, spleen and kidneys.<br><br>
The coeliac plexus innervates the abdominal viscera from the&nbsp;bottom of the oesophagus, to&nbsp;<span class=cloze>[...]</span>, including the&nbsp;liver, pancreas, spleen and kidneys.	The coeliac plexus innervates the abdominal viscera from the&nbsp;bottom of the oesophagus, to&nbsp;<span class=cloze>half-way along the transverse colon</span>, including the&nbsp;liver, pancreas, spleen and kidneys.<br><br>
The coeliac plexus innervates the abdominal viscera from the&nbsp;bottom of the oesophagus, to&nbsp;half-way along the transverse colon, including the&nbsp;<span class=cloze>[...]</span>.	The coeliac plexus innervates the abdominal viscera from the&nbsp;bottom of the oesophagus, to&nbsp;half-way along the transverse colon, including the&nbsp;<span class=cloze>liver, pancreas, spleen and kidneys</span>.<br><br>
Cordotomy is good for patients with&nbsp;<span class=cloze>[...]</span>,&nbsp;pain more than a hands breadth away from the mid line,&nbsp;pain below C4, and the patient's prognosis is&nbsp;&lt;2 years.	Cordotomy is good for patients with&nbsp;<span class=cloze>pain in a hemi-quadrant</span>,&nbsp;pain more than a hands breadth away from the mid line,&nbsp;pain below C4, and the patient's prognosis is&nbsp;&lt;2 years.<br><br>
Cordotomy is good for patients with&nbsp;pain in a hemi-quadrant,&nbsp;<span class=cloze>[...]</span>,&nbsp;pain below C4, and the patient's prognosis is&nbsp;&lt;2 years.	Cordotomy is good for patients with&nbsp;pain in a hemi-quadrant,&nbsp;<span class=cloze>pain more than a hands breadth away from the mid line</span>,&nbsp;pain below C4, and the patient's prognosis is&nbsp;&lt;2 years.<br><br>
Cordotomy is good for patients with&nbsp;pain in a hemi-quadrant,&nbsp;pain more than a hands breadth away from the mid line,&nbsp;<span class=cloze>[...]</span>, and the patient's prognosis is&nbsp;&lt;2 years.	Cordotomy is good for patients with&nbsp;pain in a hemi-quadrant,&nbsp;pain more than a hands breadth away from the mid line,&nbsp;<span class=cloze>pain below C4</span>, and the patient's prognosis is&nbsp;&lt;2 years.<br><br>
Cordotomy is good for patients with&nbsp;pain in a hemi-quadrant,&nbsp;pain more than a hands breadth away from the mid line,&nbsp;pain below C4, and the patient's prognosis is&nbsp;<span class=cloze>[...]</span>.	Cordotomy is good for patients with&nbsp;pain in a hemi-quadrant,&nbsp;pain more than a hands breadth away from the mid line,&nbsp;pain below C4, and the patient's prognosis is&nbsp;<span class=cloze>&lt;2 years</span>.<br><br>
What is the failure rate of cordotomy?	1 in 10
What is the risk of permanent weakness in cordotomy?	1 in 600
All patients will experience a minor change in sensation after cordotomy on the&nbsp;<span class=cloze>[...]</span>.	All patients will experience a minor change in sensation after cordotomy on the&nbsp;<span class=cloze>ipsilateral side of the body</span>.<br><br>
In cordotomy, 1 in 20 patients can experience weakness for up to&nbsp;<span class=cloze>[...]</span> post procedure.	In cordotomy, 1 in 20 patients can experience weakness for up to&nbsp;<span class=cloze>4 weeks</span> post procedure.<br><br>
In cordotomy, <span class=cloze>[...]</span> patients can experience weakness for up to&nbsp;4 weeks post procedure.	In cordotomy, <span class=cloze>1 in 20</span> patients can experience weakness for up to&nbsp;4 weeks post procedure.<br><br>
"<div>This is a picture of a patient's axilla. They are a type II diabetic. What is this?</div><img src=""m-h_photo_of_acanthosis_nigricans.jpg"" />"	Acanthosis nigricans
A&nbsp;<span class=cloze>[...]</span> showed that BZDs and Z-drugs have an NNT of 13, and an NNH of&nbsp;6.	A&nbsp;<span class=cloze>meta-analysis</span> showed that BZDs and Z-drugs have an NNT of 13, and an NNH of&nbsp;6.<br><br>
A&nbsp;meta-analysis showed that BZDs and Z-drugs have an NNT of <span class=cloze>[...]</span>, and an NNH of&nbsp;6.	A&nbsp;meta-analysis showed that BZDs and Z-drugs have an NNT of <span class=cloze>13</span>, and an NNH of&nbsp;6.<br><br>
A&nbsp;meta-analysis showed that BZDs and Z-drugs have an NNT of 13, and an NNH of&nbsp;<span class=cloze>[...]</span>.	A&nbsp;meta-analysis showed that BZDs and Z-drugs have an NNT of 13, and an NNH of&nbsp;<span class=cloze>6</span>.<br><br>
In the event of opioid toxicity, a 400mcg naloxone ampoule should be diluted to&nbsp;<span class=cloze>[...]</span>, and&nbsp;0.5ml/20mcg given repeatedly until the patient's respiratory rate is satisfactory	In the event of opioid toxicity, a 400mcg naloxone ampoule should be diluted to&nbsp;<span class=cloze>10ml</span>, and&nbsp;0.5ml/20mcg given repeatedly until the patient's respiratory rate is satisfactory<br><br>
In the event of opioid toxicity, a 400mcg naloxone ampoule should be diluted to&nbsp;10ml, and&nbsp;<span class=cloze>[...]</span> given repeatedly until the patient's respiratory rate is satisfactory	In the event of opioid toxicity, a 400mcg naloxone ampoule should be diluted to&nbsp;10ml, and&nbsp;<span class=cloze>0.5ml/20mcg</span> given repeatedly until the patient's respiratory rate is satisfactory<br><br>
The Cochrane review on breathlessness (2007) says that there is&nbsp;<span class=cloze>[...]</span> evidence that oral or parentral opioids improve breathlessness.	The Cochrane review on breathlessness (2007) says that there is&nbsp;<span class=cloze>strong</span> evidence that oral or parentral opioids improve breathlessness.<br><br>
A&nbsp;<span class=cloze>[...]</span> may help with pain from the&nbsp;perineum, rectum and anus.	A&nbsp;<span class=cloze>ganglion of impar block</span> may help with pain from the&nbsp;perineum, rectum and anus.<br><br>
A&nbsp;ganglion of impar block may help with pain from the&nbsp;<span class=cloze>[...]</span>.	A&nbsp;ganglion of impar block may help with pain from the&nbsp;<span class=cloze>perineum, rectum and anus</span>.<br><br>
Mirels’ scoring system is based on four characteristics:&nbsp;<div><span class=cloze>[...]</span></div><div>(2) nature of lesion, i.e whether it is lytic, blastic or mixed</div><div>(3) size of lesion</div><div>(4) pain.</div>	Mirels’ scoring system is based on four characteristics:&nbsp;<div><span class=cloze>(1) site of lesion</span></div><div>(2) nature of lesion, i.e whether it is lytic, blastic or mixed</div><div>(3) size of lesion</div><div>(4) pain.</div><br><br>
Mirels’ scoring system is based on four characteristics:&nbsp;<div>(1) site of lesion</div><div><span class=cloze>[...]</span></div><div>(3) size of lesion</div><div>(4) pain.</div>	Mirels’ scoring system is based on four characteristics:&nbsp;<div>(1) site of lesion</div><div><span class=cloze>(2) nature of lesion, i.e whether it is lytic, blastic or mixed</span></div><div>(3) size of lesion</div><div>(4) pain.</div><br><br>
Mirels’ scoring system is based on four characteristics:&nbsp;<div>(1) site of lesion</div><div>(2) nature of lesion, i.e whether it is lytic, blastic or mixed</div><div><span class=cloze>[...]</span></div><div>(4) pain.</div>	Mirels’ scoring system is based on four characteristics:&nbsp;<div>(1) site of lesion</div><div>(2) nature of lesion, i.e whether it is lytic, blastic or mixed</div><div><span class=cloze>(3) size of lesion</span></div><div>(4) pain.</div><br><br>
Mirels’ scoring system is based on four characteristics:&nbsp;<div>(1) site of lesion</div><div>(2) nature of lesion, i.e whether it is lytic, blastic or mixed</div><div>(3) size of lesion</div><div><span class=cloze>[...]</span>.</div>	Mirels’ scoring system is based on four characteristics:&nbsp;<div>(1) site of lesion</div><div>(2) nature of lesion, i.e whether it is lytic, blastic or mixed</div><div>(3) size of lesion</div><div><span class=cloze>(4) pain</span>.</div><br><br>
<div>Other than in patients with a very short life expectancy, <span class=cloze>[...]</span> are preferable to recurrent aspiration in malignant pleural effusion.</div>	<div>Other than in patients with a very short life expectancy, <span class=cloze></div><div>small-bore chest tubes followed by pleurodesis</span> are preferable to recurrent aspiration in malignant pleural effusion.</div><br><br>
<div>Other than in patients with a very short life expectancy, </div><div>small-bore chest tubes followed by pleurodesis are preferable to <span class=cloze>[...]</span> in malignant pleural effusion.</div>	<div>Other than in patients with a very short life expectancy, </div><div>small-bore chest tubes followed by pleurodesis are preferable to <span class=cloze>recurrent aspiration</span> in malignant pleural effusion.</div><br><br>
<div>In patients with malignant pleural effusion, where only <span class=cloze>[...]</span>, chemical pleurodesis may still be attempted and may provide symptomatic relief.</div>	<div>In patients with malignant pleural effusion, where only <span class=cloze>partial pleural apposition can be achieved</span>, chemical pleurodesis may still be attempted and may provide symptomatic relief.</div><br><br>
<div>In patients with malignant pleural effusion, where only partial pleural apposition can be achieved, <span class=cloze>[...]</span> and may provide symptomatic relief.</div>	<div>In patients with malignant pleural effusion, where only partial pleural apposition can be achieved, <span class=cloze>chemical pleurodesis may still be attempted</span> and may provide symptomatic relief.</div><br><br>
<div>In patients with malignant pleural effusion, where only partial pleural apposition can be achieved, chemical pleurodesis may still be attempted and may provide <span class=cloze>[...]</span>.</div>	<div>In patients with malignant pleural effusion, where only partial pleural apposition can be achieved, chemical pleurodesis may still be attempted and may provide <span class=cloze>symptomatic relief</span>.</div><br><br>
<span class=cloze>[...]</span> is the most effective sclerosant available for pleurodesis.	<span class=cloze>Talc</span> is the most effective sclerosant available for pleurodesis.<br><br>
Talc is the most effective sclerosant available for <span class=cloze>[...]</span>.	Talc is the most effective sclerosant available for <span class=cloze>pleurodesis</span>.<br><br>
<span class=cloze>[...]</span> is an alternative sclerosant for pleurodesis with a modest efficacy rate.	<span class=cloze>Bleomycin</span> is an alternative sclerosant for pleurodesis with a modest efficacy rate.<br><br>
Bleomycin is an <span class=cloze>[...]</span> for pleurodesis with a modest efficacy rate.	Bleomycin is an <span class=cloze>alternative sclerosant</span> for pleurodesis with a modest efficacy rate.<br><br>
<div><span class=cloze>[...]</span> and fever are the most common side effects of sclerosant administration.&nbsp;</div>	<div><span class=cloze>Pleuritic chest pain</span> and fever are the most common side effects of sclerosant administration.&nbsp;</div><br><br>
<div>Pleuritic chest pain and <span class=cloze>[...]</span> are the most common side effects of sclerosant administration.&nbsp;</div>	<div>Pleuritic chest pain and <span class=cloze>fever</span> are the most common side effects of sclerosant administration.&nbsp;</div><br><br>
<div>Pleuritic chest pain and fever are the <span class=cloze>[...]</span> of sclerosant administration.&nbsp;</div>	<div>Pleuritic chest pain and fever are the <span class=cloze>most common side effects</span> of sclerosant administration.&nbsp;</div><br><br>
Lambert-Eaton syndrome is a&nbsp;<span class=cloze>[...]</span>. It occurs when antibodies are formed against&nbsp;presynaptic&nbsp;calcium channels.	Lambert-Eaton syndrome is a&nbsp;<span class=cloze>paraneoplastic syndrome</span>. It occurs when antibodies are formed against&nbsp;presynaptic&nbsp;calcium channels.<br><br>
Lambert-Eaton syndrome is a&nbsp;paraneoplastic syndrome. It occurs when antibodies are formed against&nbsp;<span class=cloze>[...]</span>&nbsp;calcium channels.	Lambert-Eaton syndrome is a&nbsp;paraneoplastic syndrome. It occurs when antibodies are formed against&nbsp;<span class=cloze>presynaptic</span>&nbsp;calcium channels.<br><br>
Lambert-Eaton syndrome is a&nbsp;paraneoplastic syndrome. It occurs when antibodies are formed against&nbsp;presynaptic&nbsp;<span class=cloze>[...]</span>.	Lambert-Eaton syndrome is a&nbsp;paraneoplastic syndrome. It occurs when antibodies are formed against&nbsp;presynaptic&nbsp;<span class=cloze>calcium channels</span>.<br><br>
In&nbsp;Lambert-Eaton syndrome,&nbsp;<span class=cloze>[...]</span> are&nbsp;reduced or&nbsp;absent.	In&nbsp;Lambert-Eaton syndrome,&nbsp;<span class=cloze>distal tendon reflexes</span> are&nbsp;reduced or&nbsp;absent.<br><br>
In&nbsp;Lambert-Eaton syndrome,&nbsp;distal tendon reflexes are&nbsp;<span class=cloze>[...]</span> or&nbsp;absent.	In&nbsp;Lambert-Eaton syndrome,&nbsp;distal tendon reflexes are&nbsp;<span class=cloze>reduced</span> or&nbsp;absent.<br><br>
In&nbsp;Lambert-Eaton syndrome,&nbsp;distal tendon reflexes are&nbsp;reduced or&nbsp;<span class=cloze>[...]</span>.	In&nbsp;Lambert-Eaton syndrome,&nbsp;distal tendon reflexes are&nbsp;reduced or&nbsp;<span class=cloze>absent</span>.<br><br>
In&nbsp;Lambert-Eaton syndrome&nbsp;<span class=cloze>[...]</span> improves with&nbsp;contraction.	In&nbsp;Lambert-Eaton syndrome&nbsp;<span class=cloze>weakness</span> improves with&nbsp;contraction.<br><br>
In&nbsp;Lambert-Eaton syndrome&nbsp;weakness improves with&nbsp;<span class=cloze>[...]</span>.	In&nbsp;Lambert-Eaton syndrome&nbsp;weakness improves with&nbsp;<span class=cloze>contraction</span>.<br><br>
Lambert-Eaton syndrome is associated with <span class=cloze>[...]</span> such as xerostomia and impotence.	Lambert-Eaton syndrome is associated with <span class=cloze>some autonomic symptoms</span> such as xerostomia and impotence.<br><br>
In Lambert-Eaton syndrome,&nbsp;<span class=cloze>[...]</span>&nbsp;improves with repeated testing.	In Lambert-Eaton syndrome,&nbsp;<span class=cloze>muscle power</span>&nbsp;improves with repeated testing.<br><br>
In Lambert-Eaton syndrome,&nbsp;muscle power&nbsp;<span class=cloze>[...]</span>.	In Lambert-Eaton syndrome,&nbsp;muscle power&nbsp;<span class=cloze>improves with repeated testing</span>.<br><br>
&nbsp;Thoracoscopy is a <span class=cloze>[...]</span> with low complication rates.	&nbsp;Thoracoscopy is a <span class=cloze>safe procedure</span> with low complication rates.<br><br>
&nbsp;Thoracoscopy is a safe procedure with <span class=cloze>[...]</span>.	&nbsp;Thoracoscopy is a safe procedure with <span class=cloze>low complication rates</span>.<br><br>
According to the Office of National Statistics, there were&nbsp;<span class=cloze>[...]</span> new cancer diagnoses registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;<span class=cloze>~280000</span> new cancer diagnoses registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were <span class=cloze>[...]</span> new cancer diagnoses in women, registered in England, in 2012.	According to the Office of National Statistics, there were <span class=cloze>~140000</span> new cancer diagnoses in women, registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;<span class=cloze>[...]</span> new cancer diagnoses in men, registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;<span class=cloze>~145000</span> new cancer diagnoses in men, registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;<span class=cloze>[...]</span> new breast cancer diagnoses registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;<span class=cloze>~43000</span> new breast cancer diagnoses registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~43000 new <span class=cloze>[...]</span> diagnoses registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~43000 new <span class=cloze>breast cancer</span> diagnoses registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;<span class=cloze>[...]</span> new prostate cancer diagnoses registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;<span class=cloze>~37000</span> new prostate cancer diagnoses registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~37000 new <span class=cloze>[...]</span> diagnoses registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~37000 new <span class=cloze>prostate cancer</span> diagnoses registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;<span class=cloze>[...]</span> new lung cancer diagnoses in women registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;<span class=cloze>~16000</span> new lung cancer diagnoses in women registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~16000 new <span class=cloze>[...]</span> diagnoses in women registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~16000 new <span class=cloze>lung cancer</span> diagnoses in women registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~16000 new lung cancer diagnoses <span class=cloze>[...]</span> registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~16000 new lung cancer diagnoses <span class=cloze>in women</span> registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;<span class=cloze>[...]</span> new lung cancer diagnoses in men registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;<span class=cloze>~20000</span> new lung cancer diagnoses in men registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~20000 new <span class=cloze>[...]</span> diagnoses in men registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~20000 new <span class=cloze>lung cancer</span> diagnoses in men registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~20000 new lung cancer diagnoses <span class=cloze>[...]</span> registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~20000 new lung cancer diagnoses <span class=cloze>in men</span> registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;<span class=cloze>[...]</span> new colon/rectum cancer diagnoses in women registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;<span class=cloze>~15000</span> new colon/rectum cancer diagnoses in women registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~15000 new <span class=cloze>[...]</span> diagnoses in women registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~15000 new <span class=cloze>colon/rectum cancer</span> diagnoses in women registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~15000 new colon/rectum cancer diagnoses <span class=cloze>[...]</span> registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~15000 new colon/rectum cancer diagnoses <span class=cloze>in women</span> registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;<span class=cloze>[...]</span> new colon/rectum cancer diagnoses in men registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;<span class=cloze>~19000</span> new colon/rectum cancer diagnoses in men registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~19000 new <span class=cloze>[...]</span> diagnoses in men registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~19000 new <span class=cloze>colon/rectum cancer</span> diagnoses in men registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~19000 new colon/rectum cancer diagnoses <span class=cloze>[...]</span> registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~19000 new colon/rectum cancer diagnoses <span class=cloze>in men</span> registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;<span class=cloze>[...]</span> new uterine cancer diagnoses registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;<span class=cloze>~7000</span> new uterine cancer diagnoses registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~7000 new <span class=cloze>[...]</span> diagnoses registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~7000 new <span class=cloze>uterine cancer</span> diagnoses registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;<span class=cloze>[...]</span> new bladder cancer diagnoses in men registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;<span class=cloze>~6500</span> new bladder cancer diagnoses in men registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~6500 new <span class=cloze>[...]</span> diagnoses in men registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~6500 new <span class=cloze>bladder cancer</span> diagnoses in men registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~6500 new bladder cancer diagnoses <span class=cloze>[...]</span> registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~6500 new bladder cancer diagnoses <span class=cloze>in men</span> registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;<span class=cloze>[...]</span> new ovarian cancer diagnoses registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;<span class=cloze>~6000</span> new ovarian cancer diagnoses registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~6000 new <span class=cloze>[...]</span> diagnoses registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~6000 new <span class=cloze>ovarian cancer</span> diagnoses registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;<span class=cloze>[...]</span> new non-Hodgkins lymphoma diagnoses in men registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;<span class=cloze>~6000</span> new non-Hodgkins lymphoma diagnoses in men registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~6000 new <span class=cloze>[...]</span> diagnoses in men registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~6000 new <span class=cloze>non-Hodgkins lymphoma</span> diagnoses in men registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~6000 new non-Hodgkins lymphoma diagnoses <span class=cloze>[...]</span> registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~6000 new non-Hodgkins lymphoma diagnoses <span class=cloze>in men</span> registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;<span class=cloze>[...]</span> new melanoma diagnoses in women and men registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;<span class=cloze>~6000</span> new melanoma diagnoses in women and men registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~6000 new <span class=cloze>[...]</span> diagnoses in women and men registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~6000 new <span class=cloze>melanoma</span> diagnoses in women and men registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~6000 new melanoma diagnoses <span class=cloze>[...]</span> registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~6000 new melanoma diagnoses <span class=cloze>in women and men</span> registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;<span class=cloze>[...]</span> new non-Hodgkins lymphoma diagnoses in women registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;<span class=cloze>~5000</span> new non-Hodgkins lymphoma diagnoses in women registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~5000 new <span class=cloze>[...]</span> diagnoses in women registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~5000 new <span class=cloze>non-Hodgkins lymphoma</span> diagnoses in women registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~5000 new non-Hodgkins lymphoma diagnoses <span class=cloze>[...]</span> registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~5000 new non-Hodgkins lymphoma diagnoses <span class=cloze>in women</span> registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;<span class=cloze>[...]</span> new oesophageal cancer diagnoses in men registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;<span class=cloze>~5000</span> new oesophageal cancer diagnoses in men registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~5000 new <span class=cloze>[...]</span> diagnoses in men registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~5000 new <span class=cloze>oesophageal cancer</span> diagnoses in men registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~5000 new oesophageal cancer diagnoses <span class=cloze>[...]</span> registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~5000 new oesophageal cancer diagnoses <span class=cloze>in men</span> registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;<span class=cloze>[...]</span> new pancreatic cancer diagnoses in women registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;<span class=cloze>~4000</span> new pancreatic cancer diagnoses in women registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~4000 new <span class=cloze>[...]</span> diagnoses in women registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~4000 new <span class=cloze>pancreatic cancer</span> diagnoses in women registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~4000 new pancreatic cancer diagnoses <span class=cloze>[...]</span> registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~4000 new pancreatic cancer diagnoses <span class=cloze>in women</span> registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;<span class=cloze>[...]</span> new renal cancer diagnoses in men registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;<span class=cloze>~5000</span> new renal cancer diagnoses in men registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~5000 new <span class=cloze>[...]</span> diagnoses in men registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~5000 new <span class=cloze>renal cancer</span> diagnoses in men registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~5000 new renal cancer diagnoses <span class=cloze>[...]</span> registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~5000 new renal cancer diagnoses <span class=cloze>in men</span> registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;<span class=cloze>[...]</span> new leukaemia diagnoses in women registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;<span class=cloze>~3000</span> new leukaemia diagnoses in women registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~3000 new <span class=cloze>[...]</span> diagnoses in women registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~3000 new <span class=cloze>leukaemia</span> diagnoses in women registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~3000 new leukaemia diagnoses <span class=cloze>[...]</span> registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~3000 new leukaemia diagnoses <span class=cloze>in women</span> registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;<span class=cloze>[...]</span> new lip/oral cavity/pharynx cancer diagnoses in men registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;<span class=cloze>~4000</span> new lip/oral cavity/pharynx cancer diagnoses in men registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~4000 new <span class=cloze>[...]</span> diagnoses in men registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~4000 new <span class=cloze>lip/oral cavity/pharynx cancer</span> diagnoses in men registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~4000 new lip/oral cavity/pharynx cancer diagnoses <span class=cloze>[...]</span> registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~4000 new lip/oral cavity/pharynx cancer diagnoses <span class=cloze>in men</span> registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;<span class=cloze>[...]</span> new renal cancer diagnoses in women registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;<span class=cloze>~3000</span> new renal cancer diagnoses in women registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~3000 new <span class=cloze>[...]</span> diagnoses in women registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~3000 new <span class=cloze>renal cancer</span> diagnoses in women registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~3000 new renal cancer diagnoses <span class=cloze>[...]</span> registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~3000 new renal cancer diagnoses <span class=cloze>in women</span> registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;<span class=cloze>[...]</span> new leukaemia diagnoses in men registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;<span class=cloze>~4000</span> new leukaemia diagnoses in men registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~4000 new <span class=cloze>[...]</span> diagnoses in men registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~4000 new <span class=cloze>leukaemia</span> diagnoses in men registered in England, in 2012.<br><br>
According to the Office of National Statistics, there were&nbsp;~4000 new leukaemia diagnoses <span class=cloze>[...]</span> registered in England, in 2012.	According to the Office of National Statistics, there were&nbsp;~4000 new leukaemia diagnoses <span class=cloze>in men</span> registered in England, in 2012.<br><br>
Doses of risperidone should be&nbsp;<span class=cloze>[...]</span> in&nbsp;hepatic impairment.	Doses of risperidone should be&nbsp;<span class=cloze>reduced</span> in&nbsp;hepatic impairment.<br><br>
Doses of risperidone should be&nbsp;reduced in&nbsp;<span class=cloze>[...]</span>.	Doses of risperidone should be&nbsp;reduced in&nbsp;<span class=cloze>hepatic impairment</span>.<br><br>
<span class=cloze>[...]</span> is an absolute contraindication to using methlyphenidate.	<span class=cloze>Glaucoma</span> is an absolute contraindication to using methlyphenidate.<br><br>
Duloxetine is an&nbsp;<span class=cloze>[...]</span> type of antidepressant, recommended for&nbsp;diabetic neuropathy.	Duloxetine is an&nbsp;<span class=cloze>SNRI</span> type of antidepressant, recommended for&nbsp;diabetic neuropathy.<br><br>
Duloxetine is an&nbsp;SNRI type of antidepressant, recommended for&nbsp;<span class=cloze>[...]</span>.	Duloxetine is an&nbsp;SNRI type of antidepressant, recommended for&nbsp;<span class=cloze>diabetic neuropathy</span>.<br><br>
A <span class=cloze>[...]</span> may help pain arising from pelvic organs.	A <span class=cloze>superior hypogastric plexus block</span> may help pain arising from pelvic organs.<br><br>
A superior hypogastric plexus block may help pain arising from <span class=cloze>[...]</span>.	A superior hypogastric plexus block may help pain arising from <span class=cloze>pelvic organs</span>.<br><br>
<span class=cloze>[...]</span> may help with upper gastrointestinal pain.	<span class=cloze>Splanchnic nerve blocks</span> may help with upper gastrointestinal pain.<br><br>
Splanchnic nerve blocks may help with <span class=cloze>[...]</span> pain.	Splanchnic nerve blocks may help with <span class=cloze>upper gastrointestinal</span> pain.<br><br>
Amitryptiline is a <span class=cloze>[...]</span> whose mode of action is blocking presynaptic re-uptake of serotonin and noradrenaline.	Amitryptiline is a <span class=cloze>tricyclic antidepressant</span> whose mode of action is blocking presynaptic re-uptake of serotonin and noradrenaline.<br><br>
Amitryptiline is a tricyclic antidepressant whose mode of action is <span class=cloze>[...]</span>.	Amitryptiline is a tricyclic antidepressant whose mode of action is <span class=cloze>blocking presynaptic re-uptake of serotonin and noradrenaline</span>.<br><br>
All patients having coeliac plexus blocks require <span class=cloze>[...]</span> during the procedure, because of the risk of hypotension.	All patients having coeliac plexus blocks require <span class=cloze>IV fluids</span> during the procedure, because of the risk of hypotension.<br><br>
All patients having coeliac plexus blocks require IV fluids during the procedure, because of the risk of <span class=cloze>[...]</span>.	All patients having coeliac plexus blocks require IV fluids during the procedure, because of the risk of <span class=cloze>hypotension</span>.<br><br>
The coeliac plexus arises from the <span class=cloze>[...]</span> of the splanchnic nerves from T5-T12.	The coeliac plexus arises from the <span class=cloze>sympathetic fibres</span> of the splanchnic nerves from T5-T12.<br><br>
The coeliac plexus arises from the sympathetic fibres of the <span class=cloze>[...]</span> from T5-T12.	The coeliac plexus arises from the sympathetic fibres of the <span class=cloze>splanchnic nerves</span> from T5-T12.<br><br>
The coeliac plexus arises from the sympathetic fibres of the splanchnic nerves from <span class=cloze>[...]</span>.	The coeliac plexus arises from the sympathetic fibres of the splanchnic nerves from <span class=cloze>T5-T12</span>.<br><br>
Cordotomy is more effective for <span class=cloze>[...]</span> than for neuropathic pain syndromes.	Cordotomy is more effective for <span class=cloze>nociceptive</span> than for neuropathic pain syndromes.<br><br>
<span class=cloze>[...]</span> is the fraction of an administered dose of unchanged drug that reaches the systemic circulation.	<span class=cloze>Bioavailiblity</span> is the fraction of an administered dose of unchanged drug that reaches the systemic circulation.<br><br>
The main metabolite of Hydromorphine is <span class=cloze>[...]</span> which is an inactive metabolite.	The main metabolite of Hydromorphine is <span class=cloze>hydromorphone-3-glucuronide</span> which is an inactive metabolite.<br><br>
The main metabolite of Hydromorphine is hydromorphone-3-glucuronide which is an <span class=cloze>[...]</span>.	The main metabolite of Hydromorphine is hydromorphone-3-glucuronide which is an <span class=cloze>inactive metabolite</span>.<br><br>
A Miami-J collar limits <span class=cloze>[...]</span> between C2 and C5.&nbsp;	A Miami-J collar limits <span class=cloze>flexion, extension and rotation</span> between C2 and C5.&nbsp;<br><br>
A Miami-J collar limits flexion, extension and rotation between <span class=cloze>[...]</span>.&nbsp;	A Miami-J collar limits flexion, extension and rotation between <span class=cloze>C2 and C5</span>.&nbsp;<br><br>
What level of spinal lesion can result in autonomic dysreflexia?	A lesion above T6
In autonomic dysreflexia, <span class=cloze>[...]</span> below a spinal lesion above the level of T6 can result in&nbsp;parasympathetic overactivity above the lesion.	In autonomic dysreflexia, <span class=cloze>sympathetic overactivity</span> below a spinal lesion above the level of T6 can result in&nbsp;parasympathetic overactivity above the lesion.<br><br>
In autonomic dysreflexia, sympathetic overactivity below a spinal lesion above the level of T6 can result in&nbsp;<span class=cloze>[...]</span> above the lesion.	In autonomic dysreflexia, sympathetic overactivity below a spinal lesion above the level of T6 can result in&nbsp;<span class=cloze>parasympathetic overactivity</span> above the lesion.<br><br>
In autonomic dysreflexia, the patient may be <span class=cloze>[...]</span>.	In autonomic dysreflexia, the patient may be <span class=cloze>hypertensive, bradycardic and flushed</span>.<br><br>
Glaucoma is an <span class=cloze>[...]</span> to using methlyphenidate.	Glaucoma is an <span class=cloze>absolute contraindication</span> to using methlyphenidate.<br><br>
<span class=cloze>[...]</span> patients attempt suicide in the&nbsp;6 months after starting antidepressants.	<span class=cloze>1:1000</span> patients attempt suicide in the&nbsp;6 months after starting antidepressants.<br><br>
1:1000 patients attempt suicide in the&nbsp;<span class=cloze>[...]</span> after starting antidepressants.	1:1000 patients attempt suicide in the&nbsp;<span class=cloze>6 months</span> after starting antidepressants.<br><br>
<span class=cloze>[...]</span> are&nbsp;not recommended in palliative care.	<span class=cloze>Monoamine oxidase inhibitors</span> are&nbsp;not recommended in palliative care.<br><br>
Monoamine oxidase inhibitors are&nbsp;<span class=cloze>[...]</span> in palliative care.	Monoamine oxidase inhibitors are&nbsp;<span class=cloze>not recommended</span> in palliative care.<br><br>
The antibacterials&nbsp;<span class=cloze>[...]</span> and&nbsp;furazolidone have clinically relevant serotinergic activity.	The antibacterials&nbsp;<span class=cloze>linezolid</span> and&nbsp;furazolidone have clinically relevant serotinergic activity.<br><br>
The antibacterials&nbsp;linezolid and&nbsp;<span class=cloze>[...]</span> have clinically relevant serotinergic activity.	The antibacterials&nbsp;linezolid and&nbsp;<span class=cloze>furazolidone</span> have clinically relevant serotinergic activity.<br><br>
Triptans such as&nbsp;<span class=cloze>[...]</span> have clinically relevant serotoninergic activity.	Triptans such as&nbsp;<span class=cloze>sumatriptan</span> have clinically relevant serotoninergic activity.<br><br>
<span class=cloze>[...]</span> is involved with&nbsp;platelet aggregation.	<span class=cloze>Serotonin</span> is involved with&nbsp;platelet aggregation.<br><br>
Serotonin is involved with&nbsp;<span class=cloze>[...]</span>.	Serotonin is involved with&nbsp;<span class=cloze>platelet aggregation</span>.<br><br>
<span class=cloze>[...]</span> and&nbsp;SSRIs are useful for hot flushes associated with menopause, hormone therapy and androgen-ablation therapy for prostate cancer.	<span class=cloze>Venaflaxine</span> and&nbsp;SSRIs are useful for hot flushes associated with menopause, hormone therapy and androgen-ablation therapy for prostate cancer.<br><br>
Venaflaxine and&nbsp;<span class=cloze>[...]</span> are useful for hot flushes associated with menopause, hormone therapy and androgen-ablation therapy for prostate cancer.	Venaflaxine and&nbsp;<span class=cloze>SSRIs</span> are useful for hot flushes associated with menopause, hormone therapy and androgen-ablation therapy for prostate cancer.<br><br>
<span class=cloze>[...]</span> suggest benefit from sertraline in&nbsp;cholestatic pruritus.	<span class=cloze>Two small RCTs</span> suggest benefit from sertraline in&nbsp;cholestatic pruritus.<br><br>
Two small RCTs suggest benefit from <span class=cloze>[...]</span> in&nbsp;cholestatic pruritus.	Two small RCTs suggest benefit from <span class=cloze>sertraline</span> in&nbsp;cholestatic pruritus.<br><br>
Two small RCTs suggest benefit from sertraline in&nbsp;<span class=cloze>[...]</span>.	Two small RCTs suggest benefit from sertraline in&nbsp;<span class=cloze>cholestatic pruritus</span>.<br><br>
For pathological laughter and crying, first line treatment is&nbsp;<span class=cloze>[...]</span>.	For pathological laughter and crying, first line treatment is&nbsp;<span class=cloze>citalopram or sertaline</span>.<br><br>
For pathological laughter and crying, second line treatment includes&nbsp;<span class=cloze>[...]</span> or nortriptyline or levodopa.	For pathological laughter and crying, second line treatment includes&nbsp;<span class=cloze>amitriptyline or imipramine</span> or nortriptyline or levodopa.<br><br>
For pathological laughter and crying, second line treatment includes&nbsp;amitriptyline or imipramine or <span class=cloze>[...]</span>.	For pathological laughter and crying, second line treatment includes&nbsp;amitriptyline or imipramine or <span class=cloze>nortriptyline or levodopa</span>.<br><br>
Antidepressant discontinuation syndrome is most common in&nbsp;<span class=cloze>[...]</span>.	Antidepressant discontinuation syndrome is most common in&nbsp;<span class=cloze>paroxetine</span>.<br><br>
Antidepressant discontinuation syndrome is least common in&nbsp;<span class=cloze>[...]</span>.	Antidepressant discontinuation syndrome is least common in&nbsp;<span class=cloze>fluoxetine</span>.<br><br>
About <span class=cloze>[...]</span> advanced cancer patients develop a major depression.	About <span class=cloze>5-10%</span> advanced cancer patients develop a major depression.<br><br>
Nortriptyline is a&nbsp;<span class=cloze>[...]</span> and a&nbsp;TCA.	Nortriptyline is a&nbsp;<span class=cloze>noradrenaline reuptake inhibitor</span> and a&nbsp;TCA.<br><br>
Nortriptyline is a&nbsp;noradrenaline reuptake inhibitor and a&nbsp;<span class=cloze>[...]</span>.	Nortriptyline is a&nbsp;noradrenaline reuptake inhibitor and a&nbsp;<span class=cloze>TCA</span>.<br><br>
<span class=cloze>[...]</span> and paroxetine  are strong hepatic enzyme inhibitors.	<span class=cloze>Fluoxetine</span> and paroxetine  are strong hepatic enzyme inhibitors.<br><br>
Fluoxetine and <span class=cloze>[...]</span> are strong hepatic enzyme inhibitors.	Fluoxetine and <span class=cloze>paroxetine </span> are strong hepatic enzyme inhibitors.<br><br>
A combination of IV metoclopromide and IV ondansetron occasionally causes&nbsp;<span class=cloze>[...]</span>.	A combination of IV metoclopromide and IV ondansetron occasionally causes&nbsp;<span class=cloze>cardiac arrythmias</span>.<br><br>
<span class=cloze>[...]</span> can be used to relieve pruritus induced by&nbsp;spinal opioids.	<span class=cloze>IV ondansetron</span> can be used to relieve pruritus induced by&nbsp;spinal opioids.<br><br>
IV ondansetron can be used to relieve pruritus induced by&nbsp;<span class=cloze>[...]</span>.	IV ondansetron can be used to relieve pruritus induced by&nbsp;<span class=cloze>spinal opioids</span>.<br><br>
Paraneoplastic fevers respond to all NSAIDs except&nbsp;<span class=cloze>[...]</span>.	Paraneoplastic fevers respond to all NSAIDs except&nbsp;<span class=cloze>naproxen</span>.<br><br>
Above the age of <span class=cloze>[...]</span> the risks of NSAID related upper GI complications are significantly increased.	Above the age of <span class=cloze>65</span> the risks of NSAID related upper GI complications are significantly increased.<br><br>
If there is a history of&nbsp;<span class=cloze>[...]</span>&nbsp;in the last year&nbsp;the risks of NSAID related upper GI complications are significantly increased.	If there is a history of&nbsp;<span class=cloze>peptic ulcer and GI bleeding</span>&nbsp;in the last year&nbsp;the risks of NSAID related upper GI complications are significantly increased.<br><br>
If there is a history of&nbsp;peptic ulcer and GI bleeding&nbsp;<span class=cloze>[...]</span>&nbsp;the risks of NSAID related upper GI complications are significantly increased.	If there is a history of&nbsp;peptic ulcer and GI bleeding&nbsp;<span class=cloze>in the last year</span>&nbsp;the risks of NSAID related upper GI complications are significantly increased.<br><br>
If there is&nbsp;<span class=cloze>[...]</span> that there is evidence of upper GI bleeding with NSAIDs,&nbsp;the risks of NSAID related upper GI complications are significantly increased.	If there is&nbsp;<span class=cloze>strong clinical suspicion</span> that there is evidence of upper GI bleeding with NSAIDs,&nbsp;the risks of NSAID related upper GI complications are significantly increased.<br><br>
If there is long-term use of&nbsp;<span class=cloze>[...]</span>,&nbsp;the risks of NSAID related upper GI complications are significantly increased.	If there is long-term use of&nbsp;<span class=cloze>max doses of NSAID</span>,&nbsp;the risks of NSAID related upper GI complications are significantly increased.<br><br>
If there is concurrent serious&nbsp;<span class=cloze>[...]</span> with use of an NSAID,&nbsp;the risks of NSAID related upper GI complications are significantly increased.	If there is concurrent serious&nbsp;<span class=cloze>medical morbidity</span> with use of an NSAID,&nbsp;the risks of NSAID related upper GI complications are significantly increased.<br><br>
If there is concurrent use of an NSAID with a <span class=cloze>[...]</span>,&nbsp;low-dose aspirin or&nbsp;anticoagulant,&nbsp;the risks of NSAID related upper GI complications are significantly increased.	If there is concurrent use of an NSAID with a <span class=cloze>steroid</span>,&nbsp;low-dose aspirin or&nbsp;anticoagulant,&nbsp;the risks of NSAID related upper GI complications are significantly increased.<br><br>
If there is concurrent use of an NSAID with a steroid,&nbsp;<span class=cloze>[...]</span> or&nbsp;anticoagulant,&nbsp;the risks of NSAID related upper GI complications are significantly increased.	If there is concurrent use of an NSAID with a steroid,&nbsp;<span class=cloze>low-dose aspirin</span> or&nbsp;anticoagulant,&nbsp;the risks of NSAID related upper GI complications are significantly increased.<br><br>
If there is concurrent use of an NSAID with a steroid,&nbsp;low-dose aspirin or&nbsp;<span class=cloze>[...]</span>,&nbsp;the risks of NSAID related upper GI complications are significantly increased.	If there is concurrent use of an NSAID with a steroid,&nbsp;low-dose aspirin or&nbsp;<span class=cloze>anticoagulant</span>,&nbsp;the risks of NSAID related upper GI complications are significantly increased.<br><br>
If there is concurrent use of the antidepressants which are <span class=cloze>[...]</span> with an NSAID,&nbsp;the risks of NSAID related upper GI complications are significantly increased.	If there is concurrent use of the antidepressants which are <span class=cloze>SSRIs</span> with an NSAID,&nbsp;the risks of NSAID related upper GI complications are significantly increased.<br><br>
If the FBC shows there is&nbsp;<span class=cloze>[...]</span>,&nbsp;the risks of NSAID related upper GI complications are significantly increased.	If the FBC shows there is&nbsp;<span class=cloze>thrombopenia (&lt;50x10<sup>9</sup>/L)</span>,&nbsp;the risks of NSAID related upper GI complications are significantly increased.<br><br>
According to a Cochrane review, what agents are effective at preventing chronic NSAID-related endoscopic peptic ulcers?	PPIs<div>Misoprostol</div><div>Double-dose H<sub>2</sub>&nbsp;antagonists</div>
NSAIDs can cause a protein losing&nbsp;<span class=cloze>[...]</span> in the&nbsp;small bowel.	NSAIDs can cause a protein losing&nbsp;<span class=cloze>enteropathy</span> in the&nbsp;small bowel.<br><br>
NSAIDs can cause a protein losing&nbsp;enteropathy in the&nbsp;<span class=cloze>[...]</span>.	NSAIDs can cause a protein losing&nbsp;enteropathy in the&nbsp;<span class=cloze>small bowel</span>.<br><br>
According to SIGN guidelines, patients with a solitary brain met who have SCLC or NSCLC should be offered surgical <span class=cloze>[...]</span> followed by adjuvant&nbsp;chemotherapy.	According to SIGN guidelines, patients with a solitary brain met who have SCLC or NSCLC should be offered surgical <span class=cloze>resection</span> followed by adjuvant&nbsp;chemotherapy.<br><br>
According to SIGN guidelines, patients with a solitary brain met who have SCLC or NSCLC should be offered surgical resection followed by adjuvant&nbsp;<span class=cloze>[...]</span>.	According to SIGN guidelines, patients with a solitary brain met who have SCLC or NSCLC should be offered surgical resection followed by adjuvant&nbsp;<span class=cloze>chemotherapy</span>.<br><br>
<div>Patients with SCLC should be considered for palliative <span class=cloze>[...]</span> if they have significant chest symptoms and other treatments have been ineffective or are considered inappropriate.</div>	<div>Patients with SCLC should be considered for palliative <span class=cloze></div><div>thoracic radiotherapy</span> if they have significant chest symptoms and other treatments have been ineffective or are considered inappropriate.</div><br><br>
<div>Patients with SCLC should be considered for palliative </div><div>thoracic radiotherapy if they have significant <span class=cloze>[...]</span> and other treatments have been ineffective or are considered inappropriate.</div>	<div>Patients with SCLC should be considered for palliative </div><div>thoracic radiotherapy if they have significant <span class=cloze>chest symptoms</span> and other treatments have been ineffective or are considered inappropriate.</div><br><br>
<div>Patients who have advanced disease, are performance status 0-1,</div><div>have predominantly non-squamous NSCLC and are EGFR mutation</div><div>negative should be offered combination systemic anticancer</div><div>therapy with <span class=cloze>[...]</span>.</div>	<div>Patients who have advanced disease, are performance status 0-1,</div><div>have predominantly non-squamous NSCLC and are EGFR mutation</div><div>negative should be offered combination systemic anticancer</div><div>therapy with <span class=cloze>cisplatin and pemetrexed</span>.</div><br><br>
<div>Patients who have advanced disease, are performance status 0-1,</div><div>have predominantly non-squamous NSCLC and are EGFR mutation</div><div><span class=cloze>[...]</span> should be offered combination systemic anticancer</div><div>therapy with cisplatin and pemetrexed.</div>	<div>Patients who have advanced disease, are performance status 0-1,</div><div>have predominantly non-squamous NSCLC and are EGFR mutation</div><div><span class=cloze>negative</span> should be offered combination systemic anticancer</div><div>therapy with cisplatin and pemetrexed.</div><br><br>
<div>Second line systemic anticancer therapy with single agent</div><div><span class=cloze>[...]</span> should be considered for patients with</div><div>performance status 0-2 recurrent NSCLC who have been previously</div><div>treated with first line agents.</div>	<div>Second line systemic anticancer therapy with single agent</div><div><span class=cloze>docetaxel or erlotinib</span> should be considered for patients with</div><div>performance status 0-2 recurrent NSCLC who have been previously</div><div>treated with first line agents.</div><br><br>
<div>Second line systemic anticancer therapy with single agent</div><div>docetaxel or erlotinib should be considered for patients with</div><div>performance status 0-2 recurrent NSCLC who have been previously</div><div>treated with <span class=cloze>[...]</span>.</div>	<div>Second line systemic anticancer therapy with single agent</div><div>docetaxel or erlotinib should be considered for patients with</div><div>performance status 0-2 recurrent NSCLC who have been previously</div><div>treated with <span class=cloze>first line agents</span>.</div><br><br>
<div>Combination intravenous systemic anticancer therapy should be considered for patients with <span class=cloze>[...]</span> over 70 years of age with performance status 0-2.</div>	<div>Combination intravenous systemic anticancer therapy should be considered for patients with <span class=cloze>SCLC</span> over 70 years of age with performance status 0-2.</div><br><br>
<div>Combination intravenous systemic anticancer therapy should be considered for patients with SCLC over <span class=cloze>[...]</span> years of age with performance status 0-2.</div>	<div>Combination intravenous systemic anticancer therapy should be considered for patients with SCLC over <span class=cloze>70</span> years of age with performance status 0-2.</div><br><br>
<div>Combination intravenous systemic anticancer therapy should be considered for patients with SCLC over 70 years of age with performance status <span class=cloze>[...]</span>.</div>	<div>Combination intravenous systemic anticancer therapy should be considered for patients with SCLC over 70 years of age with performance status <span class=cloze>0-2</span>.</div><br><br>
<div>In patients with SCLC the recommended number of systemic</div><div>anticancer therapy cycles is <span class=cloze>[...]</span>.</div>	<div>In patients with SCLC the recommended number of systemic</div><div>anticancer therapy cycles is <span class=cloze>three to six</span>.</div><br><br>
<div>In patients with superior vena cava obstruction due to SCLC, <span class=cloze>[...]</span> as initial treatment, but stenting may be considered for relapse or persistent superior vena cava obstruction.</div>	<div>In patients with superior vena cava obstruction due to SCLC, <span class=cloze>systemic anti cancer therapy/radiotherapy is recommended</span> as initial treatment, but stenting may be considered for relapse or persistent superior vena cava obstruction.</div><br><br>
<div>In patients with superior vena cava obstruction due to SCLC, systemic anti cancer therapy/radiotherapy is recommended as initial treatment, but <span class=cloze>[...]</span> for relapse or persistent superior vena cava obstruction.</div>	<div>In patients with superior vena cava obstruction due to SCLC, systemic anti cancer therapy/radiotherapy is recommended as initial treatment, but <span class=cloze>stenting may be considered</span> for relapse or persistent superior vena cava obstruction.</div><br><br>
<div>In patients with superior vena cava obstruction due to NSCLC, <span class=cloze>[...]</span> may be considered as a primary treatment.</div>	<div>In patients with superior vena cava obstruction due to NSCLC, <span class=cloze>stenting</span> may be considered as a primary treatment.</div><br><br>
<div>Pre-menopausal women with ER positive invasive breast cancer</div><div>should be treated with <span class=cloze>[...]</span> for at least </div><div>five years, to a total of ten years, unless there are contraindications or side effects.</div>	<div>Pre-menopausal women with ER positive invasive breast cancer</div><div>should be treated with <span class=cloze>tamoxifen</span> for at least </div><div>five years, to a total of ten years, unless there are contraindications or side effects.</div><br><br>
<div>Pre-menopausal women with ER positive invasive breast cancer</div><div>should be treated with tamoxifen for at least <span class=cloze>[...]</span>, unless there are contraindications or side effects.</div>	<div>Pre-menopausal women with ER positive invasive breast cancer</div><div>should be treated with tamoxifen for at least <span class=cloze></div><div>five years, to a total of ten years</span>, unless there are contraindications or side effects.</div><br><br>
<div>Postmenopausal women with ER positive early breast cancer</div><div>should be considered for treatment with <span class=cloze>[...]</span> as an alternative to tamoxifen.</div>	<div>Postmenopausal women with ER positive early breast cancer</div><div>should be considered for treatment with <span class=cloze>aromatase inhibitors</span> as an alternative to tamoxifen.</div><br><br>
<div>Postmenopausal women with ER positive early breast cancer</div><div>should be considered for treatment with aromatase inhibitors as an alternative to <span class=cloze>[...]</span>.</div>	<div>Postmenopausal women with ER positive early breast cancer</div><div>should be considered for treatment with aromatase inhibitors as an alternative to <span class=cloze>tamoxifen</span>.</div><br><br>
In postmenopausal women who have breast cancer, aromatase inhibitors can be given <span class=cloze>[...]</span> for up to five years.	In postmenopausal women who have breast cancer, aromatase inhibitors can be given <span class=cloze>first line</span> for up to five years.<br><br>
In postmenopausal women who have breast cancer, aromatase inhibitors can be given first line for up to <span class=cloze>[...]</span> years.	In postmenopausal women who have breast cancer, aromatase inhibitors can be given first line for up to <span class=cloze>five</span> years.<br><br>
Postmenopausal women who have breast cancer, who are already on tamoxifen, after <span class=cloze>[...]</span> years, can switch to an aromatase inhibitor for a total of five years.	Postmenopausal women who have breast cancer, who are already on tamoxifen, after <span class=cloze>two to three</span> years, can switch to an aromatase inhibitor for a total of five years.<br><br>
Postmenopausal women who have breast cancer, who are already on tamoxifen, after two to three years, can switch to an <span class=cloze>[...]</span> for a total of five years.	Postmenopausal women who have breast cancer, who are already on tamoxifen, after two to three years, can switch to an <span class=cloze>aromatase inhibitor</span> for a total of five years.<br><br>
<div>Patients who are postmenopausal and have completed five years</div><div>of tamoxifen may be considered for extended (five years) treatment</div><div>with <span class=cloze>[...]</span>.</div>	<div>Patients who are postmenopausal and have completed five years</div><div>of tamoxifen may be considered for extended (five years) treatment</div><div>with <span class=cloze>letrozole</span>.</div><br><br>
<div><span class=cloze>[...]</span> is the platinum drug of choice in both single and</div><div>combination therapy for ovarian cancer.</div>	<div><span class=cloze>Carboplatin</span> is the platinum drug of choice in both single and</div><div>combination therapy for ovarian cancer.</div><br><br>
What does the CHADS<sub>2</sub>&nbsp;score stand for?	C. Congestive cardiac failure<div>H: Hypertension, &gt;140/90 without medication, or treated with medication</div><div>A: Age &gt;75 years</div><div>D: Diabetes</div><div>S<sub>2</sub>: Previous TIA/stroke (two marks)</div>
<div>Survivors of childhood cancer who have had anthracyclines or radiation to a field that includes the heart should have <span class=cloze>[...]</span> for cardiac dysfunction using echocardiography to determine fractional shortening and ejection fraction.</div>	<div>Survivors of childhood cancer who have had anthracyclines or radiation to a field that includes the heart should have <span class=cloze>long term monitoring</span> for cardiac dysfunction using echocardiography to determine fractional shortening and ejection fraction.</div><br><br>
<div>Teenage boys should be referred for <span class=cloze>[...]</span> if their fertility is considered to be at risk.</div>	<div>Teenage boys should be referred for <span class=cloze>semen cryopreservation</span> if their fertility is considered to be at risk.</div><br><br>
Use of NSAIDs with methotrexate can cause it to&nbsp;<span class=cloze>[...]</span>, increasing the risk of&nbsp;severe renal toxicity.	Use of NSAIDs with methotrexate can cause it to&nbsp;<span class=cloze>accumulate</span>, increasing the risk of&nbsp;severe renal toxicity.<br><br>
Use of NSAIDs with methotrexate can cause it to&nbsp;accumulate, increasing the risk of&nbsp;<span class=cloze>[...]</span>.	Use of NSAIDs with methotrexate can cause it to&nbsp;accumulate, increasing the risk of&nbsp;<span class=cloze>severe renal toxicity</span>.<br><br>
The effect of NSAIDs on the kidney&nbsp;may cause sulphonureas to&nbsp;<span class=cloze>[...]</span>, putting the patient at risk of&nbsp;hypoglycaemia.	The effect of NSAIDs on the kidney&nbsp;may cause sulphonureas to&nbsp;<span class=cloze>accumulate</span>, putting the patient at risk of&nbsp;hypoglycaemia.<br><br>
The effect of NSAIDs on the kidney&nbsp;may cause sulphonureas to&nbsp;accumulate, putting the patient at risk of&nbsp;<span class=cloze>[...]</span>.	The effect of NSAIDs on the kidney&nbsp;may cause sulphonureas to&nbsp;accumulate, putting the patient at risk of&nbsp;<span class=cloze>hypoglycaemia</span>.<br><br>
The effect of NSAIDs on the <span class=cloze>[...]</span>&nbsp;may cause sulphonureas to&nbsp;accumulate, putting the patient at risk of&nbsp;hypoglycaemia.	The effect of NSAIDs on the <span class=cloze>kidney</span>&nbsp;may cause sulphonureas to&nbsp;accumulate, putting the patient at risk of&nbsp;hypoglycaemia.<br><br>
Which NSAID carries the highest risk of acute&nbsp;myocardial infarction?	Ketoralac
Which NSAID carries the highest risk of gastritis or duodenitis?	Ketoralac
Which NSAID doesn't increase cardiovascular risk?	Naproxen
Nabumetone has&nbsp;<span class=cloze>[...]</span> on platelet aggregation in clinical studies.	Nabumetone has&nbsp;<span class=cloze>no effect</span> on platelet aggregation in clinical studies.<br><br>
What is the incidence of gastric perforation with nabumetone?	1.1%
A&nbsp;<span class=cloze>[...]</span> showed that with nabumetone, GI events were&nbsp;10-36x less likely than other NSAIDs.	A&nbsp;<span class=cloze>meta-analysis</span> showed that with nabumetone, GI events were&nbsp;10-36x less likely than other NSAIDs.<br><br>Very wide confidence intervals though...
A&nbsp;meta-analysis showed that with nabumetone, GI events were&nbsp;<span class=cloze>[...]</span> less likely than other NSAIDs.	A&nbsp;meta-analysis showed that with nabumetone, GI events were&nbsp;<span class=cloze>10-36x</span> less likely than other NSAIDs.<br><br>Very wide confidence intervals though...
There is&nbsp;<span class=cloze>[...]</span> pharmacologically for&nbsp;Step 2 of the WHO pain ladder.	There is&nbsp;<span class=cloze>no need</span> pharmacologically for&nbsp;Step 2 of the WHO pain ladder.<br><br>
There is&nbsp;no need pharmacologically for&nbsp;<span class=cloze>[...]</span> of the WHO pain ladder.	There is&nbsp;no need pharmacologically for&nbsp;<span class=cloze>Step 2</span> of the WHO pain ladder.<br><br>
Codeine is metabolised to morphine via the liver enzyme&nbsp;<span class=cloze>[...]</span>.	Codeine is metabolised to morphine via the liver enzyme&nbsp;<span class=cloze>CYP2D6</span>.<br><br>So, poor metabolisers will have no effect from morphine.
Fluoxetine and paroxetine are hepatic enzyme <span class=cloze>[...]</span> and will cause codeine, dihydrocodine and tramadol to have a diminished effect.	Fluoxetine and paroxetine are hepatic enzyme <span class=cloze>inhibitors</span> and will cause codeine, dihydrocodine and tramadol to have a diminished effect.<br><br>
Fluoxetine and paroxetine are hepatic enzyme inhibitors and will cause codeine, dihydrocodine and tramadol to have a <span class=cloze>[...]</span>.	Fluoxetine and paroxetine are hepatic enzyme inhibitors and will cause codeine, dihydrocodine and tramadol to have a <span class=cloze>diminished effect</span>.<br><br>
Fluoxetine and paroxetine are hepatic enzyme inhibitors and will cause <span class=cloze>[...]</span> to have a diminished effect.	Fluoxetine and paroxetine are hepatic enzyme inhibitors and will cause <span class=cloze>codeine, dihydrocodine and tramadol</span> to have a diminished effect.<br><br>
Tramadol acts as a mu-receptor antagonist, and a presynaptic <span class=cloze>[...]</span> reuptake inhibitor.	Tramadol acts as a mu-receptor antagonist, and a presynaptic <span class=cloze>serotonin and noradrenaline</span> reuptake inhibitor.<br><br>
Tramadol can&nbsp;<span class=cloze>[...]</span> the seizure threshold, especially in combination with&nbsp;SSRIs,&nbsp;TCAs or antipsychotics.	Tramadol can&nbsp;<span class=cloze>lower</span> the seizure threshold, especially in combination with&nbsp;SSRIs,&nbsp;TCAs or antipsychotics.<br><br>
Tramadol can&nbsp;lower the seizure threshold, especially in combination with&nbsp;<span class=cloze>[...]</span>,&nbsp;TCAs or antipsychotics.	Tramadol can&nbsp;lower the seizure threshold, especially in combination with&nbsp;<span class=cloze>SSRIs</span>,&nbsp;TCAs or antipsychotics.<br><br>
Tramadol can&nbsp;lower the seizure threshold, especially in combination with&nbsp;SSRIs,&nbsp;<span class=cloze>[...]</span> or antipsychotics.	Tramadol can&nbsp;lower the seizure threshold, especially in combination with&nbsp;SSRIs,&nbsp;<span class=cloze>TCAs</span> or antipsychotics.<br><br>
Tramadol can&nbsp;lower the seizure threshold, especially in combination with&nbsp;SSRIs,&nbsp;TCAs or <span class=cloze>[...]</span>.	Tramadol can&nbsp;lower the seizure threshold, especially in combination with&nbsp;SSRIs,&nbsp;TCAs or <span class=cloze>antipsychotics</span>.<br><br>
Methadone is a&nbsp;<span class=cloze>[...]</span>-receptor antagonist, a presynaptic&nbsp;serotonin reuptake inhibitor, and an&nbsp;NMDA receptor antagonist.	Methadone is a&nbsp;<span class=cloze>mu</span>-receptor antagonist, a presynaptic&nbsp;serotonin reuptake inhibitor, and an&nbsp;NMDA receptor antagonist.<br><br>
Methadone is a&nbsp;mu-receptor antagonist, a presynaptic&nbsp;<span class=cloze>[...]</span>, and an&nbsp;NMDA receptor antagonist.	Methadone is a&nbsp;mu-receptor antagonist, a presynaptic&nbsp;<span class=cloze>serotonin reuptake inhibitor</span>, and an&nbsp;NMDA receptor antagonist.<br><br>
Methadone is a&nbsp;mu-receptor antagonist, a presynaptic&nbsp;serotonin reuptake inhibitor, and an&nbsp;<span class=cloze>[...]</span>.	Methadone is a&nbsp;mu-receptor antagonist, a presynaptic&nbsp;serotonin reuptake inhibitor, and an&nbsp;<span class=cloze>NMDA receptor antagonist</span>.<br><br>
The main metabolites of morphine are&nbsp;<span class=cloze>[...]</span> and&nbsp;morphine-6-glucronide.	The main metabolites of morphine are&nbsp;<span class=cloze>morphine-3-glucronide</span> and&nbsp;morphine-6-glucronide.<br><br>
The main metabolites of morphine are&nbsp;morphine-3-glucronide and&nbsp;<span class=cloze>[...]</span>.	The main metabolites of morphine are&nbsp;morphine-3-glucronide and&nbsp;<span class=cloze>morphine-6-glucronide</span>.<br><br>
Both morphine-3-glucronide and morphine-6-glucronide are <span class=cloze>[...]</span>&nbsp;excreted.	Both morphine-3-glucronide and morphine-6-glucronide are <span class=cloze>renally</span>&nbsp;excreted.<br><br>
Morphine-3-glucronide is an&nbsp;<span class=cloze>[...]</span> metabolite.	Morphine-3-glucronide is an&nbsp;<span class=cloze>inactive</span> metabolite.<br><br>
Morphine-6-glucronide is an&nbsp;<span class=cloze>[...]</span> metabolite, which binds to&nbsp;opioid receptors.	Morphine-6-glucronide is an&nbsp;<span class=cloze>active</span> metabolite, which binds to&nbsp;opioid receptors.<br><br>
Morphine-6-glucronide is an&nbsp;active metabolite, which binds to&nbsp;<span class=cloze>[...]</span> receptors.	Morphine-6-glucronide is an&nbsp;active metabolite, which binds to&nbsp;<span class=cloze>opioid</span> receptors.<br><br>
Pruritus from systemic opioids is caused by what?	Cutaneous histamine release
What opioid receptors does buprenorphine act on?	Partial agonist at mu<div>ORL-1 agonist</div><div>Kappa and&nbsp;Delta antagonist</div>
The bioavailibility of oral buprenorphine is&nbsp;<span class=cloze>[...]</span>.	The bioavailibility of oral buprenorphine is&nbsp;<span class=cloze>15%</span>.<br><br>
Both buprenorphine and fentanyl are&nbsp;<span class=cloze>[...]</span> soluble.	Both buprenorphine and fentanyl are&nbsp;<span class=cloze>fat</span> soluble.<br><br>
Morphine is&nbsp;<span class=cloze>[...]</span> soluble.	Morphine is&nbsp;<span class=cloze>water</span> soluble.<br><br>
Both fentanyl and buprenorphine have little effect on the sphincter of&nbsp;<span class=cloze>[...]</span>.	Both fentanyl and buprenorphine have little effect on the sphincter of&nbsp;<span class=cloze>Oddi</span>.<br><br>
Methadone is poorly removed by&nbsp;<span class=cloze>[...]</span>.	Methadone is poorly removed by&nbsp;<span class=cloze>haemodialysis</span>.<br><br>
Methadone&nbsp;<span class=cloze>[...]</span> the QT interval.	Methadone&nbsp;<span class=cloze>prolongs</span> the QT interval.<br><br>
The ratio of methadone to morphine is&nbsp;<span class=cloze>[...]</span>, but try to use the <b>more conservative</b> ratio.	The ratio of methadone to morphine is&nbsp;<span class=cloze>1:5-10</span>, but try to use the <b>more conservative</b> ratio.<br><br>
Methadone is&nbsp;<span class=cloze>[...]</span> excreted.	Methadone is&nbsp;<span class=cloze>hepatically</span> excreted.<br><br>
To convert oral methadone to SC/IV methadone,&nbsp;<span class=cloze>[...]</span> the oral dose.	To convert oral methadone to SC/IV methadone,&nbsp;<span class=cloze>halve</span> the oral dose.<br><br>
Oxycodone is&nbsp;<span class=cloze>[...]</span> recommended in <b>severe</b>&nbsp;renal impairment.	Oxycodone is&nbsp;<span class=cloze>not</span> recommended in <b>severe</b>&nbsp;renal impairment.<br><br>
Naltrexone can be used for&nbsp;<span class=cloze>[...]</span> pruritus.	Naltrexone can be used for&nbsp;<span class=cloze>cholestatic</span> pruritus.<br><br>
The prevalence of oral yeast in patients with advanced cancer is&nbsp;<span class=cloze>[...]</span>.	The prevalence of oral yeast in patients with advanced cancer is&nbsp;<span class=cloze>~50-90%</span>.<br><br>
Metronidazole produces a disulfram-like reaction in about&nbsp;<span class=cloze>[...]</span> of patients.	Metronidazole produces a disulfram-like reaction in about&nbsp;<span class=cloze>25%</span> of patients.<br><br>
Metronidazole produces a <span class=cloze>[...]</span> reaction in about&nbsp;25% of patients.	Metronidazole produces a <span class=cloze>disulfram-like</span> reaction in about&nbsp;25% of patients.<br><br>
Topical metronidazole can improve odour in about&nbsp;<span class=cloze>[...]</span> of patients.	Topical metronidazole can improve odour in about&nbsp;<span class=cloze>50%</span> of patients.<br><br>
The improvement in odour from topical metronidazole occurs within&nbsp;<span class=cloze>[...]</span>, but can take up to&nbsp;1 month.	The improvement in odour from topical metronidazole occurs within&nbsp;<span class=cloze>2 days</span>, but can take up to&nbsp;1 month.<br><br>
The improvement in odour from topical metronidazole occurs within&nbsp;2 days, but can take up to&nbsp;<span class=cloze>[...]</span>.	The improvement in odour from topical metronidazole occurs within&nbsp;2 days, but can take up to&nbsp;<span class=cloze>1 month</span>.<br><br>
The commonest cause of UTIs is from the organism&nbsp;<span class=cloze>[...]</span>	The commonest cause of UTIs is from the organism&nbsp;<span class=cloze><i>E. coli.</i></span><br><br>
In the community, in non-catheterised women, three symptoms independently predict UTI:<div>1.&nbsp;<span class=cloze>[...]</span></div><div>2.&nbsp;dysuria</div><div>3.&nbsp;recent-onset nocturia</div>	In the community, in non-catheterised women, three symptoms independently predict UTI:<div>1.&nbsp;<span class=cloze>cloudy urine</span></div><div>2.&nbsp;dysuria</div><div>3.&nbsp;recent-onset nocturia</div><br><br>
In the community, in non-catheterised women, three symptoms independently predict UTI:<div>1.&nbsp;cloudy urine</div><div>2.&nbsp;<span class=cloze>[...]</span></div><div>3.&nbsp;recent-onset nocturia</div>	In the community, in non-catheterised women, three symptoms independently predict UTI:<div>1.&nbsp;cloudy urine</div><div>2.&nbsp;<span class=cloze>dysuria</span></div><div>3.&nbsp;recent-onset nocturia</div><br><br>
In the community, in non-catheterised women, three symptoms independently predict UTI:<div>1.&nbsp;cloudy urine</div><div>2.&nbsp;dysuria</div><div>3.&nbsp;<span class=cloze>[...]</span></div>	In the community, in non-catheterised women, three symptoms independently predict UTI:<div>1.&nbsp;cloudy urine</div><div>2.&nbsp;dysuria</div><div>3.&nbsp;<span class=cloze>recent-onset nocturia</span></div><br><br>
The presence of cloudy urine, dysuria and recent-onset nocturia, have a positive predictive value of&nbsp;<span class=cloze>[...]</span> for UTI.	The presence of cloudy urine, dysuria and recent-onset nocturia, have a positive predictive value of&nbsp;<span class=cloze>82%</span> for UTI.<br><br>
The absence of cloudy urine, dysuria and recent-onset nocturia, have a negative predictive value of <span class=cloze>[...]</span> for UTI.	The absence of cloudy urine, dysuria and recent-onset nocturia, have a negative predictive value of <span class=cloze>67%</span> for UTI.<br><br>
If a urine dipstick is nitrite +ve and either blood or leucocyte +ve, the positive-predictive value for a UTI is&nbsp;<span class=cloze>[...]</span>.	If a urine dipstick is nitrite +ve and either blood or leucocyte +ve, the positive-predictive value for a UTI is&nbsp;<span class=cloze>92%</span>.<br><br>
There is a possible relationship between&nbsp;<span class=cloze>[...]</span> and&nbsp;necrotising fascitis.	There is a possible relationship between&nbsp;<span class=cloze>skin infections with NSAIDS</span> and&nbsp;necrotising fascitis.<br><br>
There is a possible relationship between&nbsp;skin infections with NSAIDS and&nbsp;<span class=cloze>[...]</span>.	There is a possible relationship between&nbsp;skin infections with NSAIDS and&nbsp;<span class=cloze>necrotising fascitis</span>.<br><br>
Oral metronidazole is first line for treatment of&nbsp;<span class=cloze>[...]</span>	Oral metronidazole is first line for treatment of&nbsp;<span class=cloze>C. difficile</span><br><br>
The signs of severe <i>C. difficile</i> infection are:<div><span class=cloze>[...]</span><div>HR &gt;100 BPM</div><div>WCC &gt;15</div><div>Creatinine rising &gt;50% above baseline</div><div>Clinical/Radiographical evidence of colitis</div></div>	The signs of severe <i>C. difficile</i> infection are:<div><span class=cloze>T &gt;38.5</span><div>HR &gt;100 BPM</div><div>WCC &gt;15</div><div>Creatinine rising &gt;50% above baseline</div><div>Clinical/Radiographical evidence of colitis</div></div><br><br>
The signs of severe <i>C. difficile</i> infection are:<div>T &gt;38.5<div><span class=cloze>[...]</span></div><div>WCC &gt;15</div><div>Creatinine rising &gt;50% above baseline</div><div>Clinical/Radiographical evidence of colitis</div></div>	The signs of severe <i>C. difficile</i> infection are:<div>T &gt;38.5<div><span class=cloze>HR &gt;100 BPM</span></div><div>WCC &gt;15</div><div>Creatinine rising &gt;50% above baseline</div><div>Clinical/Radiographical evidence of colitis</div></div><br><br>
The signs of severe <i>C. difficile</i> infection are:<div>T &gt;38.5<div>HR &gt;100 BPM</div><div><span class=cloze>[...]</span></div><div>Creatinine rising &gt;50% above baseline</div><div>Clinical/Radiographical evidence of colitis</div></div>	The signs of severe <i>C. difficile</i> infection are:<div>T &gt;38.5<div>HR &gt;100 BPM</div><div><span class=cloze>WCC &gt;15</span></div><div>Creatinine rising &gt;50% above baseline</div><div>Clinical/Radiographical evidence of colitis</div></div><br><br>
The signs of severe <i>C. difficile</i> infection are:<div>T &gt;38.5<div>HR &gt;100 BPM</div><div>WCC &gt;15</div><div><span class=cloze>[...]</span></div><div>Clinical/Radiographical evidence of colitis</div></div>	The signs of severe <i>C. difficile</i> infection are:<div>T &gt;38.5<div>HR &gt;100 BPM</div><div>WCC &gt;15</div><div><span class=cloze>Creatinine rising &gt;50% above baseline</span></div><div>Clinical/Radiographical evidence of colitis</div></div><br><br>
The signs of severe <i>C. difficile</i> infection are:<div>T &gt;38.5<div>HR &gt;100 BPM</div><div>WCC &gt;15</div><div>Creatinine rising &gt;50% above baseline</div><div><span class=cloze>[...]</span></div></div>	The signs of severe <i>C. difficile</i> infection are:<div>T &gt;38.5<div>HR &gt;100 BPM</div><div>WCC &gt;15</div><div>Creatinine rising &gt;50% above baseline</div><div><span class=cloze>Clinical/Radiographical evidence of colitis</span></div></div><br><br>
<span class=cloze>[...]</span> is given for severe C. diff infection.	<span class=cloze>Vancomycin</span> is given for severe C. diff infection.<br><br>
In patients with C. difficile who do not respond to vancomycin, consider <span class=cloze>[...]</span>.	In patients with C. difficile who do not respond to vancomycin, consider <span class=cloze>fidaxomicin</span>.<br><br>
Bisphosphonates are a stable analogue of&nbsp;<span class=cloze>[...]</span>.	Bisphosphonates are a stable analogue of&nbsp;<span class=cloze>pyrophosphate</span>.<br><br>
In <span class=cloze>[...]</span>, zolendronate, given monthly for 1 year reduces the risk of a skeletal related event by ~40% when compared with placebo.	In <span class=cloze>breast cancer</span>, zolendronate, given monthly for 1 year reduces the risk of a skeletal related event by ~40% when compared with placebo.<br><br>
In breast cancer, <span class=cloze>[...]</span>, given monthly for 1 year reduces the risk of a skeletal related event by ~40% when compared with placebo.	In breast cancer, <span class=cloze>zolendronate</span>, given monthly for 1 year reduces the risk of a skeletal related event by ~40% when compared with placebo.<br><br>
In breast cancer, zolendronate, given monthly for 1 year reduces the risk of a skeletal related event by <span class=cloze>[...]</span> when compared with placebo.	In breast cancer, zolendronate, given monthly for 1 year reduces the risk of a skeletal related event by <span class=cloze>~40%</span> when compared with placebo.<br><br>
<span class=cloze>[...]</span> in prostate cancer results in increased bone loss.	<span class=cloze>Androgen deprivation treatment</span> in prostate cancer results in increased bone loss.<br><br>
Androgen deprivation treatment in prostate cancer results in <span class=cloze>[...]</span>.	Androgen deprivation treatment in prostate cancer results in <span class=cloze>increased bone loss</span>.<br><br>
In <span class=cloze>[...]</span> treated with androgen deprivation treatment, bisphosphonates reduce the rate of bone loss.	In <span class=cloze>prostate cancer</span> treated with androgen deprivation treatment, bisphosphonates reduce the rate of bone loss.<br><br>
In prostate cancer treated with androgen deprivation treatment, bisphosphonates <span class=cloze>[...]</span>.	In prostate cancer treated with androgen deprivation treatment, bisphosphonates <span class=cloze>reduce the rate of bone loss</span>.<br><br>
NICE Guidelines suggest <span class=cloze>[...]</span> are given to men with prostate cancer who are receiving androgen deprivation therapy who also have osteoporosis.	NICE Guidelines suggest <span class=cloze>bisphosphonates</span> are given to men with prostate cancer who are receiving androgen deprivation therapy who also have osteoporosis.<br><br>
NICE Guidelines suggest bisphosphonates are given to men with prostate cancer who are receiving <span class=cloze>[...]</span> who also have osteoporosis.	NICE Guidelines suggest bisphosphonates are given to men with prostate cancer who are receiving <span class=cloze>androgen deprivation therapy</span> who also have osteoporosis.<br><br>
NICE Guidelines suggest bisphosphonates are given to men with prostate cancer who are receiving androgen deprivation therapy who also have <span class=cloze>[...]</span>.	NICE Guidelines suggest bisphosphonates are given to men with prostate cancer who are receiving androgen deprivation therapy who also have <span class=cloze>osteoporosis</span>.<br><br>
Acute systemic inflammatory reactions causing symptoms (arthralgia, fever, myalgia, nausea, vomiting) occur in <span class=cloze>[...]</span> of patients who have IV bisphosphonates.	Acute systemic inflammatory reactions causing symptoms (arthralgia, fever, myalgia, nausea, vomiting) occur in <span class=cloze>25%</span> of patients who have IV bisphosphonates.<br><br>
<span class=cloze>[...]</span> (arthralgia, fever, myalgia, nausea, vomiting) occur in 25% of patients who have IV bisphosphonates.	<span class=cloze>Acute systemic inflammatory reactions causing symptoms</span> (arthralgia, fever, myalgia, nausea, vomiting) occur in 25% of patients who have IV bisphosphonates.<br><br>
Acute systemic inflammatory reactions causing symptoms (arthralgia, fever, myalgia, nausea, vomiting) occur in 25% of patients who have <span class=cloze>[...]</span>.	Acute systemic inflammatory reactions causing symptoms (arthralgia, fever, myalgia, nausea, vomiting) occur in 25% of patients who have <span class=cloze>IV bisphosphonates</span>.<br><br>
If the bone is probed in osteonecrosis of the jaw, it is&nbsp;<span class=cloze>[...]</span>.	If the bone is probed in osteonecrosis of the jaw, it is&nbsp;<span class=cloze>non-tender</span>.<br><br>
Bisphosphonates can rarely cause&nbsp;<span class=cloze>[...]</span> with oedema of the rectus muscle.	Bisphosphonates can rarely cause&nbsp;<span class=cloze>ocular toxicity</span> with oedema of the rectus muscle.<br><br>Pain on all eye movements.
Ibandronic acid can be used in an eGFR <span class=cloze>[...]</span>.	Ibandronic acid can be used in an eGFR <span class=cloze>&lt;30</span>.<br><br>
Hydrocortisone has <span class=cloze>[...]</span> activity and mild mineralocorticoid activity.	Hydrocortisone has <span class=cloze>glucocorticoid</span> activity and mild mineralocorticoid activity.<br><br>
Hydrocortisone has glucocorticoid activity and mild <span class=cloze>[...]</span> activity.	Hydrocortisone has glucocorticoid activity and mild <span class=cloze>mineralocorticoid</span> activity.<br><br>
<span class=cloze>[...]</span> has glucocorticoid activity and mild mineralocorticoid activity.	<span class=cloze>Hydrocortisone</span> has glucocorticoid activity and mild mineralocorticoid activity.<br><br>
Steroids reduce the <span class=cloze>[...]</span> of the chemoreceptor-trigger zone.	Steroids reduce the <span class=cloze>permeability</span> of the chemoreceptor-trigger zone.<br><br>
Steroids reduce the permeability <span class=cloze>[...]</span>.	Steroids reduce the permeability <span class=cloze>of the chemoreceptor-trigger zone</span>.<br><br>
<span class=cloze>[...]</span> hydrocortisone = 5mg prednisolone	<span class=cloze>20mg</span> hydrocortisone = 5mg prednisolone<br><br>4:1 ratio
20mg hydrocortisone = <span class=cloze>[...]</span> prednisolone	20mg hydrocortisone = <span class=cloze>5mg</span> prednisolone<br><br>4:1 ratio
<span class=cloze>[...]</span> prednisolone = 0.75mg dexamethasone.	<span class=cloze>5mg</span> prednisolone = 0.75mg dexamethasone.<br><br>
5mg prednisolone = <span class=cloze>[...]</span> dexamethasone.	5mg prednisolone = <span class=cloze>0.75mg</span> dexamethasone.<br><br>
The symptoms of steroid psychosis can occur <span class=cloze>[...]</span> after initating treatment.	The symptoms of steroid psychosis can occur <span class=cloze>4-6 days</span> after initating treatment.<br><br>
The symptoms of steroid psychosis can take <span class=cloze>[...]</span> to resolve after cessation of treatment.	The symptoms of steroid psychosis can take <span class=cloze>1-2 weeks</span> to resolve after cessation of treatment.<br><br>
Steroid myopathy generally occurs after <span class=cloze>[...]</span> of treatment.	Steroid myopathy generally occurs after <span class=cloze>&gt;2 months</span> of treatment.<br><br>
Dexamethasone has a PO bioavailibility of <span class=cloze>[...]</span>.	Dexamethasone has a PO bioavailibility of <span class=cloze>~80%</span>.<br><br>
The diagnosis of SIADH is based on:<div><span class=cloze>[...]</span></div><div>2. Low plasma osmolality &lt;270</div><div>3. High urine osmolality &gt;20</div><div>4. Euvolaemic</div>	The diagnosis of SIADH is based on:<div><span class=cloze>1. Hyponatraemia &lt;130</span></div><div>2. Low plasma osmolality &lt;270</div><div>3. High urine osmolality &gt;20</div><div>4. Euvolaemic</div><br><br>
The diagnosis of SIADH is based on:<div>1. Hyponatraemia &lt;130</div><div><span class=cloze>[...]</span></div><div>3. High urine osmolality &gt;20</div><div>4. Euvolaemic</div>	The diagnosis of SIADH is based on:<div>1. Hyponatraemia &lt;130</div><div><span class=cloze>2. Low plasma osmolality &lt;270</span></div><div>3. High urine osmolality &gt;20</div><div>4. Euvolaemic</div><br><br>
The diagnosis of SIADH is based on:<div>1. Hyponatraemia &lt;130</div><div>2. Low plasma osmolality &lt;270</div><div><span class=cloze>[...]</span></div><div>4. Euvolaemic</div>	The diagnosis of SIADH is based on:<div>1. Hyponatraemia &lt;130</div><div>2. Low plasma osmolality &lt;270</div><div><span class=cloze>3. High urine osmolality &gt;20</span></div><div>4. Euvolaemic</div><br><br>
The diagnosis of SIADH is based on:<div>1. Hyponatraemia &lt;130</div><div>2. Low plasma osmolality &lt;270</div><div>3. High urine osmolality &gt;20</div><div><span class=cloze>[...]</span></div>	The diagnosis of SIADH is based on:<div>1. Hyponatraemia &lt;130</div><div>2. Low plasma osmolality &lt;270</div><div>3. High urine osmolality &gt;20</div><div><span class=cloze>4. Euvolaemic</span></div><br><br>
Steroid-induced diabetes occurs in <span class=cloze>[...]</span> of patients who start corticosteroids.	Steroid-induced diabetes occurs in <span class=cloze>~10%</span> of patients who start corticosteroids.<br><br>
Octreotide and lanreotide are <span class=cloze>[...]</span> of somatostatin.	Octreotide and lanreotide are <span class=cloze>synthetic analogues</span> of somatostatin.<br><br>
Octreotide and lanreotide are synthetic analogues of <span class=cloze>[...]</span>.	Octreotide and lanreotide are synthetic analogues of <span class=cloze>somatostatin</span>.<br><br>
Octreotide reduces <span class=cloze>[...]</span> blood&nbsp;flow.	Octreotide reduces <span class=cloze>splanchnic</span> blood&nbsp;flow.<br><br>
Octreotide inhibits <span class=cloze>[...]</span>.	Octreotide inhibits <span class=cloze>vascular endothelial growth</span>.<br><br>
<span class=cloze>[...]</span> inhibits vascular endothelial growth.	<span class=cloze>Octreotide</span> inhibits vascular endothelial growth.<br><br>
<span class=cloze>[...]</span> reduces splanchnic blood&nbsp;flow.	<span class=cloze>Octreotide</span> reduces splanchnic blood&nbsp;flow.<br><br>
Octreotide reduces <span class=cloze>[...]</span> production.	Octreotide reduces <span class=cloze>salivary</span> production.<br><br>
<span class=cloze>[...]</span> reduces salivary production.	<span class=cloze>Octreotide</span> reduces salivary production.<br><br>
<span class=cloze>[...]</span> is recommended first-line for severe chemotherapy/radiotherapy-induced diarrhoea.	<span class=cloze>Octreotide</span> is recommended first-line for severe chemotherapy/radiotherapy-induced diarrhoea.<br><br>
Octreotide is recommended first-line for severe <span class=cloze>[...]</span> diarrhoea.	Octreotide is recommended first-line for severe <span class=cloze>chemotherapy/radiotherapy-induced</span> diarrhoea.<br><br>
Severe chemotherapy/radiotherapy-related diarrhoea is defined as:<div>1. <span class=cloze>[...]</span></div><div>2. Hospital admission</div><div>3. IV fluids</div>	Severe chemotherapy/radiotherapy-related diarrhoea is defined as:<div>1. <span class=cloze>&gt;7 stools/day over baseline</span></div><div>2. Hospital admission</div><div>3. IV fluids</div><br><br>
Severe chemotherapy/radiotherapy-related diarrhoea is defined as:<div>1. &gt;7 stools/day over baseline</div><div>2. <span class=cloze>[...]</span></div><div>3. IV fluids</div>	Severe chemotherapy/radiotherapy-related diarrhoea is defined as:<div>1. &gt;7 stools/day over baseline</div><div>2. <span class=cloze>Hospital admission</span></div><div>3. IV fluids</div><br><br>
Severe chemotherapy/radiotherapy-related diarrhoea is defined as:<div>1. &gt;7 stools/day over baseline</div><div>2. Hospital admission</div><div>3. <span class=cloze>[...]</span></div>	Severe chemotherapy/radiotherapy-related diarrhoea is defined as:<div>1. &gt;7 stools/day over baseline</div><div>2. Hospital admission</div><div>3. <span class=cloze>IV fluids</span></div><br><br>
In Type 1 diabetes, the use of stomatostatin analogues can reduce insulin needs by <span class=cloze>[...]</span>.	In Type 1 diabetes, the use of stomatostatin analogues can reduce insulin needs by <span class=cloze>50%</span>.<br><br>
In Type 1 diabetes, the use of <span class=cloze>[...]</span> can reduce insulin needs by 50%.	In Type 1 diabetes, the use of <span class=cloze>stomatostatin analogues</span> can reduce insulin needs by 50%.<br><br>
Somatostatin analogues are used for the treatment of <span class=cloze>[...]</span>, carcinoid, VIPomas and glucagonomas.	Somatostatin analogues are used for the treatment of <span class=cloze>acromegaly</span>, carcinoid, VIPomas and glucagonomas.<br><br>
Somatostatin analogues are used for the treatment of acromegaly, <span class=cloze>[...]</span>, VIPomas and glucagonomas.	Somatostatin analogues are used for the treatment of acromegaly, <span class=cloze>carcinoid</span>, VIPomas and glucagonomas.<br><br>
Somatostatin analogues are used for the treatment of acromegaly, carcinoid, <span class=cloze>[...]</span> and glucagonomas.	Somatostatin analogues are used for the treatment of acromegaly, carcinoid, <span class=cloze>VIPomas</span> and glucagonomas.<br><br>
Somatostatin analogues are used for the treatment of acromegaly, carcinoid, VIPomas and <span class=cloze>[...]</span>.	Somatostatin analogues are used for the treatment of acromegaly, carcinoid, VIPomas and <span class=cloze>glucagonomas</span>.<br><br>
Progestogens may improve appetite by increasing <span class=cloze>[...]</span> in the hypothalamus.	Progestogens may improve appetite by increasing <span class=cloze>orexogenic neurotransmitters</span> in the hypothalamus.<br><br>
Cachexia is defined as:<div>1. Loss of <span class=cloze>[...]</span></div><div>2. Loss which cannot be reversed by conventional nutritional support.</div>	Cachexia is defined as:<div>1. Loss of <span class=cloze>skeletal muscle and body fat</span></div><div>2. Loss which cannot be reversed by conventional nutritional support.</div><br><br>
Cachexia is defined as:<div>1. Loss of skeletal muscle and body fat</div><div>2. Loss which <span class=cloze>[...]</span>.</div>	Cachexia is defined as:<div>1. Loss of skeletal muscle and body fat</div><div>2. Loss which <span class=cloze>cannot be reversed by conventional nutritional support</span>.</div><br><br>
In cancer-related anxorexia-cachexia syndrome, <span class=cloze>[...]</span> act on the hypothalamus and skeletal muscle.	In cancer-related anxorexia-cachexia syndrome, <span class=cloze>IL-1 and TNF</span> act on the hypothalamus and skeletal muscle.<br><br>
In cancer-related anxorexia-cachexia syndrome, IL-1 and TNF act on the <span class=cloze>[...]</span>.	In cancer-related anxorexia-cachexia syndrome, IL-1 and TNF act on the <span class=cloze>hypothalamus and skeletal muscle</span>.<br><br>
<span class=cloze>[...]</span> can occur in 10-25% of men who take megesterol acetate.	<span class=cloze>Impotence</span> can occur in 10-25% of men who take megesterol acetate.<br><br>
Impotence can occur in <span class=cloze>[...]</span> of men who take megesterol acetate.	Impotence can occur in <span class=cloze>10-25%</span> of men who take megesterol acetate.<br><br>
Impotence can occur in 10-25% of men who take <span class=cloze>[...]</span>.	Impotence can occur in 10-25% of men who take <span class=cloze>megesterol acetate</span>.<br><br>
Megestrol acetate increases appetite in&nbsp;<span class=cloze>[...]</span> of patients.	Megestrol acetate increases appetite in&nbsp;<span class=cloze>25%</span> of patients.<br><br>
Megestrol acetate increases weight by an average of <span class=cloze>[...]</span> in ~8% of patients.	Megestrol acetate increases weight by an average of <span class=cloze>2kg</span> in ~8% of patients.<br><br>
Megestrol acetate increases weight by an average of 2kg in <span class=cloze>[...]</span> of patients.	Megestrol acetate increases weight by an average of 2kg in <span class=cloze>~8%</span> of patients.<br><br>
The adverse effects of megesterol acetate are <span class=cloze>[...]</span>, VTE and death.	The adverse effects of megesterol acetate are <span class=cloze>oedema</span>, VTE and death.<br><br>
The adverse effects of megesterol acetate are oedema, <span class=cloze>[...]</span> and death.	The adverse effects of megesterol acetate are oedema, <span class=cloze>VTE</span> and death.<br><br>
The adverse effects of megesterol acetate are oedema, VTE and <span class=cloze>[...]</span>.	The adverse effects of megesterol acetate are oedema, VTE and <span class=cloze>death</span>.<br><br>
A meta-analysis on the use of megestrol acetate showed <span class=cloze>[...]</span> evidence for effect.	A meta-analysis on the use of megestrol acetate showed <span class=cloze>poor</span> evidence for effect.<br><br>
A <span class=cloze>[...]</span> on the use of megestrol acetate showed poor evidence for effect.	A <span class=cloze>meta-analysis</span> on the use of megestrol acetate showed poor evidence for effect.<br><br>
The concurrent use of danazol (anabolic steroid) and a statin has been associated with:<div>1. <span class=cloze>[...]</span></div><div>2. pancreatitis</div><div>3. Rhabomyolysis</div>	The concurrent use of danazol (anabolic steroid) and a statin has been associated with:<div>1. <span class=cloze>acute renal impairment</span></div><div>2. pancreatitis</div><div>3. Rhabomyolysis</div><br><br>
The concurrent use of danazol (anabolic steroid) and a statin has been associated with:<div>1. acute renal impairment</div><div>2. <span class=cloze>[...]</span></div><div>3. Rhabomyolysis</div>	The concurrent use of danazol (anabolic steroid) and a statin has been associated with:<div>1. acute renal impairment</div><div>2. <span class=cloze>pancreatitis</span></div><div>3. Rhabomyolysis</div><br><br>
The concurrent use of danazol (anabolic steroid) and a statin has been associated with:<div>1. acute renal impairment</div><div>2. pancreatitis</div><div>3. <span class=cloze>[...]</span></div>	The concurrent use of danazol (anabolic steroid) and a statin has been associated with:<div>1. acute renal impairment</div><div>2. pancreatitis</div><div>3. <span class=cloze>Rhabomyolysis</span></div><br><br>
Low-grade <span class=cloze>[...]</span> occurs in &gt;80% of patients receiving thalidomide.	Low-grade <span class=cloze>peripheral neuropathy</span> occurs in &gt;80% of patients receiving thalidomide.<br><br>
Low-grade peripheral neuropathy occurs in <span class=cloze>[...]</span> of patients receiving thalidomide.	Low-grade peripheral neuropathy occurs in <span class=cloze>&gt;80%</span> of patients receiving thalidomide.<br><br>
Low-grade peripheral neuropathy occurs in &gt;80% of patients receiving <span class=cloze>[...]</span>.	Low-grade peripheral neuropathy occurs in &gt;80% of patients receiving <span class=cloze>thalidomide</span>.<br><br>
In thalidomide-induced peripheral neuropathy:<div>1. <span class=cloze>[...]</span> is preserved</div><div>2. Mild decrease in sensation distally</div><div>3. Reflexes, especially ankle jerks, may be depressed/absent</div><div>4. Distal -&gt; proximal progression</div>	In thalidomide-induced peripheral neuropathy:<div>1. <span class=cloze>Strength</span> is preserved</div><div>2. Mild decrease in sensation distally</div><div>3. Reflexes, especially ankle jerks, may be depressed/absent</div><div>4. Distal -&gt; proximal progression</div><br><br>
In thalidomide-induced peripheral neuropathy:<div>1. Strength is preserved</div><div>2. Mild decrease in <span class=cloze>[...]</span> distally</div><div>3. Reflexes, especially ankle jerks, may be depressed/absent</div><div>4. Distal -&gt; proximal progression</div>	In thalidomide-induced peripheral neuropathy:<div>1. Strength is preserved</div><div>2. Mild decrease in <span class=cloze>sensation</span> distally</div><div>3. Reflexes, especially ankle jerks, may be depressed/absent</div><div>4. Distal -&gt; proximal progression</div><br><br>
In thalidomide-induced peripheral neuropathy:<div>1. Strength is preserved</div><div>2. Mild decrease in sensation distally</div><div>3. Reflexes, especially <span class=cloze>[...]</span>, may be <span class=cloze>[...]</span></div><div>4. Distal -&gt; proximal progression</div>	In thalidomide-induced peripheral neuropathy:<div>1. Strength is preserved</div><div>2. Mild decrease in sensation distally</div><div>3. Reflexes, especially <span class=cloze>ankle jerks</span>, may be <span class=cloze>depressed/absent</span></div><div>4. Distal -&gt; proximal progression</div><br><br>
In thalidomide-induced peripheral neuropathy:<div>1. Strength is preserved</div><div>2. Mild decrease in sensation distally</div><div>3. Reflexes, especially ankle jerks, may be depressed/absent</div><div>4. <span class=cloze>[...]</span> progression</div>	In thalidomide-induced peripheral neuropathy:<div>1. Strength is preserved</div><div>2. Mild decrease in sensation distally</div><div>3. Reflexes, especially ankle jerks, may be depressed/absent</div><div>4. <span class=cloze>Distal -&gt; proximal</span> progression</div><br><br>
<span class=cloze>[...]</span> increase the risk of VTE in patients with multiple myeloma.	<span class=cloze>Thalidomide and lenalidomide</span> increase the risk of VTE in patients with multiple myeloma.<br><br>
Thalidomide and lenalidomide increase the risk of <span class=cloze>[...]</span> in patients with multiple myeloma.	Thalidomide and lenalidomide increase the risk of <span class=cloze>VTE</span> in patients with multiple myeloma.<br><br>
Thalidomide and lenalidomide increase the risk of VTE in patients with <span class=cloze>[...]</span>.	Thalidomide and lenalidomide increase the risk of VTE in patients with <span class=cloze>multiple myeloma</span>.<br><br>
Thalidomide is associated with:<div>1. <span class=cloze>[...]</span></div><div>2. Oedema</div><div>3. Hypotension</div>	Thalidomide is associated with:<div>1. <span class=cloze>Arrhythmia</span></div><div>2. Oedema</div><div>3. Hypotension</div><br><br>
Thalidomide is associated with:<div>1. Arrhythmia</div><div>2. <span class=cloze>[...]</span></div><div>3. Hypotension</div>	Thalidomide is associated with:<div>1. Arrhythmia</div><div>2. <span class=cloze>Oedema</span></div><div>3. Hypotension</div><br><br>
Thalidomide is associated with:<div>1. Arrhythmia</div><div>2. Oedema</div><div>3. <span class=cloze>[...]</span></div>	Thalidomide is associated with:<div>1. Arrhythmia</div><div>2. Oedema</div><div>3. <span class=cloze>Hypotension</span></div><br><br>
A <span class=cloze>[...]</span> rash may occur 10-14 days after starting thalidomide.	A <span class=cloze>pruritic and maculopapular</span> rash may occur 10-14 days after starting thalidomide.<br><br>
A pruritic and maculopapular rash may occur <span class=cloze>[...]</span> after starting thalidomide.	A pruritic and maculopapular rash may occur <span class=cloze>10-14 days</span> after starting thalidomide.<br><br>
A pruritic and maculopapular rash may occur 10-14 days after starting <span class=cloze>[...]</span>.	A pruritic and maculopapular rash may occur 10-14 days after starting <span class=cloze>thalidomide</span>.<br><br>
Severe skin reactions, such as <span class=cloze>[...]</span> may occur with thalidomide.	Severe skin reactions, such as <span class=cloze>Stevens-Johnson syndrome and toxic epidermal necrolysis</span> may occur with thalidomide.<br><br>
Severe skin reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis may occur with <span class=cloze>[...]</span>.	Severe skin reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis may occur with <span class=cloze>thalidomide</span>.<br><br>
Skin complications from thalidomide appear more likely when combined with <span class=cloze>[...]</span>.	Skin complications from thalidomide appear more likely when combined with <span class=cloze>corticosteroids</span>.<br><br>
Skin complications from thalidomide appear <span class=cloze>[...]</span> when combined with corticosteroids.	Skin complications from thalidomide appear <span class=cloze>more likely</span> when combined with corticosteroids.<br><br>
With thalidomide, contraception should be used:<div>1. More than <span class=cloze>[...]</span> starting treatment</div><div>2. During treatment</div><div>3. 4 weeks after stopping treatment</div>	With thalidomide, contraception should be used:<div>1. More than <span class=cloze>4 weeks before</span> starting treatment</div><div>2. During treatment</div><div>3. 4 weeks after stopping treatment</div><br><br>
With thalidomide, contraception should be used:<div>1. More than 4 weeks before starting treatment</div><div>2. <span class=cloze>[...]</span></div><div>3. 4 weeks after stopping treatment</div>	With thalidomide, contraception should be used:<div>1. More than 4 weeks before starting treatment</div><div>2. <span class=cloze>During treatment</span></div><div>3. 4 weeks after stopping treatment</div><br><br>
With thalidomide, contraception should be used:<div>1. More than 4 weeks before starting treatment</div><div>2. During treatment</div><div>3. <span class=cloze>[...]</span> stopping treatment</div>	With thalidomide, contraception should be used:<div>1. More than 4 weeks before starting treatment</div><div>2. During treatment</div><div>3. <span class=cloze>4 weeks after</span> stopping treatment</div><br><br>
Peripheral neuropathy is graded:<div>1. <span class=cloze>[...]</span> loss of function</div><div>2. Interfering with function, but not with activities of daily living</div><div>3. Interfering with ADLs</div><div>4. Disabling</div>	Peripheral neuropathy is graded:<div>1. <span class=cloze>No</span> loss of function</div><div>2. Interfering with function, but not with activities of daily living</div><div>3. Interfering with ADLs</div><div>4. Disabling</div><br><br>So - with medications which cause peripheral neuropathy:<div>- At grade 1, consider reducing the dose<br /><div>- At grade 2, the dose should be reduced or drug stopped. If there is an improvement to grade 1 or better, consider restarting treatment (risk/benefit). If no improvement, stop treatment.</div></div><div>- At grade 3 or 4, stop treatment</div>
Peripheral neuropathy is graded:<div>1. No loss of function</div><div>2. <span class=cloze>[...]</span> function, but not with <span class=cloze>[...]</span></div><div>3. Interfering with ADLs</div><div>4. Disabling</div>	Peripheral neuropathy is graded:<div>1. No loss of function</div><div>2. <span class=cloze>Interfering with</span> function, but not with <span class=cloze>activities of daily living</span></div><div>3. Interfering with ADLs</div><div>4. Disabling</div><br><br>So - with medications which cause peripheral neuropathy:<div>- At grade 1, consider reducing the dose<br /><div>- At grade 2, the dose should be reduced or drug stopped. If there is an improvement to grade 1 or better, consider restarting treatment (risk/benefit). If no improvement, stop treatment.</div></div><div>- At grade 3 or 4, stop treatment</div>
Peripheral neuropathy is graded:<div>1. No loss of function</div><div>2. Interfering with function, but not with activities of daily living</div><div>3. <span class=cloze>[...]</span> with ADLs</div><div>4. Disabling</div>	Peripheral neuropathy is graded:<div>1. No loss of function</div><div>2. Interfering with function, but not with activities of daily living</div><div>3. <span class=cloze>Interfering</span> with ADLs</div><div>4. Disabling</div><br><br>So - with medications which cause peripheral neuropathy:<div>- At grade 1, consider reducing the dose<br /><div>- At grade 2, the dose should be reduced or drug stopped. If there is an improvement to grade 1 or better, consider restarting treatment (risk/benefit). If no improvement, stop treatment.</div></div><div>- At grade 3 or 4, stop treatment</div>
Peripheral neuropathy is graded:<div>1. No loss of function</div><div>2. Interfering with function, but not with activities of daily living</div><div>3. Interfering with ADLs</div><div>4. <span class=cloze>[...]</span></div>	Peripheral neuropathy is graded:<div>1. No loss of function</div><div>2. Interfering with function, but not with activities of daily living</div><div>3. Interfering with ADLs</div><div>4. <span class=cloze>Disabling</span></div><br><br>So - with medications which cause peripheral neuropathy:<div>- At grade 1, consider reducing the dose<br /><div>- At grade 2, the dose should be reduced or drug stopped. If there is an improvement to grade 1 or better, consider restarting treatment (risk/benefit). If no improvement, stop treatment.</div></div><div>- At grade 3 or 4, stop treatment</div>
Tamsulosin is a <span class=cloze>[...]</span>.	Tamsulosin is a <span class=cloze>uroselective alpha-1-adrenergic receptor antagonist</span>.<br><br>
Dutasteride and finasteride are <span class=cloze>[...]</span>.	Dutasteride and finasteride are <span class=cloze>5-alpha-reductase inhibitors</span>.<br><br>
Oxybutynin is an <span class=cloze>[...]</span>.	Oxybutynin is an <span class=cloze>anti-muscarinic</span>.<br><br>
In anaemia of chronic disease, plasma ferritin is <span class=cloze>[...]</span>, and transferrin concentration is low.	In anaemia of chronic disease, plasma ferritin is <span class=cloze>high</span>, and transferrin concentration is low.<br><br>
In anaemia of chronic disease, plasma ferritin is high, and transferrin concentration is <span class=cloze>[...]</span>.	In anaemia of chronic disease, plasma ferritin is high, and transferrin concentration is <span class=cloze>low</span>.<br><br>
The typical dietary intake of potassium is <span class=cloze>[...]</span>mmol.	The typical dietary intake of potassium is <span class=cloze>40-80</span>mmol.<br><br>
The emergency treatment of hyperkalaemia:<div>1. Stop the <span class=cloze>[...]</span></div><div>2. 10ml of 10% calcium gluconate IV</div><div>3. Insulin-dextrose solution (10 units of insulin in 50ml of dextrose 50%)</div>	The emergency treatment of hyperkalaemia:<div>1. Stop the <span class=cloze>drug causing it</span></div><div>2. 10ml of 10% calcium gluconate IV</div><div>3. Insulin-dextrose solution (10 units of insulin in 50ml of dextrose 50%)</div><br><br>
The emergency treatment of hyperkalaemia:<div>1. Stop the drug causing it</div><div>2. <span class=cloze>[...]</span></div><div>3. Insulin-dextrose solution (10 units of insulin in 50ml of dextrose 50%)</div>	The emergency treatment of hyperkalaemia:<div>1. Stop the drug causing it</div><div>2. <span class=cloze>10ml of 10% calcium gluconate IV</span></div><div>3. Insulin-dextrose solution (10 units of insulin in 50ml of dextrose 50%)</div><br><br>
The emergency treatment of hyperkalaemia:<div>1. Stop the drug causing it</div><div>2. 10ml of 10% calcium gluconate IV</div><div>3. <span class=cloze>[...]</span></div>	The emergency treatment of hyperkalaemia:<div>1. Stop the drug causing it</div><div>2. 10ml of 10% calcium gluconate IV</div><div>3. <span class=cloze>Insulin-dextrose solution (10 units of insulin in 50ml of dextrose 50%)</span></div><br><br>
Cisplatin can cause a low serum <span class=cloze>[...]</span>.	Cisplatin can cause a low serum <span class=cloze>magnesium</span>.<br><br>
How does capsacin work?	Depletes substance P at sensory nerve endings
C fibers are <span class=cloze>[...]</span>, have a small diameter and low conduction velocity.	C fibers are <span class=cloze>unmyelinated</span>, have a small diameter and low conduction velocity.<br><br>
C fibers are unmyelinated, have a <span class=cloze>[...]</span> and low conduction velocity.	C fibers are unmyelinated, have a <span class=cloze>small diameter</span> and low conduction velocity.<br><br>
C fibers are unmyelinated, have a small diameter and <span class=cloze>[...]</span> velocity.	C fibers are unmyelinated, have a small diameter and <span class=cloze>low conduction</span> velocity.<br><br>
&nbsp;A-delta fibers are thinly <span class=cloze>[...]</span> and they send impulses faster than unmyelinated C fibers.	&nbsp;A-delta fibers are thinly <span class=cloze>myelinated</span> and they send impulses faster than unmyelinated C fibers.<br><br>
&nbsp;A-delta fibers are thinly myelinated and they send impulses <span class=cloze>[...]</span> than unmyelinated C fibers.	&nbsp;A-delta fibers are thinly myelinated and they send impulses <span class=cloze>faster</span> than unmyelinated C fibers.<br><br>
<span class=cloze>[...]</span> is released from C-fibres.	<span class=cloze>Substance P</span> is released from C-fibres.<br><br>
Substance P is released from <span class=cloze>[...]</span>.	Substance P is released from <span class=cloze>C-fibres</span>.<br><br>
For capsasin, what is the NNT for pain which is 'much or very much better' in post-herpeic neuralgia at:<div><br /></div><div>A - 8 weeks</div><div>B - 12 weeks</div>	A - 8.8<div>B - 7</div>
For capsasin, what is the NNT for pain which is 'much or very much better' in HIV related neuropathic pain at 12 weeks?<div><br /></div>	5.8
What is the NNT for topical NSAIDs to achieve a 50% pain reduction?	4.5
Baclofen works at <span class=cloze>[...]</span>-receptors.	Baclofen works at <span class=cloze>GABA</span>-receptors.<br><br>
Baclofen should be <span class=cloze>[...]</span> in renal impairment.	Baclofen should be <span class=cloze>dose-reduced</span> in renal impairment.<br><br>
Baclofen should be dose-reduced in <span class=cloze>[...]</span>.	Baclofen should be dose-reduced in <span class=cloze>renal impairment</span>.<br><br>
Dantroline acts directly on <span class=cloze>[...]</span> by binding to ryanodine receptors.	Dantroline acts directly on <span class=cloze>skeletal muscles</span> by binding to ryanodine receptors.<br><br>
Dantroline acts directly on skeletal muscles by binding to <span class=cloze>[...]</span> receptors.	Dantroline acts directly on skeletal muscles by binding to <span class=cloze>ryanodine</span> receptors.<br><br>
Dantrolene use should be monitored with <span class=cloze>[...]</span>.	Dantrolene use should be monitored with <span class=cloze>LFTs</span>.<br><br>
Tizanadine is a <span class=cloze>[...]</span> in the CNS at supraspinal and spinal levels.	Tizanadine is a <span class=cloze>central alpha-2 agonist</span> in the CNS at supraspinal and spinal levels.<br><br>
Tizanadine is a central alpha-2 agonist in the CNS at <span class=cloze>[...]</span> levels.	Tizanadine is a central alpha-2 agonist in the CNS at <span class=cloze>supraspinal and spinal</span> levels.<br><br>
What receptor does ketamine act on?	NMDA-receptor antagonist.
Ketamine causes hepatic enzyme <span class=cloze>[...]</span>.	Ketamine causes hepatic enzyme <span class=cloze>induction</span>.<br><br>
How many children worldwide could benefit from palliative care?	~20 million
A rotigotine patch will need to be removed before an <span class=cloze>[...]</span> scan.	A rotigotine patch will need to be removed before an <span class=cloze>MRI</span> scan.<br><br>
A hyoscine patch will need to be removed before an <span class=cloze>[...]</span> scan.	A hyoscine patch will need to be removed before an <span class=cloze>MRI</span> scan.<br><br>
A diclofenac patch will need to be removed before an <span class=cloze>[...]</span> scan.	A diclofenac patch will need to be removed before an <span class=cloze>MRI</span> scan.<br><br>
A lidocaine patch will need to be removed before an <span class=cloze>[...]</span> scan.	A lidocaine patch will need to be removed before an <span class=cloze>MRI</span> scan.<br><br>
What is the conversion from dihydrocodine to morphine?	10:1
What is the conversion from tramadol to morphine?	10:1
What is the conversion from oral morphine to buprenorphine?	100:1<div><br /><div><b>Multiply by 10</b> to get the <i>total 24 hour dose in micrograms (300mg oral morphine in 24 hours = 3000 micrograms buprennorphine in 24 hours)</i><div><b>Then, divide by 24 to get the hourly rate.</b></div></div></div>
What is the conversion from oral morphine to fentanyl?	100:1<div><br /><div><b>Multiply by 10</b>&nbsp;to get the&nbsp;<i>total 24 hour dose in micrograms (300mg oral morphine in 24 hours = 3000 micrograms fentanyl in 24 hours)</i><div><b>Then, divide by 24 to get the hourly rate.</b></div></div></div>
What is the conversion rate of oral morphine to alfentanyl?	30:1
Benzodiazepines increase the risk of car accidents by <span class=cloze>[...]</span>.	Benzodiazepines increase the risk of car accidents by <span class=cloze>60-80%</span>.<br><br>
Spinal analgesia is effective in <span class=cloze>[...]</span> of patients.	Spinal analgesia is effective in <span class=cloze>&gt;50%</span> of patients.<br><br>
Clonidine is an <span class=cloze>[...]</span> receptor agonist.	"Clonidine is an <span class=cloze>alpha-adrenergic</span> receptor agonist.<br><br>Used as a spinal drug in neuropathic pain.<div>Can cause <font color=""#0000ff"">dose-related hypotension and bradycardia</font>.</div><div>Abrupt cessation can cause <b>rebound hypertension</b>.</div>"
<span class=cloze>[...]</span> is used to check the correct position of an NG tube.	<span class=cloze>pH paper</span> is used to check the correct position of an NG tube.<br><br>
Central sleep apnoea is reported to occur in <span class=cloze>[...]</span> on methadone maintainance.	Central sleep apnoea is reported to occur in <span class=cloze>30% of patients</span> on methadone maintainance.<br><br>
Central sleep apnoea is reported to occur in 30% of patients on <span class=cloze>[...]</span>.	Central sleep apnoea is reported to occur in 30% of patients on <span class=cloze>methadone maintainance</span>.<br><br>
Cisplatin can cause a <span class=cloze>[...]</span> magnesium.	Cisplatin can cause a <span class=cloze>low serum</span> magnesium.<br><br>
What is the maximum mortality attributable to pprolonged QT?	6 per 10000 patient-years
What happens to the serum concentration of oxycodone when fluconazole is taken?	The oxycodone concentration goes up - fluconazole is a hepatic enzyme inhibitor.
What happens to the serum concentration of fentanyl when carbamazapine is given?	The concentration of fentanyl goes down - carbamazapine is a hepatic enzyme inducer.
Acute dystonias are associated with <span class=cloze>[...]</span>.	Acute dystonias are associated with <span class=cloze>dopamine receptor antagonists</span>.<br><br>
What % of patients treated long-term with antipsychotics develop parkinsonism?	30-60%
To treat acute dystonia caused by antipsychotics:<div>1. <span class=cloze>[...]</span> the causative drug</div><div>2. Immediate relief - <b>diazepam 5mg iv or procyclidine 5-10mg IM</b></div><div>3. Follow this with orphenadrine 50mg BD for one week.</div>	To treat acute dystonia caused by antipsychotics:<div>1. <span class=cloze>Stop, switch or reduce</span> the causative drug</div><div>2. Immediate relief - <b>diazepam 5mg iv or procyclidine 5-10mg IM</b></div><div>3. Follow this with orphenadrine 50mg BD for one week.</div><br><br>
To treat acute dystonia caused by antipsychotics:<div>1. Stop, switch or reduce the causative drug</div><div>2. Immediate relief - <b><span class=cloze>[...]</span> or <span class=cloze>[...]</span></b></div><div>3. Follow this with orphenadrine 50mg BD for one week.</div>	To treat acute dystonia caused by antipsychotics:<div>1. Stop, switch or reduce the causative drug</div><div>2. Immediate relief - <b><span class=cloze>diazepam 5mg iv</span> or <span class=cloze>procyclidine 5-10mg IM</span></b></div><div>3. Follow this with orphenadrine 50mg BD for one week.</div><br><br>
To treat acute dystonia caused by antipsychotics:<div>1. Stop, switch or reduce the causative drug</div><div>2. Immediate relief - <b>diazepam 5mg iv or procyclidine 5-10mg IM</b></div><div>3. Follow this with <span class=cloze>[...]</span> for one week.</div>	To treat acute dystonia caused by antipsychotics:<div>1. Stop, switch or reduce the causative drug</div><div>2. Immediate relief - <b>diazepam 5mg iv or procyclidine 5-10mg IM</b></div><div>3. Follow this with <span class=cloze>orphenadrine 50mg BD</span> for one week.</div><br><br>
To treat acute akathisia caused by antipsychotics:<div>1. <span class=cloze>[...]</span> the causative drug</div><div>2. Add <b>propranolol 10mg tds </b>increasing every few days to 40mg tds max</div><div>3. Add a BZD if the patient is very distressed</div>	To treat acute akathisia caused by antipsychotics:<div>1. <span class=cloze>Stop, switch or reduce</span> the causative drug</div><div>2. Add <b>propranolol 10mg tds </b>increasing every few days to 40mg tds max</div><div>3. Add a BZD if the patient is very distressed</div><br><br>
To treat acute akathisia caused by antipsychotics:<div>1. Stop, switch or reduce the causative drug</div><div>2. Add <b><span class=cloze>[...]</span> </b>increasing every few days to 40mg tds max</div><div>3. Add a BZD if the patient is very distressed</div>	To treat acute akathisia caused by antipsychotics:<div>1. Stop, switch or reduce the causative drug</div><div>2. Add <b><span class=cloze>propranolol 10mg tds</span> </b>increasing every few days to 40mg tds max</div><div>3. Add a BZD if the patient is very distressed</div><br><br>
To treat acute akathisia caused by antipsychotics:<div>1. Stop, switch or reduce the causative drug</div><div>2. Add <b>propranolol 10mg tds </b>increasing every few days to 40mg tds max</div><div>3. Add a <span class=cloze>[...]</span> if the patient is very distressed</div>	To treat acute akathisia caused by antipsychotics:<div>1. Stop, switch or reduce the causative drug</div><div>2. Add <b>propranolol 10mg tds </b>increasing every few days to 40mg tds max</div><div>3. Add a <span class=cloze>BZD</span> if the patient is very distressed</div><br><br>
In drug-induced tardive dyskinesia, what % of patients have complete resolution of symptoms <b>3 months</b> after stopping the causative drug?	30%
In drug-induced tardive dyskinesia, what % of patients have complete resolution of symptoms&nbsp;<b>5 years</b>&nbsp;after stopping the causative drug?	70%
NICE recommends nutritional support for patients with:<div>- BMI &lt;<span class=cloze>[...]</span></div><div>- Unintentional weight loss of &gt;10% in the last 3-6 months</div><div>- BMI &lt;20 and unintentional weight loss of &gt;5%</div><div>- Inadequate oral intake for &gt;5 days</div><div>- malabsorption, increased nutrient losses, increased catabolism.</div>	NICE recommends nutritional support for patients with:<div>- BMI &lt;<span class=cloze>18</span></div><div>- Unintentional weight loss of &gt;10% in the last 3-6 months</div><div>- BMI &lt;20 and unintentional weight loss of &gt;5%</div><div>- Inadequate oral intake for &gt;5 days</div><div>- malabsorption, increased nutrient losses, increased catabolism.</div><br><br>
NICE recommends nutritional support for patients with:<div>- BMI &lt;18</div><div>- Unintentional weight loss of &gt;<span class=cloze>[...]</span> in the last <span class=cloze>[...]</span> months</div><div>- BMI &lt;20 and unintentional weight loss of &gt;5%</div><div>- Inadequate oral intake for &gt;5 days</div><div>- malabsorption, increased nutrient losses, increased catabolism.</div>	NICE recommends nutritional support for patients with:<div>- BMI &lt;18</div><div>- Unintentional weight loss of &gt;<span class=cloze>10%</span> in the last <span class=cloze>3-6</span> months</div><div>- BMI &lt;20 and unintentional weight loss of &gt;5%</div><div>- Inadequate oral intake for &gt;5 days</div><div>- malabsorption, increased nutrient losses, increased catabolism.</div><br><br>
NICE recommends nutritional support for patients with:<div>- BMI &lt;18</div><div>- Unintentional weight loss of &gt;10% in the last 3-6 months</div><div>- BMI &lt;<span class=cloze>[...]</span> and unintentional weight loss of &gt;<span class=cloze>[...]</span></div><div>- Inadequate oral intake for &gt;5 days</div><div>- malabsorption, increased nutrient losses, increased catabolism.</div>	NICE recommends nutritional support for patients with:<div>- BMI &lt;18</div><div>- Unintentional weight loss of &gt;10% in the last 3-6 months</div><div>- BMI &lt;<span class=cloze>20</span> and unintentional weight loss of &gt;<span class=cloze>5%</span></div><div>- Inadequate oral intake for &gt;5 days</div><div>- malabsorption, increased nutrient losses, increased catabolism.</div><br><br>
NICE recommends nutritional support for patients with:<div>- BMI &lt;18</div><div>- Unintentional weight loss of &gt;10% in the last 3-6 months</div><div>- BMI &lt;20 and unintentional weight loss of &gt;5%</div><div>- Inadequate oral intake for &gt;<span class=cloze>[...]</span> days</div><div>- malabsorption, increased nutrient losses, increased catabolism.</div>	NICE recommends nutritional support for patients with:<div>- BMI &lt;18</div><div>- Unintentional weight loss of &gt;10% in the last 3-6 months</div><div>- BMI &lt;20 and unintentional weight loss of &gt;5%</div><div>- Inadequate oral intake for &gt;<span class=cloze>5</span> days</div><div>- malabsorption, increased nutrient losses, increased catabolism.</div><br><br>
NICE recommends nutritional support for patients with:<div>- BMI &lt;18</div><div>- Unintentional weight loss of &gt;10% in the last 3-6 months</div><div>- BMI &lt;20 and unintentional weight loss of &gt;5%</div><div>- Inadequate oral intake for &gt;5 days</div><div>- <span class=cloze>[...]</span>, increased <span class=cloze>[...]</span> losses, increased <span class=cloze>[...]</span>.</div>	NICE recommends nutritional support for patients with:<div>- BMI &lt;18</div><div>- Unintentional weight loss of &gt;10% in the last 3-6 months</div><div>- BMI &lt;20 and unintentional weight loss of &gt;5%</div><div>- Inadequate oral intake for &gt;5 days</div><div>- <span class=cloze>malabsorption</span>, increased <span class=cloze>nutrient</span> losses, increased <span class=cloze>catabolism</span>.</div><br><br>
The diagnosis of cancer-cachexia is <b>any</b> of the following:<div>1. Weight loss &gt;<span class=cloze>[...]</span>% over the past <span class=cloze>[...]</span> months</div><div>2. BMI &lt;20 and weight loss of &gt;2%</div><div>3. Sarcopenia and weight loss &gt;2%</div>	The diagnosis of cancer-cachexia is <b>any</b> of the following:<div>1. Weight loss &gt;<span class=cloze>5</span>% over the past <span class=cloze>6</span> months</div><div>2. BMI &lt;20 and weight loss of &gt;2%</div><div>3. Sarcopenia and weight loss &gt;2%</div><br><br>
The diagnosis of cancer-cachexia is <b>any</b> of the following:<div>1. Weight loss &gt;5% over the past 6 months</div><div>2. BMI &lt;<span class=cloze>[...]</span> and weight loss of &gt;<span class=cloze>[...]</span>%</div><div>3. Sarcopenia and weight loss &gt;2%</div>	The diagnosis of cancer-cachexia is <b>any</b> of the following:<div>1. Weight loss &gt;5% over the past 6 months</div><div>2. BMI &lt;<span class=cloze>20</span> and weight loss of &gt;<span class=cloze>2</span>%</div><div>3. Sarcopenia and weight loss &gt;2%</div><br><br>
The diagnosis of cancer-cachexia is <b>any</b> of the following:<div>1. Weight loss &gt;5% over the past 6 months</div><div>2. BMI &lt;20 and weight loss of &gt;2%</div><div>3. <span class=cloze>[...]</span> and weight loss &gt;2%</div>	The diagnosis of cancer-cachexia is <b>any</b> of the following:<div>1. Weight loss &gt;5% over the past 6 months</div><div>2. BMI &lt;20 and weight loss of &gt;2%</div><div>3. <span class=cloze>Sarcopenia</span> and weight loss &gt;2%</div><br><br>
The diagnosis of cancer-cachexia is <b>any</b> of the following:<div>1. Weight loss &gt;5% over the past 6 months</div><div>2. BMI &lt;20 and weight loss of &gt;2%</div><div>3. Sarcopenia and weight loss &gt;<span class=cloze>[...]</span>%</div>	The diagnosis of cancer-cachexia is <b>any</b> of the following:<div>1. Weight loss &gt;5% over the past 6 months</div><div>2. BMI &lt;20 and weight loss of &gt;2%</div><div>3. Sarcopenia and weight loss &gt;<span class=cloze>2</span>%</div><br><br>
What BMI is a high-risk for refeeding syndrome?	&lt;16
What % weight loss over 3-6 months is a high risk for refeeding syndrome?	&gt;15%
After how many days of little to no nutritional intake is a high risk for refeeding syndrome?	10 days
Patients who have two or more of the following are at high risk of refeeding syndrome:<div>- BMI &lt;<span class=cloze>[...]</span></div><div>- Unintentional weight loss of &gt;15% in the past 3-6 months</div><div>- Little to no nutritional intake for &gt;5 days</div><div>- Hx of ETOHXS, drug abuse,&nbsp;IDDM, concurrent chemotherapy, antacids, diuretics</div>	Patients who have two or more of the following are at high risk of refeeding syndrome:<div>- BMI &lt;<span class=cloze>18</span></div><div>- Unintentional weight loss of &gt;15% in the past 3-6 months</div><div>- Little to no nutritional intake for &gt;5 days</div><div>- Hx of ETOHXS, drug abuse,&nbsp;IDDM, concurrent chemotherapy, antacids, diuretics</div><br><br>
Patients who have two or more of the following are at high risk of refeeding syndrome:<div>- BMI &lt;18</div><div>- Unintentional weight loss of &gt;<span class=cloze>[...]</span>% in the past <span class=cloze>[...]</span> months</div><div>- Little to no nutritional intake for &gt;5 days</div><div>- Hx of ETOHXS, drug abuse,&nbsp;IDDM, concurrent chemotherapy, antacids, diuretics</div>	Patients who have two or more of the following are at high risk of refeeding syndrome:<div>- BMI &lt;18</div><div>- Unintentional weight loss of &gt;<span class=cloze>15</span>% in the past <span class=cloze>3-6</span> months</div><div>- Little to no nutritional intake for &gt;5 days</div><div>- Hx of ETOHXS, drug abuse,&nbsp;IDDM, concurrent chemotherapy, antacids, diuretics</div><br><br>
Patients who have two or more of the following are at high risk of refeeding syndrome:<div>- BMI &lt;18</div><div>- Unintentional weight loss of &gt;15% in the past 3-6 months</div><div>- Little to no nutritional intake for &gt;<span class=cloze>[...]</span> days</div><div>- Hx of ETOHXS, drug abuse,&nbsp;IDDM, concurrent chemotherapy, antacids, diuretics</div>	Patients who have two or more of the following are at high risk of refeeding syndrome:<div>- BMI &lt;18</div><div>- Unintentional weight loss of &gt;15% in the past 3-6 months</div><div>- Little to no nutritional intake for &gt;<span class=cloze>5</span> days</div><div>- Hx of ETOHXS, drug abuse,&nbsp;IDDM, concurrent chemotherapy, antacids, diuretics</div><br><br>
Patients who have two or more of the following are at high risk of refeeding syndrome:<div>- BMI &lt;18</div><div>- Unintentional weight loss of &gt;15% in the past 3-6 months</div><div>- Little to no nutritional intake for &gt;5 days</div><div>- Hx of <span class=cloze>[...]</span>, drug abuse,&nbsp;IDDM, concurrent chemotherapy, antacids, diuretics</div>	Patients who have two or more of the following are at high risk of refeeding syndrome:<div>- BMI &lt;18</div><div>- Unintentional weight loss of &gt;15% in the past 3-6 months</div><div>- Little to no nutritional intake for &gt;5 days</div><div>- Hx of <span class=cloze>ETOHXS</span>, drug abuse,&nbsp;IDDM, concurrent chemotherapy, antacids, diuretics</div><br><br>
Patients who have two or more of the following are at high risk of refeeding syndrome:<div>- BMI &lt;18</div><div>- Unintentional weight loss of &gt;15% in the past 3-6 months</div><div>- Little to no nutritional intake for &gt;5 days</div><div>- Hx of ETOHXS, <span class=cloze>[...]</span>,&nbsp;IDDM, concurrent chemotherapy, antacids, diuretics</div>	Patients who have two or more of the following are at high risk of refeeding syndrome:<div>- BMI &lt;18</div><div>- Unintentional weight loss of &gt;15% in the past 3-6 months</div><div>- Little to no nutritional intake for &gt;5 days</div><div>- Hx of ETOHXS, <span class=cloze>drug abuse</span>,&nbsp;IDDM, concurrent chemotherapy, antacids, diuretics</div><br><br>
Patients who have two or more of the following are at high risk of refeeding syndrome:<div>- BMI &lt;18</div><div>- Unintentional weight loss of &gt;15% in the past 3-6 months</div><div>- Little to no nutritional intake for &gt;5 days</div><div>- Hx of ETOHXS, drug abuse,&nbsp;<span class=cloze>[...]</span>, concurrent chemotherapy, antacids, diuretics</div>	Patients who have two or more of the following are at high risk of refeeding syndrome:<div>- BMI &lt;18</div><div>- Unintentional weight loss of &gt;15% in the past 3-6 months</div><div>- Little to no nutritional intake for &gt;5 days</div><div>- Hx of ETOHXS, drug abuse,&nbsp;<span class=cloze>IDDM</span>, concurrent chemotherapy, antacids, diuretics</div><br><br>
Patients who have two or more of the following are at high risk of refeeding syndrome:<div>- BMI &lt;18</div><div>- Unintentional weight loss of &gt;15% in the past 3-6 months</div><div>- Little to no nutritional intake for &gt;5 days</div><div>- Hx of ETOHXS, drug abuse,&nbsp;IDDM, concurrent <span class=cloze>[...]</span>, antacids, diuretics</div>	Patients who have two or more of the following are at high risk of refeeding syndrome:<div>- BMI &lt;18</div><div>- Unintentional weight loss of &gt;15% in the past 3-6 months</div><div>- Little to no nutritional intake for &gt;5 days</div><div>- Hx of ETOHXS, drug abuse,&nbsp;IDDM, concurrent <span class=cloze>chemotherapy</span>, antacids, diuretics</div><br><br>
Patients who have two or more of the following are at high risk of refeeding syndrome:<div>- BMI &lt;18</div><div>- Unintentional weight loss of &gt;15% in the past 3-6 months</div><div>- Little to no nutritional intake for &gt;5 days</div><div>- Hx of ETOHXS, drug abuse,&nbsp;IDDM, concurrent chemotherapy, <span class=cloze>[...]</span>, diuretics</div>	Patients who have two or more of the following are at high risk of refeeding syndrome:<div>- BMI &lt;18</div><div>- Unintentional weight loss of &gt;15% in the past 3-6 months</div><div>- Little to no nutritional intake for &gt;5 days</div><div>- Hx of ETOHXS, drug abuse,&nbsp;IDDM, concurrent chemotherapy, <span class=cloze>antacids</span>, diuretics</div><br><br>
Patients who have two or more of the following are at high risk of refeeding syndrome:<div>- BMI &lt;18</div><div>- Unintentional weight loss of &gt;15% in the past 3-6 months</div><div>- Little to no nutritional intake for &gt;5 days</div><div>- Hx of ETOHXS, drug abuse,&nbsp;IDDM, concurrent chemotherapy, antacids, <span class=cloze>[...]</span></div>	Patients who have two or more of the following are at high risk of refeeding syndrome:<div>- BMI &lt;18</div><div>- Unintentional weight loss of &gt;15% in the past 3-6 months</div><div>- Little to no nutritional intake for &gt;5 days</div><div>- Hx of ETOHXS, drug abuse,&nbsp;IDDM, concurrent chemotherapy, antacids, <span class=cloze>diuretics</span></div><br><br>
If a patient is leaving/entering the UK for &lt;3 months and carrying &lt;3 months supply of Schedule 2, 3, or 4 drugs, what else do they need to carry with them?	A covering letter from the prescribing doctor.
If a patient is leaving/entering the UK for &lt;3 months and carrying &lt;3 months supply of Schedule 2, 3, or 4 drugs, what does the covering letter from the doctor needs to state:<div><br /></div><div>1. Patient's <span class=cloze>[...]</span></div><div>2. Destinations and dates of outward and return travel</div><div>3. Names, forms, strengths and total amounts of the drugs being carried.</div>	If a patient is leaving/entering the UK for &lt;3 months and carrying &lt;3 months supply of Schedule 2, 3, or 4 drugs, what does the covering letter from the doctor needs to state:<div><br /></div><div>1. Patient's <span class=cloze>name, address and date of birth</span></div><div>2. Destinations and dates of outward and return travel</div><div>3. Names, forms, strengths and total amounts of the drugs being carried.</div><br><br>
If a patient is leaving/entering the UK for &lt;3 months and carrying &lt;3 months supply of Schedule 2, 3, or 4 drugs, what does the covering letter from the doctor needs to state:<div><br /></div><div>1. Patient's name, address and date of birth</div><div>2. Destinations and dates of <span class=cloze>[...]</span> and <span class=cloze>[...]</span> travel</div><div>3. Names, forms, strengths and total amounts of the drugs being carried.</div>	If a patient is leaving/entering the UK for &lt;3 months and carrying &lt;3 months supply of Schedule 2, 3, or 4 drugs, what does the covering letter from the doctor needs to state:<div><br /></div><div>1. Patient's name, address and date of birth</div><div>2. Destinations and dates of <span class=cloze>outward</span> and <span class=cloze>return</span> travel</div><div>3. Names, forms, strengths and total amounts of the drugs being carried.</div><br><br>
If a patient is leaving/entering the UK for &lt;3 months and carrying &lt;3 months supply of Schedule 2, 3, or 4 drugs, what does the covering letter from the doctor needs to state:<div><br /></div><div>1. Patient's name, address and date of birth</div><div>2. Destinations and dates of outward and return travel</div><div>3. <span class=cloze>[...]</span>, forms, strengths and total amounts of the drugs being carried.</div>	If a patient is leaving/entering the UK for &lt;3 months and carrying &lt;3 months supply of Schedule 2, 3, or 4 drugs, what does the covering letter from the doctor needs to state:<div><br /></div><div>1. Patient's name, address and date of birth</div><div>2. Destinations and dates of outward and return travel</div><div>3. <span class=cloze>Names</span>, forms, strengths and total amounts of the drugs being carried.</div><br><br>
If a patient is leaving/entering the UK for &lt;3 months and carrying &lt;3 months supply of Schedule 2, 3, or 4 drugs, what does the covering letter from the doctor needs to state:<div><br /></div><div>1. Patient's name, address and date of birth</div><div>2. Destinations and dates of outward and return travel</div><div>3. Names, <span class=cloze>[...]</span>, strengths and total amounts of the drugs being carried.</div>	If a patient is leaving/entering the UK for &lt;3 months and carrying &lt;3 months supply of Schedule 2, 3, or 4 drugs, what does the covering letter from the doctor needs to state:<div><br /></div><div>1. Patient's name, address and date of birth</div><div>2. Destinations and dates of outward and return travel</div><div>3. Names, <span class=cloze>forms</span>, strengths and total amounts of the drugs being carried.</div><br><br>
If a patient is leaving/entering the UK for &lt;3 months and carrying &lt;3 months supply of Schedule 2, 3, or 4 drugs, what does the covering letter from the doctor needs to state:<div><br /></div><div>1. Patient's name, address and date of birth</div><div>2. Destinations and dates of outward and return travel</div><div>3. Names, forms, <span class=cloze>[...]</span> and total amounts of the drugs being carried.</div>	If a patient is leaving/entering the UK for &lt;3 months and carrying &lt;3 months supply of Schedule 2, 3, or 4 drugs, what does the covering letter from the doctor needs to state:<div><br /></div><div>1. Patient's name, address and date of birth</div><div>2. Destinations and dates of outward and return travel</div><div>3. Names, forms, <span class=cloze>strengths</span> and total amounts of the drugs being carried.</div><br><br>
If a patient is leaving/entering the UK for &lt;3 months and carrying &lt;3 months supply of Schedule 2, 3, or 4 drugs, what does the covering letter from the doctor needs to state:<div><br /></div><div>1. Patient's name, address and date of birth</div><div>2. Destinations and dates of outward and return travel</div><div>3. Names, forms, strengths <span class=cloze>[...]</span> of the drugs being carried.</div>	If a patient is leaving/entering the UK for &lt;3 months and carrying &lt;3 months supply of Schedule 2, 3, or 4 drugs, what does the covering letter from the doctor needs to state:<div><br /></div><div>1. Patient's name, address and date of birth</div><div>2. Destinations and dates of outward and return travel</div><div>3. Names, forms, strengths <span class=cloze>and total amounts</span> of the drugs being carried.</div><br><br>
If a patient is leaving/entering the UK for &lt;3 months and carrying &lt;3 months supply of Schedule <span class=cloze>[...]</span> drugs, a letter from the prescriber is advised, but not required.	If a patient is leaving/entering the UK for &lt;3 months and carrying &lt;3 months supply of Schedule <span class=cloze>5</span> drugs, a letter from the prescriber is advised, but not required.<br><br>
If a patient is leaving/entering the UK for &lt;3 months and carrying &lt;3 months supply of Schedule 5 drugs, a letter from the prescriber is <span class=cloze>[...]</span>, but not <span class=cloze>[...]</span>.	If a patient is leaving/entering the UK for &lt;3 months and carrying &lt;3 months supply of Schedule 5 drugs, a letter from the prescriber is <span class=cloze>advised</span>, but not <span class=cloze>required</span>.<br><br>
If a patient flying abroad needs to carry liquid medication &gt;100ml, can they do so?	Yes, but the patient may require prior approval from the airline to do so.&nbsp;<div><br /></div><div>It may also need to be inspected, X-Rayed and verified.</div>
In depression, what gender is a high risk for suicide?	Male
In depression, what in the family history would place a patient in a high-risk group for suicide?	A family history of mental disorder
What does a history of previous suicide attempts do to a patient's suicide risk?	Becomes <b>high risk</b>
What features of depression mean that a patient is at high risk of suicide?	- Severe depression<div>- Anxiety</div><div>- feelings of hopelessness</div>
If a a patient has a personality disorder and depressed, they are at <span class=cloze>[...]</span> risk for suicide.	If a a patient has a personality disorder and depressed, they are at <span class=cloze>high</span> risk for suicide.<br><br>
If a a patient has a <span class=cloze>[...]</span> disorder and depressed, they are at high risk for suicide.	If a a patient has a <span class=cloze>personality</span> disorder and depressed, they are at high risk for suicide.<br><br>
If a a patient has a personality disorder and <span class=cloze>[...]</span>, they are at high risk for suicide.	If a a patient has a personality disorder and <span class=cloze>depressed</span>, they are at high risk for suicide.<br><br>
If a a patient has a personality disorder and depressed, they are at high risk for <span class=cloze>[...]</span>.	If a a patient has a personality disorder and depressed, they are at high risk for <span class=cloze>suicide</span>.<br><br>
If a depressed patient has a history of <span class=cloze>[...]</span> or self harm, they are a high risk for suicide.	If a depressed patient has a history of <span class=cloze>previous suicide attempts</span> or self harm, they are a high risk for suicide.<br><br>
If a depressed patient has a history of previous suicide attempts or <span class=cloze>[...]</span>, they are a high risk for suicide.	If a depressed patient has a history of previous suicide attempts or <span class=cloze>self harm</span>, they are a high risk for suicide.<br><br>
If a depressed patient has a history of previous suicide attempts or self harm, they are a <span class=cloze>[...]</span> risk for suicide.	If a depressed patient has a history of previous suicide attempts or self harm, they are a <span class=cloze>high</span> risk for suicide.<br><br>
The possible protective factors for suicide include:<div>- <span class=cloze>[...]</span></div><div>- Religious belief</div><div>- Being responsible for children</div>	The possible protective factors for suicide include:<div>- <span class=cloze>Social support</span></div><div>- Religious belief</div><div>- Being responsible for children</div><br><br>
The possible protective factors for suicide include:<div>- Social support</div><div>- <span class=cloze>[...]</span></div><div>- Being responsible for children</div>	The possible protective factors for suicide include:<div>- Social support</div><div>- <span class=cloze>Religious belief</span></div><div>- Being responsible for children</div><br><br>
The possible protective factors for suicide include:<div>- Social support</div><div>- Religious belief</div><div>- <span class=cloze>[...]</span></div>	The possible protective factors for suicide include:<div>- Social support</div><div>- Religious belief</div><div>- <span class=cloze>Being responsible for children</span></div><br><br>
Of the risks of suicide in depression, previous <span class=cloze>[...]</span> is the most important, followed by a family history of self harm or suicide.	Of the risks of suicide in depression, previous <span class=cloze>self harm</span> is the most important, followed by a family history of self harm or suicide.<br><br>
Of the risks of suicide in depression, previous self harm is the most important, followed by a <span class=cloze>[...]</span> history of self harm or suicide.	Of the risks of suicide in depression, previous self harm is the most important, followed by a <span class=cloze>family</span> history of self harm or suicide.<br><br>
Of the risks of suicide in depression, previous self harm is the most important, followed by a family history of <span class=cloze>[...]</span> or <span class=cloze>[...]</span>.	Of the risks of suicide in depression, previous self harm is the most important, followed by a family history of <span class=cloze>self harm</span> or <span class=cloze>suicide</span>.<br><br>
In depression, an adjustment reaction to a newly diagnosed physical illness, especially if it is painful, is a risk for <span class=cloze>[...]</span>.	In depression, an adjustment reaction to a newly diagnosed physical illness, especially if it is painful, is a risk for <span class=cloze>suicide</span>.<br><br>
In depression, exposure to the suicidal behaviour of others, directly or indirectly (i.e. via the media) is a risk for <span class=cloze>[...]</span>.	In depression, exposure to the suicidal behaviour of others, directly or indirectly (i.e. via the media) is a risk for <span class=cloze>suicide</span>.<br><br>
In depression, exposure to the <span class=cloze>[...]</span> of others, directly or indirectly (i.e. via the media) is a risk for suicide.	In depression, exposure to the <span class=cloze>suicidal behaviour</span> of others, directly or indirectly (i.e. via the media) is a risk for suicide.<br><br>
In depression, a recent discharge from <span class=cloze>[...]</span> care is a risk for suicide.	In depression, a recent discharge from <span class=cloze>inpatient psychiatric</span> care is a risk for suicide.<br><br>
In depression, a recent discharge from inpatient psychiatric care is a risk for <span class=cloze>[...]</span>.	In depression, a recent discharge from inpatient psychiatric care is a risk for <span class=cloze>suicide</span>.<br><br>
In depression, access to potentially lethal means of <span class=cloze>[...]</span>, is a risk for suicide.	In depression, access to potentially lethal means of <span class=cloze>self-harm or suicide</span>, is a risk for suicide.<br><br>
"What condition causes this?<div><img src=""Dermatomyositis9.jpg"" /></div>"	Heliotrope rash of dermatomyositis
Dermatomyositis is a&nbsp;<span class=cloze>[...]</span> syndrome.&nbsp;	Dermatomyositis is a&nbsp;<span class=cloze>paraneoplastic</span> syndrome.&nbsp;<br><br>
"A patient with pancreatic cancer shows his hands to you - what is it?<div><img src=""Dermatomyositis6.jpg"" /><br /><div><br /></div></div>"	Gottrons papules - dermatomyositis
A patient with breast cancer tests positive for anti-Mi-2 antibodies. She has a facial rash. What is the diagnosis?	Dermatomyositis
A patient with ovarian cancer is referred to you with bilateral muscle weakness. She reports an itchy rash over her flexor surfaces. You note a heliotrope rash over her face.<div>What is the paraneoplastic syndrome?</div>	Dermatomyositis
"A patient with uterine cancer presents with a facial rash:<div><img src=""Dermatomyositis13.jpg"" /></div><div>What is the paraneoplastic syndrome?</div>"	Dermatomyositis
"A patient with non-Hodgkin lymphoma reports their hands are rough and scaly:<div><img src=""Dermatomyositis.jpg"" /></div><div>They also report weakness in their arms and legs. What is the paraneoplastic syndrome?</div>"	Dermatomyositis
"A patient with uterine cancer reports darkening of her neck:<div><img src=""acanthosis_nigricans_1_high.jpg"" /></div><div>What is this?</div>"	Acanthosis nigricans
"A patient with lung cancer reports skin tags and darkening of the axilla:<div><img src=""701_2.jpg"" /></div><div>What is this?</div>"	Acanthosis nigricans
"You notice this on the neck of a patient with stomach cancer:<div><img src=""acantosis_nigricans_benigna5.jpg"" /></div><div>What is this?</div>"	Acanthosis nigricans
A patient with NHL reports dysphagia, difficulty with getting up from a chair and climbing stairs. There is no rash. What is the likely cause?	Polymyositis, a paraneoplastic syndrome
A patient with lung cancer reports they can no longer hang the washing up to dry. On examination, they have power of 3/5 in bilateral upper limbs, and weakness in hip flexors. There is no rash.<div>What is the likely paraneoplastic syndrome?</div>	Polymyositis
A man with bladder cancer reports he is tiring quickly when walking his dog. On examination, he is unable to lift his arms over his head. There is no rash.<div>What is the likely paraneoplastic syndrome?</div>	Polymyositis
CK in polymyositis?	High
A patient with pancreatic cancer reports flushing and diarrhoea.&nbsp;<div>What is the likely paraneoplastic syndrome?</div>	Carcinoid
"A patient with gastric carcinoma reports diarrhoea. On arrival to clinic, their face looks like this:<div><img src=""Flushingfig2_large.jpg"" /></div><div>What is the likely paraneoplastic syndrome?</div>"	Carcinoid
Paraneoplastic cerebellar degeneration is an autoimmune reaction against CNS components, especially <span class=cloze>[...]</span> cells.	Paraneoplastic cerebellar degeneration is an autoimmune reaction against CNS components, especially <span class=cloze>Purkinjie</span> cells.<br><br>
Paraneoplastic cerebellar degeneration is an <span class=cloze>[...]</span> reaction against CNS components, especially Purkinjie cells.	Paraneoplastic cerebellar degeneration is an <span class=cloze>autoimmune</span> reaction against CNS components, especially Purkinjie cells.<br><br>
A patient with a bronchial adenoma appears flushed. What other symptom of carcinoid might they report?	Diarrhoea
A patient with small-cell lung cancer reports increased weight and headaches. A recent MRI scan shows no known brain metastases. Their blood pressure is 220/120.&nbsp;<div><br /></div><div>What is the likely paraneoplastic syndrome?</div>	Cushing syndrome
"A woman with pancreatic cancer presents with weight gain and hypertension. She reported facial changes. These are her facial appearences:<div><img src=""30701tn.jpg"" /></div><div>What is the paraneoplastic syndrome?</div>"	Cushing syndrome
A blood test comes back anti-Jo-1 antibody +ve. What paraneoplastic syndrome is associated with this result?	Polymyositis
A muscle biopsy report comes back from one of your patients with non-Hogkins lymphoma, who has been complaining of a facial rash, and difficulty walking up the stairs. The report says:<div><br /></div><div><i>Microscopic findings:&nbsp;</i></div><div><i>- A mixed B- and T-cell perivascular inflammatory infiltrate</i></div><div><i>- Perifascicular muscle fiber atrophy</i></div><div><br /></div><div>What is the likely paraneoplastic syndrome?</div>	Dermatomyositis
"A patient who has a glucagonoma has this rash:<div><img src=""2994425_rt-2009-1-e6-g001.png"" /></div><div>What is it?</div>"	Necrolytic migratory erythema
"A patient with limited small-cell lung cancer presents to the in-patient unit of a hospice. The family report that the patient has been confused, with new onset seizures. A recent MRI scan shows no brain metastatic disease, but <i>""hyperintensity of the temporal lobes on FLAIR""</i>&nbsp;. A blood test done in hospital showed:<div><br /></div><div>- <i>Anti-Hu antibody positive</i><br /><div><br /></div><div>On review, he appeared cognitively impaired, with short-term memory loss. He had paranoid thoughts, and reported auditory hallucinations.&nbsp;</div></div><div><br /></div><div>What is the likely paraneoplastic syndrome?</div>"	Limbic encephalitis.
"A patient with colorectal cancer reports a sudden appearence of a lumpy rash on his back. On examination, you see this:<div><img src=""Seborrheic_keratosis_on_human_back.jpg"" /></div><div>What is this sign called?</div>"	Leser–Trélat sign (explosive appearence of&nbsp;multiple seborrheic keratoses)
"A patient with stomach cancer reports her hands have changed texture. On examination, you see this:<div><img src=""m-h_photo_of_acanthosis_nigricans_tripe_palm.jpg"" /></div><div>What is this called?</div>"	"""Tripe palm"" or acanthosis nigricans of the palm"
"A man with a squamous cell carcinoma of the pharynx reports dry skin on his ear. On examination, you see this:<div><img src=""img0066.jpg"" /></div><div>He also has a rash which looks psoriatic in nature. What is the likely paraneoplastic syndrome?</div>"	Acrokeratosis paraneoplastica&nbsp;
"A woman with radically treated bowel cancer reports a sudden disappearance of a rash. She has not started any recent medications. On previous review prior to treatment, your colleague noted:<div><br /><div>- sudden appearence of multiple seborrhaeic keratoses</div><div><br /></div><div>There is a photo of the resolved rash:</div><div><img src=""leser-trelat-sign-aparaneoplastic-syndrome4.jpg"" /></div></div><div>What paraneoplastic syndrome is this?</div>"	Leser-Trélat's sign<div>Often disappears when the cancer is in remission</div>
"A patient with a squamous cell carcinoma of the base of tongue reports painful fingers. On examination, they look like this:<div><img src=""img0043.jpg"" /></div><div>What is the likely paraneoplastic syndrome?</div>"	Acrokeratosis paraneoplastica&nbsp;
Other name for acrokeratosis paraneoplastica?	Bazex syndrome
A patient with breast cancer and a facial rash has been investigated for muscle weakness. The EMG report says:<div><br /></div><div><i>EMG findings of spontaneous muscle fibrillation and short polyphasic muscle potentials.</i></div><div><br /></div><div>What is the likely paraneoplastic syndrome?</div>	Dermatomyositis
CK levels in polymyositis?	High
Dermatomyositis is a paraneoplastic disease which is associated with the following cancers:<div>- <span class=cloze>[...]</span></div><div>- Breast</div><div>- Ovarian</div><div>- pancreas</div><div>- stomach</div><div>- colorectal</div><div>- NHL</div>	Dermatomyositis is a paraneoplastic disease which is associated with the following cancers:<div>- <span class=cloze>Lung</span></div><div>- Breast</div><div>- Ovarian</div><div>- pancreas</div><div>- stomach</div><div>- colorectal</div><div>- NHL</div><br><br>
Dermatomyositis is a paraneoplastic disease which is associated with the following cancers:<div>- Lung</div><div>- <span class=cloze>[...]</span></div><div>- Ovarian</div><div>- pancreas</div><div>- stomach</div><div>- colorectal</div><div>- NHL</div>	Dermatomyositis is a paraneoplastic disease which is associated with the following cancers:<div>- Lung</div><div>- <span class=cloze>Breast</span></div><div>- Ovarian</div><div>- pancreas</div><div>- stomach</div><div>- colorectal</div><div>- NHL</div><br><br>
Dermatomyositis is a paraneoplastic disease which is associated with the following cancers:<div>- Lung</div><div>- Breast</div><div>- <span class=cloze>[...]</span></div><div>- pancreas</div><div>- stomach</div><div>- colorectal</div><div>- NHL</div>	Dermatomyositis is a paraneoplastic disease which is associated with the following cancers:<div>- Lung</div><div>- Breast</div><div>- <span class=cloze>Ovarian</span></div><div>- pancreas</div><div>- stomach</div><div>- colorectal</div><div>- NHL</div><br><br>
Dermatomyositis is a paraneoplastic disease which is associated with the following cancers:<div>- Lung</div><div>- Breast</div><div>- Ovarian</div><div>- <span class=cloze>[...]</span></div><div>- stomach</div><div>- colorectal</div><div>- NHL</div>	Dermatomyositis is a paraneoplastic disease which is associated with the following cancers:<div>- Lung</div><div>- Breast</div><div>- Ovarian</div><div>- <span class=cloze>pancreas</span></div><div>- stomach</div><div>- colorectal</div><div>- NHL</div><br><br>
Dermatomyositis is a paraneoplastic disease which is associated with the following cancers:<div>- Lung</div><div>- Breast</div><div>- Ovarian</div><div>- pancreas</div><div>- <span class=cloze>[...]</span></div><div>- colorectal</div><div>- NHL</div>	Dermatomyositis is a paraneoplastic disease which is associated with the following cancers:<div>- Lung</div><div>- Breast</div><div>- Ovarian</div><div>- pancreas</div><div>- <span class=cloze>stomach</span></div><div>- colorectal</div><div>- NHL</div><br><br>
Dermatomyositis is a paraneoplastic disease which is associated with the following cancers:<div>- Lung</div><div>- Breast</div><div>- Ovarian</div><div>- pancreas</div><div>- stomach</div><div>- <span class=cloze>[...]</span></div><div>- NHL</div>	Dermatomyositis is a paraneoplastic disease which is associated with the following cancers:<div>- Lung</div><div>- Breast</div><div>- Ovarian</div><div>- pancreas</div><div>- stomach</div><div>- <span class=cloze>colorectal</span></div><div>- NHL</div><br><br>
Dermatomyositis is a paraneoplastic disease which is associated with the following cancers:<div>- Lung</div><div>- Breast</div><div>- Ovarian</div><div>- pancreas</div><div>- stomach</div><div>- colorectal</div><div>- <span class=cloze>[...]</span></div>	Dermatomyositis is a paraneoplastic disease which is associated with the following cancers:<div>- Lung</div><div>- Breast</div><div>- Ovarian</div><div>- pancreas</div><div>- stomach</div><div>- colorectal</div><div>- <span class=cloze>NHL</span></div><br><br>
What requires monitoring if clozapine is started?	White cell count
What is there a risk of with starting clozapine?	Agranulocytosis
<span class=cloze>[...]</span>% of people who start clozapine have agranulocytosis.	<span class=cloze>1</span>% of people who start clozapine have agranulocytosis.<br><br>
1% of people who start clozapine have <span class=cloze>[...]</span>.	1% of people who start clozapine have <span class=cloze>agranulocytosis</span>.<br><br>
A stellate ganglion block is aimed at <span class=cloze>[...]</span>, and is for head and neck cancer	A stellate ganglion block is aimed at <span class=cloze>C6/7/8</span>, and is for head and neck cancer<br><br>
A stellate ganglion block is aimed at C6/7/8, and is for <span class=cloze>[...]</span> cancer	A stellate ganglion block is aimed at C6/7/8, and is for <span class=cloze>head and neck</span> cancer<br><br>
Psoas compartment blocks are for <span class=cloze>[...]</span>	Psoas compartment blocks are for <span class=cloze>hip pain</span><br><br>
<span class=cloze>[...]</span> compartment blocks are for hip pain	<span class=cloze>Psoas</span> compartment blocks are for hip pain<br><br>
What are the safe antipsychotics to use in parkinsons disease according to NICE?	Quetiapine<div>Clozapine (needs monitoring)</div>
According to NICE, the management of oscillopsia in MS is:<div>1st line: <span class=cloze>[...]</span></div><div>2nd line: Memantadine</div>	According to NICE, the management of oscillopsia in MS is:<div>1st line: <span class=cloze>Gabapentin</span></div><div>2nd line: Memantadine</div><br><br><br /><div><br /></div>
According to NICE, the management of oscillopsia in MS is:<div>1st line: Gabapentin</div><div>2nd line: <span class=cloze>[...]</span></div>	According to NICE, the management of oscillopsia in MS is:<div>1st line: Gabapentin</div><div>2nd line: <span class=cloze>Memantadine</span></div><br><br><br /><div><br /></div>
